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Major depressive disorder (MDD) is a debilitating disease characterized by low mood, 
memory deficits, poor sleep quality and alterations in biochemical markers associated 
with neuroplasticity. Less than half of MDD patients receive an efficacious treatment, 
warranting the need for novel treatment strategies. Exercise as an add-on therapy is a 
promising approach shown to improve mood, however, its mechanism of action remains 
unknown. To advance our understanding of the mechanisms by which exercise affects 
brain function this thesis studied both healthy and MDD individuals. Study One used a 
functional magnetic resonance imaging (fMRI) subsequent memory paradigm to 
investigate the effects of an eight-week exercise intervention on neural function in 
healthy and MDD groups. FMRI results showed significant deactivation in the 
hippocampus and across several memory-associated regions in both groups suggesting a 
potential increase in neural efficiency. Study Two evaluated exercise as an add-on to 
antidepressant medication (ADM) and cognitive behavioural group therapy (CBGT) for 
MDD. Exercise led to a robust decrease in depression scores (p=0.007, d=2.06), with 
75% of the patients achieving either response or remission compared to 25% of those 
who received ADM and CBGT only. Exercise also led to greater improvements in sleep 
quality (p=0.046, d=1.28), cognitive function (p=0.046, d=1.08) and plasma brain-
derived neurotrophic factor (BDNF), p=0.003, d=6.46. Furthermore, BDNF was 
positively correlated with improvements in depression (p=0.002, R2 = 0.50) and sleep 
quality (p=0.011, R2 = 0.38). Study Three found that exercise for healthy, young adults 
did not improve cognitive performance or biomarkers, despite the neural changes seen in 
the fMRI study. Overall, this thesis demonstrates that exercise promotes neuroplasticity 
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in both healthy and MDD patients, substantially improving mood and cognitive 
performance in MDD. Plasma BDNF levels and sleep quality appear to be good 
indicators of treatment response and potential biomarkers associated with the clinical 
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Chapter 1 - Introduction  
1.1 Statement of the problem and general thesis objectives 
The effects of Major Depressive Disorder (MDD) are profound and far-reaching, 
being one of the leading contributors to the global burden of disease (WHO, 2008). MDD 
is a common (Patten, Williams et al. 2015), costly (Patten and Beck 2004), and highly 
recurrent disorder (Belsher and Costello 1988), that is associated with significant 
morbidity and mortality rates (Wells, Stewart et al. 1989, Fawcett 1993, Harris and 
Barraclough 1998, Ustun, Rehm et al. 1999). Despite many efforts to develop effective 
antidepressant therapies, depression remains a severely undertreated and under 
recognized disorder in the primary care setting (Shelton 2006). It has been estimated that 
only half of depressed Canadians seek medical treatment and of those, less than half 
receive an efficacious treatment (Andrews, Sanderson et al. 2000, Patten and Beck 2004). 
Moreover, a recent meta-analysis raised the possibility that the side effects associated 
with antidepressant medication (ADM) may outweigh the small therapeutic effects in 
many individuals (Jakobsen, Katakam et al. 2017). As such, the role of a non-
pharmacologic treatment option for depression in becoming increasingly important.  
Exercise is a treatment option with proven benefits in the treatment of MDD, 
however, its mechanism of action remains unknown. To fully understand the magnitude 
of effects of exercise and to capitalize on the full treatment potential of exercise in 
depressed populations, we must first identify physiological mechanisms that are specific 
to depression. Currently, there is a shortage of reporting sedentary behaviour, physical 
activity levels and cardiovascular fitness parameters in the depression literature. As such, 
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some of the physiological differences observed in studies comparing depressed 
individuals to healthy controls might be confounded by an inactive lifestyle, which is 
more prevalent in depressed populations (Appelhans, Whited et al. 2012). There is an 
extensive body of literature from both elderly humans and animals that have identified 
mechanisms associated with neuroplasticity and cognitive function that are also 
associated with the onset and recovery of MDD. It is therefore critical that we understand 
the impact of physical activity and cardiorespiratory fitness levels on neural function in 
those with MDD as well as healthy individuals in order to delineate physiological 
mechanisms unique to depression and independent of physical activity levels. Once we 
understand why and how exercise works to alleviate symptoms in MDD, we will be able 
to better prescribe exercise, identify patients who will benefit from exercise, and develop 
more efficacious ADMs or combination of pharmaceutical agents that target these 
mechanisms.  
The primary goal of this PhD thesis was to determine the mechanisms by which 
exercise as an add-on therapy to ADM and cognitive behavioural group therapy (CBGT), 
improves the symptoms of those with MDD. To identify unique biomarkers associated 
with MDD, independent of physical activity and fitness variables, this study investigated 
the effects of exercise in both MDD patients and healthy individuals who were 
considered low active and cardiorespiratory unfit. This study will add further insight into 
the pathophysiology of MDD as well as indicators that are associated with treatment 
response from exercise. Accordingly, this study used a multidisciplinary approach using a 
combination of neuroimaging, biochemical analyses and behavioural assessments to 
measure the effects of exercise on depressive symptoms, neural function, cognitive 
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function and sleep quality, and to identify putative biomarkers related to treatment 
response.  This study also explored the neural effects of exercise in young and healthy 
adults who were considered low active and with low levels of cardiorespiratory fitness, to 
provide normative values for comparison and to contribute knowledge to this sparse area 
in the literature. 
This thesis research will significantly advance knowledge, as it is the first to use a 
combination of functional neuroimaging, biochemical analyses and behavioural measures 
to measure changes in brain function following a structured, supervised exercise 
intervention in people with MDD undergoing antidepressant therapy. By correlating 
changes in neural activity with clinical changes, and changes in biochemical markers 
shown to be altered in MDD, it will add to our understanding of which biomarkers are 
most predictive of improved cognitive function. This study will also distinguish which 
biomarkers change with ADM plus psychotherapy plus exercise versus ADM plus 
psychotherapy. Importantly, this research will begin to elucidate how exercise affects 
young and healthy adults and will help determine whether exercise has an effect on brain 
function before the onset of any age-related neurodegeneration.   
Overall, this research project will create a more solid literature base for multi-
disciplinary research approaches in the future. Ideally, it may be possible to use a patients 
biochemical and clinical signature to determine which combination of exercise, 
pharmacotherapy and/or psychological interventions are required to maximize treatment 
outcomes. This work has the potential to provide a tool to improve exercise prescription 
and to guide the development of a holistic treatment approach to optimize clinical 
outcomes for MDD in Canada. 
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1.2 Review of the literature 
1.2.1 Depression statistics 
Major depressive disorder (MDD) is an international public-health problem and 
considered the most prevalent and most cumbersome to treat of all psychiatric disorders. 
Depression is currently the second leading cause of disability worldwide and is projected 
to be the leading cause by the year of 2020 (Ferrari, Charlson et al. 2013). The economic 
burden of depression in Canada has been estimated at over 32 billion dollars annually 
(Stonebridge and Sutherland, 2016), and is associated with an approximately 50% 
increase in healthcare costs when comorbid with a chronic medical illness (Katon 2003). 
The lifetime prevalence rate of a major depressive episode (MDE) is 11%, with the rate 
for women nearly double the rate for men (Patten, Williams et al. 2015). Depression is 
associated with negative health habits, such as smoking, substance abuse, poor diet, a 
physically inactive lifestyle and noncompliance with medical treatment (Farmer, Locke et 
al. 1988, Patton, Carlin et al. 1998, DiMatteo, Lepper et al. 2000, Hasin, Goodwin et al. 
2005, Appelhans, Whited et al. 2012).  There is also strong evidence that depression 
plays a role in the aetiology of other medical illnesses including coronary heart disease 
(Whang, Kubzansky et al. 2009), type 2 diabetes (Pan, Lucas et al. 2010), decreased bone 
density (Williams, Bjerkeset et al. 2011), peptic ulcers (Scott, Alonso et al. 2013), obesity 
(Onyike, Crum et al. 2003) and death due to unnatural causes (Wulsin, Vaillant et al. 
1999). Furthermore, depression when comorbid with other chronic diseases has been 
shown to worsen health outcomes compared with any combination of chronic diseases 
without depression (Moussavi, Chatterji et al. 2007).  
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Depression is a severely undertreated and under recognized disorder in the 
primary care setting (Diverty and Beaudet 1997). It seems that many patients feel the 
stigma of seeking treatment is greater than the stigma of living with the disorder 
(Mojtabai and Olfson 2006). It has been estimated that only 56% of depressed Canadians 
seek medical treatment (Patten and Beck 2004). Of those patients who so seek medical 
help for their depression, only 32% receive an efficacious treatment (Andrews, Sanderson 
et al. 2000). It has also been estimated that over 40% of depressed patients who do 
achieve partial or full remission of their disease, continue to experience residual 
symptoms putting them at greater risk for relapse (Fava et al., 2006; Paykel et al., 1995). 
Taken together, it is critical that depression is a considered public-health priority that 
must consider innovative and more cost-effective interventions to lessen its burden 
(Ferrari, Charlson et al. 2013). 
1.2.2 Major Depressive Disorder 
MDD is characterized by a wide range of behavioral, emotional, and cognitive 
symptoms, including depressed mood, anhedonia, feelings of worthlessness or guilt, 
suicidal ideation, changes in body weight or appetite, sleep disturbance, lack of energy, 
psychomotor agitation or retardation and decreased ability to think or concentrate. The 
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-V) defines 
a MDE as a period greater than two weeks characterized by five or more of these 
symptoms and at least one of the symptoms is either (1) depressed mood or (2) loss of 




1.2.3 Depression and cognitive impairment 
Cognitive impairment is present in approximately 90% of patients with MDD and 
is associated with poorer treatment response (Story, Potter et al. 2008, Conradi, Ormel et 
al. 2011). It has been reported that nearly half of the patients who achieve remission 
continue to experience cognitive impairment as a residual symptom of MDD (Conradi, 
Ormel et al. 2011) revealing an independent relationship between cognition and 
depression severity . The DSM-V recognizes and incorporates cognitive impairment as 
“diminished ability to think or concentrate” in the diagnostic criteria for MDD (APA and 
DSM-IV 2000). Cognitive impairments in depression are most apparent during tasks that 
require effortful processing and executive control (Hartlage, Alloy et al. 1993). Several 
meta-analyses have reported deficits in executive function, attention, cognitive 
processing speed, visual learning and memory in depressed populations (Zakzanis, Leach 
et al. 1998b, Lee, Hermens et al. 2012, Snyder 2013). However, the magnitude of 
cognitive impairment associated with MDD is unknown due to the variability of effects 
sizes and methodological inconsistencies across studies. To address these drawbacks in 
the literature, a recent systematic review and meta-analysis investigated the degree of 
cognitive impairment in patients with depression during both symptomatic and remitted 
states. To increase interstudy homogeneity, researchers included studies that used a 
specific neuropsychological test battery called the Cambridge Neuropsychological Test 
Automated Battery (CANTAB), to examine a broad range of cognitive domains. Results 
showed significant moderate effect sizes (Cohen's d) for deficits in executive function, 
memory and attention, ranging from −0.34 to −0.65 in patients experiencing depressive 
episodes compared to healthy controls. Results also showed significant moderate effect 
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sizes for deficits in attention and executive function that range from −0.52 to −0.61, and 
small to moderate effect sizes for deficits in memory that range from −0.22 to −0.54, in 
patients who were considered remitted (Rock, Roiser et al. 2013). These results suggest 
that cognitive impairment is a core and clinically important feature of depression that 
persists beyond symptoms of low mood. These findings also suggest there to be an 
underlying mechanism that is associated with cognitive function independent of 
depressive mood.  
Behavioural evidence of impaired memory in depression 
Memory impairment is the most frequently reported cognitive symptom in people 
with depression (Airaksinen, Larsson et al. 2004). However, research in this area has 
presented mixed findings in terms of the type, severity and specificity of memory 
deficits.  One finding that has been well established is the impairment in declarative 
memory, particularly episodic memory (memory for a specific past experience in one’s 
life) with a sparing of semantic memory (present knowledge of universal truths such as 
“the sky is blue”), and short-term memory (Burt, Zembar et al. 1995, Ilsley, Moffoot et 
al. 1995, Tulving and Markowitsch 1998, Zakzanis, Leach et al. 1998a, Sweeney, Kmeic 
et al. 2000).   
Episodic memory has been defined as “the conscious recollection of previous 
experiences of events, happenings, and situations” (Tulving and Markowitsch 1998) that 
involves the binding of information about what, where and when it occurred. Research 
has shown the that largest deficits in episodic memory processes is the inability to bind or 
encode features of an event in MDD populations (Zakzanis, Leach et al. 1998a). The 
8 
 
most widely used test to evaluate episodic memory in MDD populations is the 
Autobiographic Memory Test (Williams and Broadbent 1986), in which participants are 
asked to retrieve specific personal memories when given an emotional cue-word. 
Impairments in autobiographic memory have been consistently reported (Brittlebank, 
Scott et al. 1993, Peeters, Wessel et al. 2002, Söderlund, Moscovitch et al. 2014), in 
which patients have difficulty retrieving a single remembered event and instead 
overgeneralize by summarizing categories of events (Williams, Barnhofer et al. 2007). 
More recently, episodic memory impairments in MDD have been further supported by 
evidence from functional neuroimaging techniques that will be later discussed. 
Behavioural evidence of impaired executive function in depression 
The concept of executive function is a broad term that has been defined as a 
“complex cognitive process requiring the co-ordination of several sub processes to 
achieve a particular goal” (Elliott 2003). Studies investigating executive function have 
mainly used tasks that assess cognitive control, inhibition, flexibility, planning, and 
working memory (Funahashi 2001). There is a general consensus that neural processes 
involved in cognitive control (the ability to coordinate thought and action in harmony 
with internal goals; Miller & Cohen, 2001), and cognitive flexibility (the ability to 
change goal states; Ravizza & Carter, 2008) underlie the impairment in executive 
function observed in MDD populations (Fossati, Ergis et al. 2002, Beck 2008, Lee, 
Hermens et al. 2012). Cognitive control is an important component of executive function 
as it enables focussed attention to relevant stimuli while also inhibiting interfering and 
irrelevant stimuli to achieve a task goal (Hasher and Zacks 1988, Gotlib and Joormann 
2010). Inhibition is considered the deliberate, controlled suppression of an automatic or 
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prepotent response, that can interfere with the correct response (Miyake, Friedman et al. 
2000). Inhibition deficiencies have been reported in those suffering with MDD (Snyder 
2013). For instance, deficits in attentional control have been demonstrated in depressed 
patients by their difficulties with inhibiting emotionally distracting negative information 
(Goeleven, De Raedt et al. 2006, Joormann 2006). Inhibition deficits have also been 
demonstrated using emotionally neutral stimuli during reading tasks that involve ignoring 
semantically distracting words, in which depressed patients read more slowly and 
produce more errors than healthy controls. (Gohier, Ferracci et al. 2009). The Stroop task 
is another test that requires inhibitory control processes and is commonly used in the 
MDD literature. In this test participants must inhibit the inclination to produce a more 
automatic and incorrect response (i.e., name the colour of the word RED that is displayed 
in blue). Several studies have reported that depressed patients produce significantly more 
errors (i.e. reading the word) and are significantly slower to name the colour of 
incongruent colour words than healthy controls. A long-term perspective study examined 
inhibition in MDD patients during the symptomatic period and at six months following 
antidepressant therapy. Findings revealed no improvement in Stroop performance at six 
months despite significant improvement depressive symptoms (Hammar, SØRensen et al. 
2010). These results provide further evidence that deficits in cognitive function are 
independent of depressive severity and persist as a residual symptom of MDD. 
The Wisconsin Card Sorting Test (Heaton, Chelune et al. 1993) is set-shifting test 
that is widely used to examine cognitive flexibility in depressed populations. Initially, 
participants are required to sort cards based on dimensions of colour, shape and number 
of shapes on each card. After learning a dimension, negative feedback is provided 
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requiring participants to then to learn the new rule and switch to a different dimension. A 
number of studies have shown that depressed individuals make more perseverative 
responses and errors and show longer times to reach the first category, fewer categories, 
fewer conceptual-level responses and lower learning-to-learn scores than healthy controls 
(Channon 1996, Merriam, Thase et al. 1999, Ilonen, Leinonen et al. 2000, Must, Szabó et 
al. 2006). Set-shifting deficits in MDD have also been demonstrated with the 
Intradimensional/Extradimensional Shift task (Robbins, James et al. 1998). Like the 
Wisconsin Card Sorting Task, the Intradimensional/Extradimensional Shift task requires 
learning from negative feedback to select a visual stimulus based on one dimension, 
switching back to the previous stimulus (intradimensional shift), and then switching to a 
third stimulus dimension (extradimensional shift). Studies have shown that depressed 
individuals take more trials to reach the criteria for the intradimensional stage of the task 
and are more likely to fail the task at the extradimensional shift stage versus healthy 
controls (Purcell, Maruff et al. 1997, Clark, Sarna et al. 2005, Michopoulos, Zervas et al. 
2006, Reppermund, Ising et al. 2009). However, it has also been argued that negative 
feedback provided by the Intradimensional/Extradimensional Shift task may elicit 
thoughts about failure that consequently disrupt performance in MDD patients (Elliott, 
Sahakian et al. 1996, Murphy, Michael et al. 2003). 
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1.2.4 Neural correlates of episodic memory  
The hippocampus 
In humans, the hippocampal formation is located in the medial temporal lobe 
(MTL) and protrudes into the temporal horn of the lateral ventricle laying along the 
posterior-to-anterior axis forming an arch around the mesencephalon (see Figure 1.1). 
Resembling the shape of a seahorse, the hippocampal formation is a bilaminar structure 
consisting of the hippocampal proper, the dentate gyrus (DG), the subicular complex, and 
the entorhinal cortex. The HF is comprised of six layers based on neuronal function: the 
alveus, stratum oriens, stratum pyramidale, stratum radiatum, stratum lacunosum,and 
stratum moleculare.. The hippocampal proper is mainly comprised of layer II, the stratum 
pyramidale, and is further divided into subfields of the cornu ammonis (CA1-CA3) based 
on different aspects of its pyramidal neurons. The DG is separated from CA1–CA3 by the 
hippocampal sulcus and is structurally composed of three layers: the granule cell layer 
(striatum granulosum), molecular layer, and the polymorphic layer (hilus). The general 
antatomical arrangement of the hippocampal formation can be divided into three 
segments; a body when sagittally oriented, an anterior (head) and a posterior (tail) region 
when transversely oriented, see Figure 1.2 (Duvernoy 2005, Deshmukh and Knierim 




Figure 1. 1 - Anatomy of the medial temporal lobe (MTL): This represents a sagittal 
segmented MTL: amygdala (blue), hippocampus (brown), anterior parahippocampus 
(dark brown), posterior parahippocampus (gold), perforant path (white) Adapted from: 
(Seidman, Rosso et al. 2014).  
 
Figure 1. 2 - Histology-derived volumetric annotation of the human hippocampal 
subfields in postmortem MRI. Abbreviations: CA=cornu ammonis; DG=dentate gyrus; 
SUB=subiculum; SRLM-HS=stratum radiatum, lacunosum-moleculare, and hippocampal 




Information processing within the MTL 
Several lines of evidence from brain lesion studies (Mayes, Holdstock et al. 
2004), electrophysiology (Shapiro and Eichenbaum 1999) and functional neuroimaging 
studies (Kapur, Friston et al. 1995, Henke, Buck et al. 1997, Grady, McIntosh et al. 1998) 
have identified the hippocampus and neighbouring cortices (perirhinal, entorhinal, and 
parahippocampal) to be involved in episodic memory processing. The MTL facilitates the 
flow of information between the neocortex, notably the prefrontal and retrosplenial 
cortices, and the hippocampus (see Figure 1.3).  
 
Figure 1. 3 - Schematic illustration of the medial temporal lobe memory system. The 
perirhinal and parahippocampal cortices receive projections from unimodal and 
polymodal regions in the frontal, temporal, and parietal lobes. Two-thirds of the cortical 
input to the entorhinal cortex is received from the perirhinal and parahippocampal 
cortices which are the main source of cortical input to the hippocampal formation. The 
entorhinal cortex also receives other direct inputs from orbital frontal cortex, cingulate 
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cortex, insular cortex and superior temporal gyrus (Adapted from Zola-Morgan, Squire & 
Ramus, 1994).  
 
The trisynaptic pathway is the primary neural circuit involved in the feed-forward 
flow of information processing by the hippocampus. The entorhinal cortex is a major 
source of cortical sensory information that the hippocampus uses to perform its functions. 
In sequence, the entorhinal cortex is the main excitatory neuron output to the 
hippocampus, with the strongest projections passing through the perforant path to the 
DG. The DG is the major termination of projections from the entorhinal cortex and 
therefore considered the first step in the processing of information into episodic memory 
(Amaral, Scharfman et al. 2007). The DG projects a powerful excitatory output to the 
CA3 region via the mossy fiber pathway and the CA3 projects excitatory output to the 
CA1 region via the Schaffer Collateral pathway with the CA1 projecting back to the 
entorhinal cortex (See Figures 1.4). Subsequently passing through the hippocampus, the 
information to be remembered is stored in the association cortex (Yeckel and Berger 




Figure 1. 4 - Schematic illustration of the unidirectional trisynaptic neural circuitry 
involved for the processing of information processing by the hippocampus. The main 
input to the hippocampus is from the entorhinal cortex that projects to the DG and CA3 
pyramidal neurons via the performant path. CA3 neurons receive input from the DG via 
the mossy fibres. The CA3 projects to the CA1 pyramidal cells via the Schaffer collateral 
pathway. CA1 neurons receive input from the perforant path and project back to the 
entorhinal cortex forming a loop. 
  
The DG granule cell system is considered a competitive learning network that 
removes redundant information to produce a more orthogonal, sparse, and categorised set 
of neural outputs to the CA3 neurons. Consequently, the DG facilitates an effective 
autoassociation process in the pyramidal cells of the CA3 where the learning of non-
related associations are binded as one event (Norman and O'reilly 2003, Gruart, Muñoz et 
al. 2006, Rolls and Kesner 2006). Pattern separation is another key component of the DG, 
where the transformation of relatively similar input patterns into significantly different 
output patterns occur (Bakker, Kirwan et al. 2008). The main inhibitory control of 
granule cell output is provided by gamma-aminobutyric acid (GABA)ergic interneurons, 
that act to balance excitatory and inhibitory neural activity to enable the coordination, 
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separation and accurate transmission of information to the CA3 subregion (Hasselmo, 
Wyble et al. 1996, Duvernoy 2005, Rolls and Kesner 2006, Knierim 2015).  
Although the exact function of the hippocampus in creating successful memories 
is not fully understood, converging evidence from animal models of amnesia (Zola, 
Squire et al. 2000) and neuroimaging studies in humans (Köhler, Moscovitch et al. 2000, 
Heckers, Weiss et al. 2002, Sperling, Chua et al. 2003, Kirwan and Stark 2004, Bray 
2014) have found the hippocampus to play an essential role in the encoding and retrieval 
process of episodic memories. During memory encoding, the hippocampus plays an 
important role in creating new associations between previously unrelated items of 
information into an integrated memory trace that can be subsequently retrieved (Squire 
1992, Eichenbaum, Schoenbaum et al. 1996, Davachi and Wagner 2002, Konkel, Warren 
et al. 2008). The subsequent memory paradigm is an event-related functional magnetic 
resonance imaging (fMRI) method and a powerful tool to identify neural correlates of 
memory that identifies brain activity elicited during episodic memory encoding that is 
associated with successful subsequent memory retrieval. Specifically, the subsequent 
memory effect is a measure of neural activity during memory encoding that is correlated 
with later remembered items. Studies using this approach have provided evidence that the 
hippocampus mediates the relational binding of items into a cohesive memory trace so 
that the event can be later retrieved (Wagner 1998, Davachi and Wagner 2002, Paller and 
Wagner 2002). Furthermore, fMRI investigations have reported robust subsequent 
memory effects in the anterior hippocampal region that include the CA2, CA3 and the 
DG region during encoding of face-name pairs (Sperling, Chua et al. 2003, Zeineh, Engel 
et al. 2003, Fairhall, Sharma et al. 2010) 
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The prefrontal cortex (PFC) 
Episodic memory is associated with a widespread network of brain regions such 
as the MTL and PFC (Cabeza and Nyberg 2006, Eichenbaum, Yonelinas et al. 2007, 
Dickerson and Eichenbaum 2010, Dietsche, Backes et al. 2014). The PFC is strongly 
connected with MTL structures and thought to govern the basic processes of the MTL 
(Spaniol, Davidson et al. 2009). Subregions within the PFC activate cognitive control 
processes that augment memory processes such as the selection and organization of 
information at encoding, directing search at retrieval, and the appraisal of memories to 
ensure they align with task goals (Moscovitch and Winocur 2002, Blumenfeld and 
Ranganath 2007). A meta-analyses investigation demonstrated that both episodic 
encoding, as measured in the subsequent-memory paradigm and retrieval success were 
associated with activation in the parietal, medial-temporal, and prefrontal regions. 
Notably, the ventrolateral PFC and medial-temporal regions were strongly involved 
during memory encoding, whereas the superior parietal and dorsolateral and anterior PFC 
regions were strongly involved in memory retrieval (Spaniol, Davidson et al. 2009). 
1.2.5 Alterations in brain structure and function in MDD 
Structural brain changes in depression 
Alterations in brain structure have been implicated in the pathophysiology of MDD 
(Drevets, Price et al. 2008, Fitzgerald, Laird et al. 2008). Among the MDD literature, 
reduced volume of the PFC and hippocampus are the most consistently reported findings 
(Videbech and Ravnkilde 2004, Hickie, Naismith et al. 2005, McKinnon, Yucel et al. 
2009, Savitz and Drevets 2009). Volumetric reductions in these brain regions have been 
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negatively correlated to both number of depressive episodes and illness duration (Sheline, 
Wang et al. 1996, Sheline, Sanghavi et al. 1999, MacQueen, Campbell et al. 2003, 
Treadway, Waskom et al. 2015). Meta analyses have reported hippocampal volumes to 
be approximately 4-8% smaller in patients with MMD compared to healthy controls 
(Campbell, Marriott et al. 2004, Videbech and Ravnkilde 2004, McKinnon, Yucel et al. 
2009, Cole, Costafreda et al. 2011). Animal models of depression and post-mortem 
studies investigating brain tissue from clinically depressed subjects, have also revealed 
alterations at the neural level, such as dendritic atrophy, reduction in glial numbers, and 
glial densities in both the PFC and the hippocampus (Öngür, Drevets et al. 1998, 
Rajkowska, Miguel-Hidalgo et al. 1999, Sousa, Lukoyanov et al. 2000, Cotter, Mackay et 
al. 2002, Chana, Landau et al. 2003, Stockmeier, Mahajan et al. 2004, Banasr, Dwyer et 
al. 2011). 
Functional alterations in depression 
Considering the large number of studies investigating the structure of the 
hippocampus in MDD, very few neuroimaging studies have investigated the functional 
integrity of the hippocampus in this group during a hippocampal-dependant task. 
Considering also that MDD is associated with attentional bias toward negative emotional 
stimuli and enhanced memory for negative events (Leppänen 2006), there is a shortage of 
studies using emotionally neutral stimuli. As such, it remains unclear as to whether the 
neural dysfunction observed in MDD is one of hippocampal hyperreactivity or 
hyporeactivity. To investigate hippocampal function during the encoding and retrieval 
processes in MDD patients, Werner et al. (2009) used an event-related fMRI subsequent 
memory paradigm of emotionally neutral stimuli. During the encoding phase, participants 
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were instructed to learn several face-occupation associated pairs. During the retrieval 
phase, only the faces from the encoding trials were presented and participants were 
instructed to indicate the occupation that was paired with each face during the learning 
phase. Results showed that MDD patients and healthy controls did not differ in either 
performance or hippocampal activity during the encoding or retrieval of remembered or 
forgotten trials (Werner, Meindl et al. 2009). A similar fMRI subsequent memory 
paradigm examined hippocampal integrity exclusively during the encoding of a neutral 
face-name associative memory task (Fairhall, Sharma et al. 2010). Although groups did 
not differ in performance and there was no main effect of group in the hippocampus, 
researchers observed a distinct activation pattern in the anterior hippocampal region 
during the encoding of successfully remembered items in the healthy controls that was 
absent in those with MDD. Researchers interpreted these findings as a breakdown in 
memory-related hippocampal function (dysregulation) rather than hypo- or 
hyperactivation of the hippocampus. This study also revealed greater activity in the 
intraparietal cortex during successful encoding in MDD patients compared to the healthy 
controls, suggesting MDD  patients used compensatory mechanisms to complete the task 
(Fairhall, Sharma et al. 2010). In agreement with the Fairhall et al. study, Dietsche et al. 
(2014) used an fMRI subsequent memory paradigm of emotionally neutral face-sex pairs. 
Findings revealed both poorer performance and lower levels of hippocampal activity in 
MDD patients during the encoding of remembered items compared to healthy controls. 
Also, the healthy controls showed a strong association between hippocampal and 
parahippocampal activation during memory encoding and subsequent memory 
performance that was absent in the MDD patients.  However, MDD was associated with 
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increased activity in the right inferior frontal gyrus during retrieval, suggesting 
compensatory brain regions were recruited to perform the cognitive task (Dietsche, 
Backes et al. 2014). Compensatory brain mechanisms counteract age-related neural 
decline in which there is a reorganization of neurocognitive networks so that additional 
brain resources are activated to ‘compensate’ for the deficit (Cabeza, Anderson et al. 
2002, Ward 2006, Park and Reuter-Lorenz 2009). Further support for compensatory brain 
mechanisms in MDD are characterized by increased activity in the lateral PFC during the 
n-back working memory task (Harvey, Fossati et al. 2005, Matsuo, Glahn et al. 2007), 
Stroop task  (Banich, Milham et al. 2000, Wagner, Sinsel et al. 2006), delayed match-to-
sample working memory task (Walter, Wolf et al. 2007) and Tower of London planning 
task (Fitzgerald, Srithiran et al. 2008).   
Altogether, MDD is associated with a dysregulation of cognitive neural networks, 
particularly those involved with episodic memory and executive function. However, the 
relationship between MDD and cognitive function remains unclear partly due to the 
heterogeneity across patient samples and study designs. Since many studies fail to assess 
or control for variables such as age, comorbidity, depressive subtype, symptom severity, 
illness duration and medication, and the effects of increased sedentary lifestyles in 
depression, more research is needed to differentiate the effects of each of these variables 
(Snyder 2013). 
1.2.6 Mechanisms associated with depression 
Given the extensive range of symptoms and comorbidities associated with MDD, 
there have been significant challenges for both the diagnosis and development of 
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efficacious therapies. Further, we do not yet understand the pathophysiology of this 
disorder due to the heterogeneous nature and multimodal biological mechanisms shown 
to be associated with the disorder.  
1.2.6.1 Neuroplasticity 
The relationship between the cognitive deficits and structural and functional 
alteration in the hippocampus in MDD remains elusive (Werner, Meindl et al. 2009). The 
animal literature has provided insight to our understanding of both the neuroplastic 
changes that occur within the brain when exposed to stressful environments and the 
biological mechanisms that underlie these changes. The hippocampus is an extremely 
adaptive brain structure that undergoes rapid plasticity at the molecular, cellular, 
structural and functional levels in response to stimuli (DeCarolis and Eisch 2010). A 
remarkable feature of the hippocampus is the ability of the subgranular zone in the DG to 
generate new neurons throughout the lifespan (Gould, Beylin et al. 1999, Ming and Song 
2005, Leuner, Gould et al. 2006). The rodent literature has shown that these newly 
generated cells correlate with  hippocampal-dependent memory performance (Drapeau, 
Mayo et al. 2003) and when neurogenesis is experimentally interrupted hippocampal-
dependent memory becomes impaired (Winocur, Wojtowicz et al. 2006). Animal studies 
have also demonstrated the capacity of hippocampal neurogenesis in altered 
environments. For example, environmental enrichment including increased living space, 
social interaction, and physical activity increase cell proliferation and cell survival time 
for newly generated hippocampal neurons (Gould, Beylin et al. 1999, van Praag, 
Kempermann et al. 1999, Deng, Aimone et al. 2010). On the other hand, rodents that are 
exposed to chronic stress exhibit volumetric reductions of the hippocampus similar to that 
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seen in MDD (Sapolsky 2000, Czéh, Michaelis et al. 2001). At the cellular level, chronic 
stress is associated with a reduction in neurons, neuronal atrophy, dendritic retraction and 
decreased capillary density within the DG (Watanabe, Gould et al. 1992, Czéh, Abumaria 
et al. 2010). Physiologically, chronic stress has also been shown to alter the synaptic 
transmission in the hippocampus while also improving spatial learning and memory 
(Sousa, Lukoyanov et al. 2000).  Synaptic plasticity is displayed by long-term 
potentiation (LTP) that occurs predominately in the hippocampus, and considered to be a 
critical mechanism that facilitates the formation of learning and memory (Bliss and 
Collingridge 1993). Evidence from animals has shown that chronic stress induces a site-
specific suppression of LTP in the medial perforant input to the DG altering the flow of 
information through the trisynaptic circuit of the hippocampus. (Pavlides, Nivón et al. 
2002). 
Dysregulation of hippocampal function and the ability for neuroplasticity partly 
underlie the cognitive impairments observed in MDD. Playing a central role in episodic 
memory, the hippocampus is also a key regulator of PFC function that work 
cooperatively together to regulate explicit memory (Pittenger and Duman 2007). As such, 
disruption of hippocampal function likely contributes to the deficits in executive function 
as previously described. Several cellular and molecular mechanisms that regulate 
different aspects neuroplasticity have also been implicated in pathophysiology of MDD 
and will be further discussed.  
1.2.6.2 The hypothalamic pituitary adrenal (HPA) axis in MDD 
Chronic stress is known to be a strong causal factor in the onset of depression 
(Kendler, Karkowski et al. 1999). Too much stress and increased cortisol is a major risk 
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factor for mental illness such as depression and other psychotic disorders (Brown, 
Varghese et al. 2004, Phillips, McGorry et al. 2006). It has been well established that a 
history of prolonged stressful events predict subsequent depression (Kessler 1997) and 
stressful events are often associated with the onset of MDD (Kendler, Thornton et al. 
2000). 
The stress response is a biochemical cascade of neurochemical reactions triggered 
by the HPA axis that can affect several brain structures and physiological processes (Kim 
and Diamond 2002).  In short, the HPA axis is controlled by the hypothalamic 
paraventricular nucleus (PVN). The PVN synthesizes and releases corticotropin-releasing 
hormone (CTH) and vasopressin (AVP) which triggers the synthesis and release of 
corticotropin hormone (ACTH) from the pituitary which then stimulates the release of the 
glucocorticoids (cortisol in humans and corticosterone in rodents) from the adrenal 
cortex. Under normal conditions, the release of glucocorticoids to their receptors located 
at multiple target sites, initiate an inhibitory response for further release via a negative 
feedback mechanism. The hippocampus has been found to have the highest levels of 
glucocorticoid receptors of any brain structure and lesions on this structure are associated 
with excessive glucocorticoid release (Sapolsky, Krey et al. 1984). Both the hippocampus 
and PFC play an important inhibitory role on the regulation of the HPA axis through 
projections to the hypothalamus (Herman, Ostrander et al. 2005).  
Cortisol is a lipophilic steroid hormone synthesized by the adrenal cortex in 
response to stress. Approximately 80% of cortisol is inactive and bound to cortisol-
binding globulin (CBG) while the remaining 20% is free and biologically active (Le 
Roux, Sivakumaran et al. 2002). Free cortisol enters the saliva through passive diffusion 
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and active transport mechanisms (Vining, McGinley et al. 1983). Research has shown 
that salivary measures of cortisol tend to be more accurate and sensitive to subtle changes 
versus plasma or serum and considered to be a more convenient method in clinical 
populations (Guechot, Fiet et al. 1982, Vining, McGinley et al. 1983, Gozansky, Lynn et 
al. 2005). 
 The main function of cortisol is the stimulation of gluconeogenesis in the liver.  
Cortisol is also an inhibitor of the HPA and pituitary–gonadal axis and known to suppress 
acute inflammatory reactions of the immune system (Kleine and Rossmanith 2016).  
Cortisol secretion follows a distinct circadian rhythm with levels peaking in the early 
morning and lowest in the evening. Within 30 minutes upon awakening, there is a 
dramatic  50-75% increase in cortisol secretion that is referred to as the cortisol 
awakening response (CAR; Wust et al., 2000b). The CAR represents a transition from 
sleep to full alertness that is a reciprocal switching between activation in cortical and sub-
cortical brain regions (Pruessner, Wolf et al. 1997, Balkin, Braun et al. 2002, Clow, 
Thorn et al. 2004).  
The CAR is considered a reliable marker of HPA axis activity as it measures the 
reactivity of the HPA axis in response to the natural challenge of awakening (Clow, 
Thorn et al. 2004). Dysfunction of the HPA axis is characterized by an abnormal CAR in 
often observed in MDD (Stetler and Miller 2005, Adam, Hawkley et al. 2006, Huber, Issa 
et al. 2006). However, the nature of CAR abnormalities observed in MDD have been 
inconsistent with patients showing both an exaggerated CAR (Bhagwagar, Hafizi et al. 
2005, Vreeburg, Hoogendijk et al. 2009) and blunted CAR (Huber, Issa et al. 2006, 
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Hsiao, Yang et al. 2010, Mondelli, Dazzan et al. 2010) when compared to healthy 
controls.   
In healthy individuals, periods of elevated cortisol are beneficial as it redistributes 
energy, to increase ones focus, alertness, and memory to cope with a stressful event 
(Krugers & Hoogenraad, 2009; McEwen & Sapolsky, 1995). However, chronically 
elevated levels of cortisol have deleterious effects on neuroanatomy and cognitive 
function. Chronic elevations of cortisol are a hallmark finding in people with MDD and 
also considered to be a risk factor risk for the onset of MDD  (Davis, Greenblatt et al. 
1987, Newcomer, Selke et al. 1999, Harris, Borsanyi et al. 2000, Sapolsky 2000, Young, 
Carlson et al. 2001, Brown, Varghese et al. 2004, Kim, Song et al. 2006, Krishnan and 
Nestler 2008). Chronically high levels of cortisol have been shown to impair memory 
(Bemelmans, Goekoop et al. 1996, Vythilingam, Vermetten et al. 2004, Hinkelmann, 
Muhtz et al. 2013), attention (Hinkelmann, Moritz et al. 2009), inhibitory control (Bora, 
Harrison et al. 2013), new learning and executive function (O’Brien, Lloyd et al. 2004).  
The animal literature has provided evidence that chronic elevations in 
glucocorticoid concentrations lead to hippocampal degeneration such as, reduced cell 
survival, impaired neurogenesis, neuronal atrophy and impaired neural function 
(McEwen 2000, Sapolsky 2000, Kim and Diamond 2002). Electrophysiological studies 
have revealed that stress-induced elevations in corticosterone suppress synaptic plasticity 
which likely disrupts the flow of information through the trisynaptic circuit. Specifically, 
chronic elevations in corticosterone inhibits LTP in the CA1, CA3 and DG subfields and 
also in the medial performant input to the DG and in the commissural/associational input 
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to the CA3 (Pavlides, Watanabe et al. 1993, McEwen and Sapolsky 1995, Pavlides, 
Nivón et al. 2002). 
The neurotoxic effects of glucocorticoids are linked to impaired glutamate 
clearance via glial resulting in an accumulation of glutamate at the synapse. As a result, 
increases in calcium produce aberrant overactivity of calcium-dependent enzymes and the 
generation of toxic oxygen radicals that eventually lead to neuron death  (Sapolsky 2000, 
Lee, Ogle et al. 2002). Additionally, chronic exposure to high doses of corticosterone has 
been shown to down-regulate BDNF gene expression and protein concentrations in all 
subfields of the hippocampus (Chao and McEwen 1994, Smith, Makino et al. 1995). 
Consequentially, the neuroprotective effects of BDNF on cell metabolism and glutamate 
neurotoxicity becomes diminished, making hippocampal neurons more vulnerable to 
insult. Together these data suggest that chronically elevated cortisol levels have 
deleterious effects on neurogenesis and neural integrity and is a candidate mechanism 
underlying the pathophysiology of MDD (MacQueen, Campbell et al. 2003, Belmaker 
and Agam 2008, Dedovic, Engert et al. 2010, Mondelli, Pariante et al. 2010).  
1.2.6.3 Cytokines 
Early research on depression, neurodegeneration and cognitive function mainly 
focused on the neurotoxic effects of elevated glucocorticoids. More recently, MDD has 
been linked to a dysregulated immune system that is characterized by a chronic 
inflammatory state (Schiepers, Wichers et al. 2005). The ‘inflammatory response system’ 
model of major depression (Maes 1999), the ‘macrophage theory of depression’(Smith 
1991) and the ‘cytokine hypothesis of depression’ (Yirmiya, Weidenfeld et al. 1999) all 
imply that MDD is a psychoneuroimmunological condition in which peripheral immune 
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activation, via the release of proinflammatory cytokines, underlies the various 
behavioural and neurophysiological alterations that are associated with this disorder 
(Schiepers, Wichers et al. 2005).  
As a component of the innate immune response, cytokines are a large and 
heterogeneous group of pleiotropic proteins that are the body’s first line defence 
mechanism against tissue injury, pathogen invasion or antigenic stimulation. Released by 
macrophages and lymphocytes, especially helper T cells, and a variety of non-immune 
tissues, cytokines function as intercellular signalling mechanisms that regulate immune 
response. Cytokines can produce an autocrine action by affecting the cells that releases 
them, a paracrine action by affecting nearby cells or an endocrine action by affecting 
distant cells. Through receptor binding, cytokines can produce an array of responses, 
depending on the cytokine and target cell. Cytokines are grouped into two broad classes 
based on their effects on the immune response, although some can be considered both 
pro- and anti-inflammatory such as interleukin (IL)-6. Pro-inflammatory cytokines are 
released at the site of injury or infection and trigger a cytotoxic inflammatory response by 
attracting a host of other immune cells such as monocytes, neutrophils, and also acute-
phase proteins. Anti-inflammatory cytokines attentuate inflammatory processes by 
inhibiting that activity of immune cells, such as replication, activation, and synthesis of 
other cytokines (Robles, Glaser et al. 2005, Schiepers, Wichers et al. 2005, Duque and 
Descoteaux 2014).  
Peripheral cytokines are reasonably large hydophilic molecules that do not freely 
pass through the blood-brain barrier (BBB). The animal research has demonstrated that 
cytokines in the circulation can enter the brain parenchyma via several pathways such as 
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activation of the vagus nerve, a leaky BBB, active transport, or binding to the surface of  
endothelial cells (Dantzer, O'Connor et al. 2008, Miller, Maletic et al. 2009, Raison, 
Borisov et al. 2009, Loftis, Huckans et al. 2010). Once entering the brain parenchyma, 
peripheral cytokines are able to bind to cytokine receptors on the surface of various cells, 
including microglia, astrocytes and neurons. In addition to entry from the periphery, 
cytokines including IL-1β, IL-6 and tumor necrosis factor alpha (TNF-α), and their 
receptors, are constitutively released in the CNS, primarily by astrocytes and microglia 
and sometimes neurons (Maier and Watkins 1998, Schiepers, Wichers et al. 2005). Brain 
regions that produce and release cytokines include the circumventricular regions, 
hypothalamus, hippocampus, cerebellum, forebrain regions, basal ganglia, and the 
brainstem nuclei (Anisman and Merali 2002). Pro-inflammatory cytokines have complex 
and contrasting functional roles in the CNS (Miller, Maletic et al. 2009). Under normal 
conditions, IL-1β, IL-6, and TNF-α are important for providing trophic support to 
neurons, promoting neurogenesis and synaptic plasticity (Maier and Watkins 1998, 
Miller, Maletic et al. 2009). However, when there is excessive and/or prolonged 
activation, cytokine networks within the CNS disrupt the brain parenchyma (Miller, 
Maletic et al. 2009). Within the CNS, microglial cells play a similar role as macrophages 
do in pheripheral tissue being the brains first line defense mechanism against pathogens 
or injury (Tilleux and Hermans 2007). Animal experiments that use direct exposure to the 
bacterial endotoxin lipopolysaccharide (LPS) to induce neuroinflammation have shown a 
robust microglial activation and release of  TNF-α, IL-1β, and interferon gamma (IFN-γ). 
Elevations of hippocampal TNF-α and IL-1β, are associated with a down-regulation of 
BDNF expression and its receptor tyrosine kinase-B (TrkB), as well as reduced 
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hippocampal neurogenesis (Wu, Chen et al. 2007). Additionally pro-inflammatory 
cytokines, notably TNF- α and IL-1β, potentiate glutamate excitotoxicity through 
inhibition of glutamate uptake by astrocytes (Tilleux and Hermans 2007). However, 
blocking glutamate receptors with a N-methyl-D-aspartate (NMDA) receptor antagonist 
has been shown to protect neurons against neuroinflammatory insult (Willard, Hauss-
Wegrzyniak et al. 2000). 
MDD is highly prevalent in patients suffering from  neurodegenerative, 
autoimmune, and infectious diseases (Pollak and Yirmiya 2002, Rook and Lowry 2008). 
Evidence from experimental models that assess the acute immune response to infection in 
humans via administration of the endotoxin LPS, have shown increases in pro-
inflammatory cytokines produce behavioural symptoms similar to those found in MDD 
(Reichenberg, Yirmiya et al. 2001, Dantzer, O'Connor et al. 2008, Harrison, Brydon et al. 
2009, Eisenberger, Inagaki et al. 2010, Loftis, Huckans et al. 2010, Haroon, Raison et al. 
2011). A dose-response effect has also been observed, in which higher pro-inflammatory 
concentrations produce greater depression severity (Miller, Maletic et al. 2009, Janssen, 
Caniato et al. 2010). Exogenous cytokine administration in patients undergoing long-term 
cytokine therapy have shown to produce depression-like symptoms. For instance, up to 
50% of patients receiving chronic IFN-α therapy for the treatment of infectious diseases 
or cancer subsequently develop clinical case of depression (Musselman, Lawson et al. 
2001, Capuron, Raison et al. 2003, Asnis and De La Garza 2006).  
Psychological stressors can activate immune cells in both the periphery and CNS 
that lead to neurochemical and behavioural changes (Maier and Watkins 1998). The 
depression-cytokine literature has identified IL-1β, IL-6, IFN-γ and TNF-α to be the most 
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reliable peripheral pro-inflammatory biomarkers in MDD (Mössner, Mikova et al. 2007). 
A meta-analyses that examined pro-inflammatory cytokines in MDD patients revealed 
that peripheral TNF-α, IL-6, and IL-1β concentrations were all significantly elevated 
during the initial diagnosis phase (Howren, Lamkin et al. 2009, Dowlati, Herrmann et al. 
2010). Post-mortem studies in depressed individuals who committed suicide have 
revealed increased IL-6 concentration in cerebrospinal fluid compared to non-depressed 
individuals (Lindqvist, Janelidze et al. 2009). Studies have also shown the ratio of pro- to 
anti-inflammatory cytokines also to be altered in MDD (Dhabhar, Burke et al. 2009). 
Decreased concentrations of the immunomodulatory/anti-inflammatory IL-10 cytokine 
and a higher IL-6/IL-10 ratio prevent the counterbalancing role of IL-10 in response to 
increasing IL-6 concentrations. Consequently, lower IL-10 concentrations are not able to 
dampen the pro-inflammatory cytokine actions of IL-6 and resolve inflammation 
(Dhabhar, Burke et al. 2009). 
Poor sleep quality is a frequently reported symptom of MDD and has been 
suggested to be a strong inducer of neuroinflammation (Bryant, Trinder et al. 2004). 
Sleep disturbance in non-depressed individuals is associated increased peripheral 
concentration of IL-6, and TNF-α, when compared to periods of uninterrupted sleep 
(Vgontzas, Zoumakis et al. 2004, Irwin, Wang et al. 2006, Irwin, Olmstead et al. 2016). 
Although there has been no study that has systematically evaluated whether elevated 
levels of pro-inflammatory cytokines mediate the relationship between poor sleep quality 




The pro-inflammatory signalling network is intricately connected with the HPA 
axis. Under normal conditions, glucocorticoids exert anti-inflammatory actions by 
increasing anti-inflammatory cytokine concentrations and decreasing pro-inflammatory 
cytokine concentrations. However, during episodes of chronic stress, pro-inflammatory 
cytokines disrupt glucocorticoid signalling and the negative feedback regulation of the 
HPA axis, which in turn exacerbates pro-inflammatory cytokine activity increasing the 
risk for depression (Kim, Na et al. 2016). Particularly, IL-1β, IL-6, TNF- α and IFN- γ 
increase HPA axis activity and the release of glucocorticoids (Song 2002, O'Brien, Scott 
et al. 2004, Hayley, Poulter et al. 2005, Schiepers, Wichers et al. 2005, Dantzer, 
O'Connor et al. 2008).  Moreover, chronic administration of IFN-α in humans has been 
associated with an increase in cortisol concentrations and flattening of the diurnal cortisol 
slope that was also associated with depressive behaviours (Raison, Borisov et al. 2008).  
Normally, pro-inflammatory cytokines play an important role in providing 
neurotrophic support to neurons, augmenting neuroplasticity and contributing to 
hippocampal-dependent memory processes (Goshen, Kreisel et al. 2007b, Bernardino, 
Agasse et al. 2008). However, the literature has shown that during episodes of excessive 
and/or prolonged activation, cytokine networks within the CNS can induce an 
interconnected cascade of neuroplastic abnormalities underlying the pathophysiology of 
MDD, such as decreased neurotrophic support, decreased neurogenesis, cellular apoptosis 
and impaired cognitive function (Hayley, Poulter et al. 2005, Miller, Maletic et al. 2009, 
Dowlati, Herrmann et al. 2010). The animal literature has shown that both exogenous and 
endogenous (chronic stress models) increases in hippocampal IL-1β in the DG and CA 
subfields result in impaired hippocampal-dependent memory, impaired LTP,  reductions 
32 
 
in cell proliferation and increased cell atrophy (Vereker, Campbell et al. 2000, Song 
2002, Avital, Goshen et al. 2003, Barrientos, Higgins et al. 2006, Goshen, Kreisel et al. 
2007a, Hennigan, Trotter et al. 2007, Pickering and O’Connor 2007, Chen, Buchanan et 
al. 2008). Studies using in vivo and in vitro methodologies have provided evidence that 
depressive-like behaviours and decreases in cell proliferation through activation of IL-1β 
signalling in the hippocampus are mediated via activation of the nuclear factor kappa-
light-chain-enhancer of activated B cells (NF- κB) signalling pathway. Researchers have 
also demonstrated that administration of the IL-1β receptor antagonist (ra), IL-1ra, 
decreases NF- κB signalling and blocks the antineurogenic and antiproliferative actions 
of chronic stress (Koo and Duman 2008, Koo, Russo et al. 2010).  
1.2.6.4 Brain-derived neurotrophic factor (BDNF) 
BDNF is a polypeptide that is a member of the neurotrophin family of growth 
factors. It is broadly expressed in the mammalian brain, with high concentrations in the 
hippocampus (Poo 2001). BDNF is also produced in peripheral tissues including skeletal 
muscle and adipose tissue and is able to cross the blood-brain barrier (BBB) by a high-
capacity, saturable transport system (Pan, Banks et al. 1998, Poo 2001, Klein, Williamson 
et al. 2011b). Known for its neuroprotective effects, BDNF promotes growth and 
development of dopaminergic, GABAergic, cholinergic, and serotonergic neurons and 
plays a critical role in a variety of neural processes including cell proliferation, neuronal 
survival, neurogenesis and synaptic plasticity (Poo 2001, Monteggia, Barrot et al. 2004, 
Autry and Monteggia 2012). BDNF also exerts excitoprotective effects that suppress 
glutamate-induced neurotoxicity via the activation of signalling pathways that induce the 
expression of antioxidant enzymes, anti-apoptotic proteins, and apoptosis inhibitor 
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proteins (Mattson 2008). The BDNF protein is synthesized as a pre-pro BDNF precursor 
that is cleaved into pro-BDNF, and subsequently cleaved into its mature form (Lessmann, 
Gottmann et al. 2003). The conversion of pro-BDNF to mature BDNF is not an effective 
process leaving a large portion of intracellular pro-BDNF uncleaved and active in the 
CNS (Lessmann, Gottmann et al. 2003). Activating different signalling pathways that 
induce opposing effects, pro-BDNF binds to its low-affinity neurotropin receptor p75NTR 
that promotes cell death whereas mature BDNF binds to its high-affinity TrkB receptor 
that promotes neural growth and survival (Roux and Barker 2002, Lu, Pang et al. 2005). 
Being an activity-dependent protein, BDNF expression is sensitive to electrical activity 
and regulated by neuronal activity via non-NMDA glutamate receptors (Zafra, Hengerer 
et al. 1990, Poo 2001). BDNF acts at both excitatory and inhibitory synapses and is 
known to facilitate LTP through the conversion of early LTP to late LTP and by 
enhancing subthreshold neural activity to elicit LTP (Autry and Monteggia 2012). The 
BDNF gene and its protein have been extensively studied and BDNF activity is 
considered a strong candidate mechanism underlying neurodegenerative and psychiatric 
disorders such as MDD. 
Several studies have shown reduced peripheral BDNF concentrations in people 
with MDD (Shimizu, Hashimoto et al. 2003, Karege, Vaudan et al. 2005a, Lee, Kim et al. 
2007, Brunoni, Lopes et al. 2008, Bocchio-Chiavetto, Bagnardi et al. 2010) with greater 
reductions in those who are more severely depressed (Shimizu, Hashimoto et al. 2003). 
Findings from post-mortem tissue studies in depressed suicide victims have revealed 
reduced levels of BDNF and its main receptor TrkB in regions of the hippocampus and 
PFC when compared to tissues from non-suicide controls (Karege, Vaudan et al. 2005a, 
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Ray, Weickert et al. 2011). Several studies have shown reduced BDNF concentrations in 
MDD patients that can be normalized by successful ADM treatment (Karege, Vaudan et 
al. 2005b, Piccinni, Marazziti et al. 2008). The relationship between circulating BDNF 
concentrations and brain structure and function has also been investigated in non-
depressed populations. In elderly adults, lower BDNF concentrations are associated with 
reductions in hippocampal and white matter volume (Erickson, Prakash et al. 2009, 
Driscoll, Martin et al. 2012), poorer memory (Li, Peskind et al. 2009), poorer 
neuropsychological function (Gunstad, Benitez et al. 2008) and faster age-related 
cognitive decline (Laske, Stellos et al. 2011). Compared to healthy controls, lower BDNF 
concentrations correlate with cognitive deficits in schizophrenic patients (Carlino, Leone 
et al. 2011, Zhang, Liang et al. 2012) and in patients with type 2 diabetes (Zhen, Zhang et 
al. 2013). 
The pro-neurogenic effects of BDNF have been consistently demonstrated in the 
animal literature. A single, unilateral infusion of BDNF in the rat DG, induces LTP of the 
medial perforant path, upregulates bilateral hippocampal neurogenesis and produces rapid 
antidepressant effects similar in magnitude with repeated systemic administration of 
antidepressant agents (Shirayama, Chen et al. 2002, Scharfman, Goodman et al. 2005, 
Kuipers, Trentani et al. 2016). In contrast, blockade of hippocampal BDNF signalling, 
has been shown to inhibit LTP, decrease neurogenesis, increase depressive behaviour and 
impair learning and memory (Korte, Carroll et al. 1995, Shirayama, Chen et al. 2002, 
Heldt, Stanek et al. 2007).  
Several lines of evidence suggest there to be a more complex association for 
BDNF-driven neuroplasticity that is based on the imbalance between mature BDNF-TrkB 
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receptor signalling and pro-BDNF- p75NTR receptor signalling (Castrén and Rantamäki 
2010). For instance, activation of the pro-BDNF - p75NTR receptor signalling pathway has 
been shown to induce neuronal atrophy, dendritic pruning, apoptosis and the induction of 
LTD. As such, excessive pro-BDNF- p75NTR receptor signalling has been suggested to 
underlie several neurodegenerative and psychiatric conditions such as MDD (Lu, Pang et 
al. 2005, Martinowich, Manji et al. 2007, Yang, Je et al. 2009). In support of this 
hypothesis, post-mortem evidence has revealed increased levels of p75NTR in the brain 
tissue of depressed suicide subjects versus non-suicide controls (Dwivedi, Rizavi et al. 
2009). Research has indicated that reduced BDNF-TrkB signalling pathway activity is 
associated with MDD may be partly mediated by sequence variations within the BDNF 
gene. A single nucleotide polymorphism (SNP) has been identified in the BDNF 
prodomain region that leads to a nucleotide change from a guanine to adenine producing 
a valine (Val) to methionine (Met) substitution at codon 66 (val66met) that dramatically 
alters the intracellular trafficking and packaging of BDNF (Egan, Kojima et al. 2003). 
The in vitro data has shown that the val66met substitution affects the activity-dependent 
secretion of BDNF and the met BDNF protein cannot be secreted at synapses that may 
impede local and synapse-specific regulation by BDNF leading to impairments in 
hippocampal function (Egan, Kojima et al. 2003). Thus, the Met allele has been 
associated with impaired episodic memory, reduced hippocampal volume and abnormal 
hippocampal activation (Bueller, Aftab et al. 2006, Hajek, Kopecek et al. 2012, 
Kambeitz, Bhattacharyya et al. 2012). However, the relationship between the val66met 
genotype and MDD remains unclear as some studies have reported a relationship (Frodl, 
Schüle et al. 2007, Colle, Trabado et al. 2017) whereas others have not found a 
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relationship (Lang, Hellweg et al. 2005, Domschke, Lawford et al. 2010, Verhagen, Van 
Der Meij et al. 2010).  
Taken together, the literature has consistently reported that BDNF expression is 
attentuated in MDD and shown to increase in response to ADM (Shimizu, Hashimoto et 
al. 2003). As such, many researchers have focused on BDNF as a “biomarker” in MDD 
and as a candidate mechanism underlying treatment response. 
1.2.7 Current therapies for depression 
To determine whether an antidepressant treatment has been effective, a set of 
criteria defining specific change points during the course of depressive illness has been 
established. Achieving a state of remission is the desired outcome for all antidepressant 
treatments. Remission is determined once a patient reaches a specific cut-off score as 
indicated by the depression rating scale and is characterized by the absence of depressive 
symptoms (Frank, Prien et al. 1991, Rush, Kraemer et al. 2006, Shelton 2006). A 
therapeutic response is a useful indicator that determines whether a patient is responding 
to treatment. Response is defined as a > 50% improvement from the baseline score on a 
recognized rating scale for depression, however, the patient is still experiencing 
depressive symptoms (Rush, Kraemer et al. 2006, Shelton 2006). These universal 
definitions also allow researchers to make cross-study comparisons enabling the abil 
evaluate the efficacy of antidepressants therapies. 
The first-line treatment recommendations for MDD include antidepressant 
monotherapy, psychotherapy, and the combination of both (Davidson 2010). In very 
severe cases, or in treatment-resistant MDD, the use of electroconvulsive therapy (ECT) 
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may be recommended. Despite high remission rates, ECT is associated with significant 
cognitive impairments and up to 50% of patients have a subsequent MDE relapse within 
6 months following treatment (Fava and Kendler 2000, Davidson 2010, Prudic, Haskett 
et al. 2013). As such, ECT is considered a last-resort treatment option. Even with the 
availability of many pharmacological agents and psychological interventions, there are 
wide variations in the efficacy and tolerability of treatments that leaves many individuals 
undertreated (Shelton 2006). 
Selective serotonin uptake inhibitors (SSRIs) are the most frequently prescribed 
therapeutic class of antidepressant agents. SSRIs target the monoamine neurotransmitter 
systems to increase signalling at the synapse through increased levels of extracellular 
serotonin, 5-Hydroxytryptophan (5-HT) in the synaptic cleft via the blockade of the 
serotonin transporter (5-HTT) on the presynaptic nerve terminals (Vaswani, Linda et al. 
2003). Fundamentally, SSRIs affect the potentiation of 5-HT by the inhibition of its 
neuronal uptake pump. Although SSRIs have rapid immediate synaptic effects they are 
associated with delayed onset of clinical efficacy (Autry and Monteggia 2012) suggesting 
the primary mechanism of action is not antagonism of 5-HT reuptake but likely the 
substrates, receptors and pathways for 5-HT that underlie its therapeutic actions 
(Vaswani, Linda et al. 2003). The onset of action time for SSRI therapy is approximately 
2 to 3 weeks (Blier and De Montigny 1994). Therefore, any immediate therapeutic effects 
have been ascribed to a placebo effect (Quitkin, Rabkin et al. 1987). However many 
patients undergoing SSRI therapy experience immediate unwanted side effects such as 
movement disorders, sexual dysfunction, headache, poor sleep, anorexia and nausea 
causing them to prematurely discontinue treatment (Vaswani, Linda et al. 2003).  
38 
 
CBT is also a first-line treatment for MDD that is often prescribed in combination 
with ADM or when ADM is contraindicated (Alexopoulos 2005, Shelton 2006). CBT 
focuses on identifying and changing maladaptive, dysfunctional thoughts and behaviours 
while engaging in enjoyable social activities. Cognitive and behavioural strategies teach 
the patient to monitor negative thoughts; recognize the links between cognition, mood 
and behaviour; assess previous experience for and against distorted automatic thoughts; 
substitute rational interpretations for biased cognitions and gather data to disprove 
dysfunctional beliefs (Beck 1979). Initially, a functional analysis is conducted to 
establish the features of the abnormal behaviours, emotions, and cognitions, as well as 
their functional relationships with each other (Arch and Craske 2009). The contribution 
of environmental and cultural factors to these relationships is also evaluated in order to 
elucidate the variables that underlie a specific problem (Arch and Craske 2009). This 
functional analysis then guides the therapist to develop an appropriate treatment 
approach. CBT interventions often consist of self-monitoring, psychoeducation, muscle 
relaxation, cognitive restructuring, activity scheduling, self-control techniques, social 
skills training, stress management and problem solving (Jarrett and John Rush 1994, Arch 
and Craske 2009). CBT as an add-on treatment to ADM has been shown to increase the 
rates of remission compared to ADM alone, with the greatest effects in those with more 
severe MDD (Hollon, DeRubeis et al. 2014) . A meta-analysis of randomized trials 
examined the effects of treatment with ADM combined with CBT and ADM 
monotherapy in with MDD and comorbid anxiety. Researchers found a moderately large 
effect, Hedges' g = 0.43, that favoured a combined treatment approach for MDD. 
(Cuijpers, Sijbrandij et al. 2014).  
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The efficacy of CBT and SSRI therapy are comparable, with less than 50% of 
MDD patients who achieve remission (Thase, Entsuah et al. 2001, DeRubeis, Hollon et 
al. 2005, Thase, Haight et al. 2005). Consequently, more than 50% of patients continue to 
experience symptoms and are functionally impaired (Fava and Davidson 1996). This 
large portion of nonresponders imposes a significant challenge to healthcare practitioners, 
who must seek out additional therapeutic options in over half of their patients to achieve 
a therapeutic response (Rush and Trivedi 1995). 
1.2.8 Effects of exercise 
Exercise for the treatment of depression is a common research theme. Many 
studies have reported higher levels of cardiorespiratory fitness and increased habitual 
physical activity being associated with lower depressive symptomatology and greater 
emotional well-being (Martinsen 1990, Galper, Trivedi et al. 2006, Boettger, Wetzig et 
al. 2009, Kelley and Kelley 2012), whereas low levels of cardiorespiratory fitness being 
linked with an increased risk of developing MDD (Åberg, Waern et al. 2012). Exercise 
alone or in combination with other conventional treatments, such as pharmacotherapy or 
cognitive behavioural therapy have all been effective in alleviating depressive symptoms 
with response and remission rates for exercise being comparable to these first-line 
therapies (Martinsen, Medhus et al. 1985, Blumenthal, Babyak et al. 1999, Babyak, 
Blumenthal et al. 2000, Stathopoulou, Powers et al. 2006, Blumenthal, Babyak et al. 
2007, Perraton, Kumar et al. 2010). Exercise has also been shown to improve cognitive 
function (Khatri et al., 2001) and sleep quality (Rethorst, Sunderajan et al. 2013) which 
are the two of the most frequently reported residual symptoms among patients with MDD 
who achieve remission (Conradi, Ormel, & de Jonge, 2011). 
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The beneficial effects of exercise on overall brain health have also been observed 
in non-depressed populations. In elderly adults with dementia, exercise has been shown 
to slow disease progression (Stevens and Killeen 2006) and improve overall cognitive 
function (Heyn, Abreu et al. 2004, Ahlskog, Geda et al. 2011). In non-demented elderly 
populations, aerobic exercise protects against the development of neurodegenerative 
diseases (Ahlskog, Geda et al. 2011), improves memory performance (Erickson et al., 
2011; Voss et al., 2013) and executive function (Voss et al., 2010). Neuroimaging studies 
have also demonstrated the effects of exercise on brain structure and function. In 
schizophrenics, a three month aerobic exercise intervention increased hippocampal 
volume by 12% that was positively correlated with fitness, and also improved short-term 
memory that was positively correlated with change in hippocampal volume (Pajonk, 
Wobrock et al. 2010). In aging populations, an aerobic exercise intervention reverses age 
associated brain volume loss (Colcombe et al., 2006; Erickson et al., 2009) and increases 
task-related activity in attentional control regions such as the superior frontal gyrus, 
middle frontal gyrus and the superior parietal lobe (Colcombe, Kramer et al. 2004). More 
recently, an fMRI study showed that a six month aerobic exercise intervention increased 
neural specificity, the degree to which neural representations of different stimuli can be 
distinguished, and that changes in neural plasticity were positively correlated with 
changes in fitness (Kleemeyer, Polk et al. 2017). Another recent fMRI study showed that 
a six month aerobic exercise intervention decreased neural activity in the left lateral 
occipital cortex and right superior temporal gyrus that was associated with improved 
executive function during a flanker task (Hsu, Best et al. 2017).  
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The effects of exercise on neural structure and function have been demonstrated 
in the animal literature. In rodents, long-term exercise increases cell proliferation and 
neurogenesis in the DG (van Praag, Kempermann et al. 1999, Pereira, Huddleston et al. 
2007), increases dendritic spine synapses in granule cells of the DG and the stratum 
radiatum of the CA1 region (Dietrich, Andrews et al. 2008), induces the formation of 
new blood vessels (Lopez-Lopez, LeRoith et al. 2004), and improves dendritic 
morphology in the hippocampus (Redila and Christie 2006, Yau, Lau et al. 2011). 
Exercise has also been shown to enhance learning and memory on tasks mediated by the 
hippocampus including the Morris Water maze task (Adlard, Perreau et al. 2004, 
Vaynman, Ying et al. 2004, Van Praag, Shubert et al. 2005) and reduce depressive-like 
symptoms when exposed to chronic stress (Solberg, Horton et al. 1999, Sigwalt, Budde et 
al. 2011, Patki, Li et al. 2014). 
The neurogenic effects of exercise are partly mediated by an increase in cerebral 
blood volume in the DG that facilitates an interactive cascade of growth factor signalling 
essential for neuroplasticity (Cotman, Berchtold et al. 2007, Pereira, Huddleston et al. 
2007, Hillman, Erickson et al. 2008, Davenport, Hogan et al. 2012). Increased levels of 
BDNF, insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor 
(VEGF) have all been associated with long-term exercise and suggested to underlie the 
neurogenic effects of exercise (Fabel, Fabel et al. 2003, Lopez-Lopez, LeRoith et al. 
2004, Hillman, Erickson et al. 2008). Rodent studies have shown that blockade of BDNF, 
IGF-1 and VEGF abrogates the exercise-induced increase in newborn granule cells, 
angiogenic and anti-depressant effects in exercised animals (Fabel, Fabel et al. 2003, 
Lopez-Lopez, LeRoith et al. 2004, Rossi, Angelucci et al. 2006, Kiuchi, Lee et al. 2012).  
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In humans, the effects of exercise on growth factors is less clear and far less 
investigated. Part of the reason is the ambiguity over whether peripheral growth factor 
concentrations represent those in brain-tissue. Of the growth factors that have been linked 
to neuroplasticity, BDNF has received the most attention.  An eloquent study conducted 
in pigs, has recently shown that measures of blood and plasma BDNF concentrations 
reflect BDNF concentrations in the hippocampus (Klein, Williamson et al. 2011a). 
Human studies have consistently shown increased peripheral BDNF concentrations 
following a single bout of acute aerobic exercise in both healthy individuals (Ferris, 
Williams et al. 2007, Dinoff, Herrmann et al. 2017, Håkansson, Ledreux et al. 2017) and 
individuals with MDD. However, the long-term effects of exercise on resting BDNF 
concentrations have been mixed and remain unclear (Huang, Larsen et al. 2014). For 
instance, a study investigated the effects of a five-week aerobic activity on resting serum 
BDNF concentrations in young and healthy adults. Researchers also compared resting 
serum BDNF concentrations in trained athletes and untrained adults. Trained athletes 
showed significantly higher BDNF concentrations than their untrained counterparts, and 
exercise significantly increased resting BDNF concentrations in the untrained participants 
(Zoladz, Pilc et al. 2008). A recent study investigated effects of a four-week exercise 
invention in patients suffering from MDD. All participants were medicated with SSRI 
agents at study enrolment. Patients performed aerobic exercise on a treadmill for 45 
minutes, three times per week. Result showed a significant decrease in depression 
severity and a significant increase in plasma BDNF concentrations at four weeks (Salehi, 
Hosseini et al. 2016). In contrast, the Treatment with Exercise Augmentation for 
Depression (TREAD) study investigated a dosed aerobic exercise intervention in partial 
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responders to antidepressant medication. Depressed participants were randomized to 
either a high (16 kcal/kg/week) or low (4 kcal/kg/week) energy expenditure exercise for a 
duration of 12 weeks. Resting serum BDNF concentrations were quantified at baseline 
and at 12 weeks. Findings revealed no change in serum BDNF concentrations at 12 
weeks for either group. The authors concluded that participants entered the study with 
resting BDNF levels that may have been already normalized by SSRI treatment (Toups, 
Greer et al. 2011a). Similar results have been recently reported from a study that 
investigated the effects of a 12-week supervised exercise intervention on non-medicated 
individuals with mild to moderate depression. Participants performed three 45-minute 
aerobic sessions per week at an intensity of 80% of their maximal HR. Despite a 
significant increase in fitness, no change in serum BDNF, IGF-1 or VEGF concentrations 
were observed at 12 weeks (Krogh, Rostrup et al. 2014). Taken together, it remains 
difficult to understand the relationship between exercise, BDNF and depression. One 
possible explanation may be the methodology difference in measuring plasma versus 
serum BDNF concentrations across studies. Animal research has shown that plasma 
BDNF concentrations reflects hippocampal BDNF concentrations while there is no 
relationship with serum BDNF (Karege, Schwald et al. 2002, Klein, Williamson et al. 
2011a). Although the origin of BDNF in blood is not entirely clear, research has 
demonstrated that the brain is the main contributor to peripheral BDNF concentrations 
during exercise and therefore plasma measures may be more accurate (Rasmussen, 
Brassard et al. 2009).  
Regular exercise has also been shown to reduce systemic inflammation in other 
pathological conditions such as cardiovascular disease and Type 2 diabetes mellitus 
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(Balducci et al., 2010; Meirelles et al., 2014; Pedersen, 2006). Such studies have reported 
a simultaneous increase in the systemic levels of cytokines with anti-inflammatory 
properties including IL-10, IL-1ra and a decrease in the pro-inflammatory cytokines IL-6 
and TNF-α (Júnior, Lopes, Seelaender, & Lopes, 2009; Petersen & Pedersen, 2007). 
 The anti-inflammatory effects of long-term exercise may be partly mediated by 
muscle-derived IL-6. The immune response to exercise contrasts the response that is 
produced by severe infections. IL-6 is considered both a pro- and anti-inflammatory 
cytokine that is released in the circulation by contracting skeletal muscle during exercise. 
During acute exercise, circulatory levels of IL-6 increase up to 100-fold and then decline 
in the postexercise period (Pedersen, Steensberg et al. 2001, Suzuki, Nakaji et al. 2002, 
Petersen and Pedersen 2007). Once released in the circulation, IL-6 is linked to increased 
production of anti-inflammatory cytokines IL-1ra and IL-10 and decreased production of 
the proinflammatory cytokine TNF-α (Mizuhara, O'Neill et al. 1994, Petersen and 
Pedersen 2005). Unlike IL-6 signalling in monocytes or macrophages, which trigger the 
activation of NFκB signalling pathways, intramuscular IL-6 expression induces a cascade 
of signalling networks including the nuclear factor of activated T-cells (NFTA) and 
mitogen activated protein kinase (MAPK) pathways creating an anti-inflammatory 
response (Brandt and Pedersen 2010). Nonetheless, the literature examining the 
relationship between exercise and inflammatory markers in MDD populations is limited.  
More recently, Moon et al., (2016) identified a novel protein that may play a key 
role in the beneficial effects of exercise on neural function.  Cathepsin B (CTHB), a 
cysteine proteinase produced by contracting skeletal muscle, is capable of penetrating the 
blood-brain barrier and upregulating both BDNF expression and hippocampal 
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neurogenesis in wild-type mice (Moon et al., 2016). Following long-term running, 
researchers observed an increase in plasma CTHB concentrations associated with 
improved memory performance in mice, Rhesus monkeys and humans. CTHB is an 
autophagy-related protein also shown to prevent memory deficits in Alzheimer’s disease 
by upregulating autophagic-lysosomal processes and reducing accumulations of amyloid-
β peptides in the brain (Mueller-Steiner et al., 2006; Yang et al., 2011). However, the role 
of CTHB  in neuroplastic processes requires further investigation. 
Finally, the inconsistent findings among studies may be a result of the 
heterogeneous nature of the exercise interventions. For instance, not all studies define 
exercise prescription variables such as the type, frequency, intensity and duration of the 
exercise (Lee 2007). There is also a wide range of methods that report the quantity and 
intensity of exercise in various ways making it difficult to interpret findings. Although 
many studies provide a general description of the exercise intervention such as the type, 
frequency, and duration of the exercise, the majority of studies do not provide 
information as to whether intensity was maintained throughout the exercise session. For 
instance, many exercise interventions are based on self-reported feedback from 
participants to ensure they fulfilled the exercise prescription while others are supervised 






The literature has shown MDD to be a severely undertreated disorder in the 
primary care setting. Current treatments for MDD are far from satisfactory warranting the 
the need for more efficacious treatment options. MDD is a heterogeneous disorder both 
clinically and biologically. In addition to low mood, MDD is associated with cognitive 
impairments that persist beyond the remissive and recovery period. Structural and 
functional neuroimaging studies have implicated abnormalities in the hippocampal region 
to underlie the memory impairments observed in MDD. Studies have shown that MDD is 
associated with abnormal HPA axis functioning, lower levels of BDNF and increased 
levels of inflammation, which have been shown to attenuate neuroplasticity within the 
hippocampus. 
Converging evidence from animals and non-depressed human studies have shown 
that exercise targets mechanisms suggested to underlie MDD. The animal literature has 
consistently shown exercise to enhance neuroplasticity in the hippocampus. These 
findings suggest that the underlying mechanism involved in the etiology and 
pathogenesis of MDD may be confounded by physical activity and fitness variables that 
are often not reported in the MDD literature. 
In humans, the effects of exercise on cognitive performance and mechanisms 
underlying cognitive function are mixed. The inconsistent findings among studies may be 
a result of the heterogeneous nature of the exercise interventions. Not all studies define 
exercise prescription variables and there is a wide range of methods that report the 
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quantity and intensity of exercise. Many exercise interventions are based on self-reported 
feedback and very few are supervised by an exercise professional.  
The vast majority of findings from the exercise-cognition literature comes from 
elderly adults or those with age-associated neurodegenerative diseases. As such, there is a 
gap in the literature demonstrating the effects of exercise on brain function in young and 
healthy adults. This makes it difficult to determine the magnitude of effect of exercise on 
cognitive function and mechanisms associated with cognitive function before the onset 
on any age-related neurodegeneration or psychiatric illness. 
Exercise is an effective treatment option in MDD, but its mechanism of action 
remains unknown. The ‘typical’ MDD patient seen in the primary care setting is treated 
with ADM and/or psychotherapy. To date, there are no studies that have used a multi-
disciplinary approach to investigate the effects of exercise in combination with ADM and 
CBT, on clinical symptoms, cognitive symptoms, neural function and biochemical 






1.4 Research objectives: research questions and hypotheses 
1.4.1 Study 1: Research objectives, questions and hypotheses 
Research objectives 
Memory impairment is the most frequently reported cognitive symptom in MDD 
(Airaksinen, Larsson et al. 2004) and often persists as a residual symptom following 
antidepressant therapy (Shilyansky, Williams et al. 2016). Research suggests that the 
hippocampus, which plays a critical role in the formation of new memories, also plays a 
role in the pathogenesis of MDD (Campbell and MacQueen 2004). Functional 
neuroimaging evidence has identified hippocampal dysregulation during the encoding of 
episodic memory (Fairhall, Sharma et al. 2010). In animals, exercise has been shown to 
enhance neuroplasticity within the hippocampus and improve performance on 
hippocampal-dependent tasks (Van Praag, Shubert et al. 2005). In humans, exercise has 
been shown to delay age-related neurodegeneration and cognitive decline (Colcombe, 
Kramer et al. 2004, Chang, Jonsson et al. 2010). However, it remains unknown the 
effects of exercise on brain function in young and healthy adults. Also, exercise has been 
shown to be an effective treatment for MDD but there are no studies that have 
investigated the effects of exercise on hippocampal function during a memory task. 
The main objectives of study one were to investigate the effects of a well-defined, 
supervised exercise prescription on depressive symptoms, cognitive function, neural 
function and fitness in a group of MDD patients.  I also included a sample of young and 
healthy adults to determine if the effects of exercise on brain function can be generalized 
to those without psychiatric illness or any age-related cognitive decline. I used an fMRI 
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subsequent memory paradigm to examine memory encoding within the hippocampus 
during an associative memory task.  
Research question 
Does a structured, moderate-intensity supervised eight-week exercise intervention 
improve depressive symptoms in medicated patients with MDD? In addition, will 
exercise improve fitness, episodic memory and change hippocampal activity during 
memory encoding in untrained MDD patients and untrained young and healthy adults?  
Hypotheses 
At baseline, the healthy controls will perform significantly better on the 
associative face-name memory task compared to the MDD group. FMRI results will 
show a significant difference in hippocampal activation during the successful encoding of 
face-name pairs between the healthy controls and MDD patients. Following the eight-
week intervention, both the MDD and healthy control groups will show improvements in 
fitness. The MDD group will show significant improvements in depressive symptoms. 
The MDD group will also perform better on the episodic memory task and will show a 
more normalized hippocampal activation pattern during the encoding of successfully 
remembered items similar to the healthy control group. There will be no change in 
memory performance or hippocampal fMRI measures for the healthy control group. 
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1.4.2 Study 2: Research objectives, question and hypotheses 
Research objectives 
More than half of the MDD population fail to receive effective treatment for their 
disorder warranting the need for additional treatment options (Shelton 2006). Exercise 
has been shown to be effective in treating depressive symptoms, however its mechanism 
of action is unknown. In non-depressed populations, exercise has been shown to increase 
circulating BDNF concentrations, normalize cortisol secretion and reduce inflammation 
by balancing the ratio of pro- and anti-inflammatory cytokines (Cotman and Berchtold 
2002, Cotman, Berchtold et al. 2007). Recently, exercise was shown to concomitantly 
increase CTHB and improve memory performance in both animals and healthy adults 
(Moon, Becke et al. 2016). 
The main objectives of study two was to investigate the additional effects of 
exercise in combination with ADM and CBGT in low active patients with MDD. 
Depressive symptoms, cognitive function, sleep quality, cardiorespiratory fitness and 
biochemical markers shown to be altered in MDD were measured. The results were 
compared to those of low active MDD patients who received ADM and CBGT only. A 
group of non-depressed, young and healthy adults who were considered low active were 
recruited to provide normal healthy values for comparison. 
Research questions 
Does a structured, moderate-intensity, supervised eight-week exercise 
intervention in addition to ADM and CBGT improve depressive symptoms, anxiety, 
sleep quality and cognitive function in patients with MDD more so than for a group who 
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received only ADM and CBGT? In addition, will exercise normalize cortisol, BDNF, 
CTHB and cytokine concentrations known to be altered in MDD? Will changes in 
depression, sleep quality and cognitive function be associated with changes in 
biochemical markers? At baseline, will sleep quality, cognitive performance and 




At baseline, the MDD groups will show significantly higher depression, anxiety 
and sleep quality scores compared to the healthy controls. The MDD group will perform 
more poorly on the cognitive tasks and will have altered biochemical marker profiles 
compared to the healthy controls. Following the eight-week exercise intervention, the 
MDD exercise group will shower greater improvements in depression, anxiety, sleep 
quality and cognitive performance compared to the non-exercise MDD group. The MDD 
exercise group will also show improved fitness and a more normalized biochemical 
marker profile whereas the non-exercise MDD group will show no change.  
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1.4.3 Study 3: Research objectives, questions and hypotheses 
Research objectives 
Regular exercise has been linked to better cognitive function during various 
periods throughout the lifespan. Higher levels of cardiorespiratory fitness are associated 
with better cognitive function in children (Hillman, Castelli et al. 2005) adolescents 
(Stroth, Kubesch et al. 2009) and in elderly adults (Colcombe and Kramer 2003). 
However, the effects of exercise on cognitive function in younger adults is unclear and 
under-researched. Researchers have postulated that cognitive performance peaks during 
early adulthood leaving little room for improvement (Hillman, Erickson et al. 2008). 
However, the animal literature provides evidence that exercise enhances neuroplasticity 
and improves cognitive performance in younger animals and these effects are mediated 
by increases in BDNF expression (Kobilo, Liu et al. 2011). In humans, acute exercise 
increases circulatory BDNF concentrations, however the long-term effects of exercise on 
BDNF concentrations have presented mixed findings. A novel protein CTHB was 
recently found to be increased following long-term exercise and associated with 
enhanced neurogenesis in animals and better cognitive functioning in healthy humans 
(Moon, Becke et al. 2016). However, further research is needed to confirm these results.  
Research question 
Does a structured, moderate-intensity supervised eight-week exercise program 
improve fitness and cognitive function in low active, young and healthy adults? In 
addition, will exercise change plasma BDNF and CTHB concentrations in young and 
healthy adults? Will changes in plasma BDNF and CTHB concentrations be related to 





Following the eight-week exercise program, the exercise group will show 
improvements in fitness and cognitive performance. The exercise group will also show an 
increase in plasma BDNF and CTHB concentrations that will be associated with 
improvements in cognitive performance. The non-exercise group will show no change in 






Chapter 2: Exercise Promotes Neuroplasticity in Both Healthy 
and Depressed Brains: An fMRI Pilot Study 
Adapted from: Gourgouvelis, J., Yielder, P., & Murphy, B. (2017). Exercise Promotes 
Neuroplasticity in Both Healthy and Depressed Brains: An fMRI Pilot Study. Neural 
Plasticity, 2017, 1–13. 
2.1 Abstract 
Memory impairments are a frequently reported cognitive symptom in people 
suffering from major depressive disorder (MDD) and often persist despite antidepressant 
therapy. Neuroimaging studies have identified abnormal hippocampal activity during 
memory processes in MDD. Exercise as an ad-on treatment for MDD is a promising 
therapeutic strategy shown to improve mood, cognitive function, and neural structure and 
function. To advance our understanding of how exercise impacts neural function in 
MDD, we must also understand how exercise impacts healthy individuals without MDD. 
This pilot study used a subsequent memory paradigm to investigate the effects of an 
eight-week exercise intervention on hippocampal function in low active healthy (n=8) 
and low active MDD (n=8) individuals. Results showed a marked improvement in 
depression scores for the MDD group (p < .0001) and no change in memory performance 
for either group (p > .05). Functional imaging results showed a marginally significant 
decrease in hippocampal activity in both groups following the exercise intervention. Our 
whole brain analysis collapsed across groups revealed a similar deactivation pattern 
across several memory-associated regions. These results suggest that exercise may 
enhance neural efficiency in low-fit individuals while still resulting in a substantially 
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greater mood effect for those suffering from MDD.  
This trial is registered with clinical trials.gov NCT03191994. 
2.2 Introduction 
Memory impairment is the most frequently reported cognitive symptom in people 
suffering from major depressive disorder (MDD) and often persists as a residual 
symptom following antidepressant therapy [1, 2]. Although the neural underpinnings of 
impaired memory in MDD remain unclear, research suggests that the hippocampus, 
which plays a critical role in the formation of new memories, also plays a role in the 
pathogenesis of MDD. To date, cognitive literature has presented mixed findings in terms 
of the type, severity, and specificity of memory deficits in people with MDD, although 
the plurality of data has suggested an impairment in episodic (autobiographical) memory 
with a sparing of semantic (general knowledge) memory and short-term memory [3–8]. 
The hippocampus has been shown to play an essential role in the encoding of episodic 
memories [5, 9–13], and pathologies associated with this neural structure may underlie 
the episodic memory impairments observed in MDD populations. The relationship 
between MDD, memory impairments, and hippocampal structure and function is based 
on converging lines of research from animal studies, neuroimaging, neuropsychology, 
and postmortem investigations which have all shown hippocampal abnormalities at the 
structural, functional, and cellular level. Structural brain imaging studies have shown 
robust hippocampal volume reductions particularly in persistent and early onset MDD 
[14–16]. Functional neuroimaging studies have found that both the memory encoding and 
retrieval processes within the hippocampus are to be impaired in MDD [4, 6, 17–19]. 
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Neuropathological evidence from animal models of depression and postmortem studies in 
depressed humans have revealed cellular abnormalities in the hippocampus such as 
dendritic atrophy and reduced neuron and glial densities [20–24]. 
Despite many efforts to develop effective antidepressant therapies, MDD remains 
a severely undertreated disorder in the primary care setting leaving more than half of 
individuals plagued with symptoms [25–28]. Exercise as an add-on to conventional 
antidepressant therapies is a promising treatment strategy for MDD. It is well established 
that exercise is efficacious in treating mild to moderate depression with response rates 
comparable to mainstream therapies such as antidepressant medication and cognitive 
behavioral therapy [29–34]. However, there is a lack of understanding of the 
neurobiological mechanisms that underlie or mediate the antidepressant effects of 
exercise. It is well established that exercise facilitates neuroplasticity [35–37]. To date, 
much of our understanding of how exercise facilitates neural and cognitive plasticity has 
come from the extensive animal literature. For instance, rodent studies have shown that 
exercise increases new cells in the dentate gyrus of the hippocampus, and this is 
associated with improved learning and spatial memory [36, 38–40]. Further evidence has 
shown that exercise increases synaptogenesis [41] and angiogenesis [42] and improves 
dendritic morphology in the hippocampus [43, 44]. However, the effects of exercise on 
brain structure and function in humans have been more equivocal. In elderly populations, 
aerobics exercise training has been shown to improve spatial memory [45], executive 
function [46, 47], and short-term memory [48]; however, others observed no benefits 
[49–52]. Neuroimaging studies have found that aerobics exercise reverses age-associated 
brain volume loss in the prefrontal and temporal cortices [53, 54], improves functional 
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connectivity in the default mode and frontal executive networks [47], and increases 
hippocampal volume in schizophrenics [55]. To date, the literature examining the effects 
of chronic exercise on neural function in both healthy and MDD populations remains 
scant. To capitalize on the full treatment potential of exercise in MDD populations, we 
must also understand the relationship between cardiovascular fitness, neural function, and 
cognitive performance in healthy individuals in order to identify neural mechanisms 
specific to MDD. 
To our knowledge, this is the first study using a subsequent memory paradigm to 
determine the effects of an eight-week exercise prescription on the functional integrity of 
the hippocampus in low active patients with MDD and low active healthy individuals. 
The aim of this pilot study was twofold: (1) using fMRI to examine changes in 
hippocampal function following an exercise intervention, and (2) to conduct an 
exploratory whole brain analysis to determine how exercise affects overall brain activity. 
2.3 Materials and Methods 
2.3.1 Participants 
Eight patients (mean age = 37.25, SD = 8.00; 7 females) with comorbid MDD and 
anxiety were recruited from an outpatient Mental Health Day Treatment Program at a 
local hospital in Oshawa, Ontario Canada. Eight healthy participants (mean age = 20.63, 
SD = 1.19; 4 females) with no history of mental health illness or neurological disease 
were recruited from a local university in Oshawa, Ontario Canada. Depressed patients 
had a diagnosis of MDD according to an unstructured clinical interview by hospital 
psychiatrists based on Diagnostic and Statistical Manual of Mental Disorders—Fourth 
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Edition (DSM-IV-TR) [56] criteria, no coexisting DSM-V Axis I disorders apart from 
anxiety, and a score >20 on the Beck Depression Inventory—Second Edition (BDI-II) 
[57], and their pharmacological treatment was stabilized a minimum of six weeks prior to 
study enrolment. In order to be considered eligible for the study, participants needed to 
indicate that they exercised less than 20 minutes, three times per week. Both groups were 
also safety screened for MRI and screened with the Physical Activity Readiness 
Questionnaire (PAR-Q) to ensure they had no medical contraindications to exercise. All 
participants provided written consent. 
2.3.2. Psychometric Evaluation 
Participants completed the Montreal Cognitive Assessment (MoCA) which is a 
brief neurocognitive tool with high sensitivity for screening patients with mild cognitive 
impairment. This cognitive assessment was performed to identify participants who may 
have difficulty performing the associative memory task. The internal consistency of the 
MoCA is good, with a coefficient alpha of 0.83 [58]. Depression was measured using the 
Beck Depression Inventory (BDI-II) [57] which is one of the most widely used self-
reported instrument capable of measuring depression severity ranging from not depressed 
to severely depressed. The BDI–II demonstrated excellent internal consistency, with a 
coefficient alpha of 0.91 [59]. All measures were performed before and after the eight-
week exercise intervention. 
2.3.3 Fitness Assessment 
Cardiorespiratory fitness was measured before and after the exercise intervention 
using the YMCA cycle ergometer protocol recommended by the American College of 
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Sports Medicine [60–62]. The YMCA cycle ergometer protocol is an indirect 
submaximal exercise test used to estimate maximal oxygen consumption (VO2max) from 
heart rate (HR) measurements. The protocol consists of two or more consecutive 3-
minute stages at a given workload. The objective was to elevate the participant’s HR to a 
target zone to approximately 85% of the age-predicted maximum HR for two consecutive 
stages. The initial workload consisted of a 25-watt workload at a cadence of 50 
revolutions per minute. HR was measured and recorded using the radial pulse method 
during the final 15 seconds of each minute, which determined the workload of subsequent 
stages indicated by the YMCA protocol. Once a steady state HR (two successive 
measures that differ from <5 bpm) was within 10 bpm of the 85% age-predicted 
maximum HR, the test was complete. VO2max was estimated using an equation that 
includes workload, body mass, and derived constants. 
2.3.4 Exercise Intervention 
Participants performed an individualized eight-week exercise program consisting 
of three weekly sessions (described below). Exercise sessions were performed alone, on 
nonconsecutive days, and each session was supervised by a qualified exercise 
professional to increase compliance [34]. Attendance was recorded and all participants 
completed >80% of the exercise sessions. 
The exercise prescription was based on international recommendation to obtain at 
least 150 minutes per week of moderate to vigorous intensity aerobics exercise and to 
perform strengthening activities twice per week, for developing and maintaining 
cardiorespiratory, musculoskeletal, and neuromotor fitness in healthy adults [63, 64]. 
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This minimum-effective dose of exercise was prescribed to encourage better compliance 
since people with depression, and are , tend to be less motivated [65]. Research has also 
shown that combining aerobics with strength training improves depression and cognitive 
function such as attention, processing speed, executive function, and memory 
performance more than aerobics exercise alone [51, 66]. 
2.3.4.1 Resistance Sessions 
Resistance sessions were completed twice per week and incorporated a whole-
body exercise prescription using larger muscle groups. Each session included eight 
resistance exercises using both resistance training machines and free weights. Initial 
workloads were approximately 95% of the 10 repetition maximum to ensure proper form. 
Exercises were performed in two or three supersets (one set of each exercise with no rest 
between sets) with an 8–12 repetition range in order to decrease rest times and to 
maintain target HR. Workload was increased approximately 5% once participants were 
able to complete three sets of 12 repetitions with proper form. Specific exercises were 
changed every four weeks; however, they targeted the same muscle groups. Resistance 
exercises included variations of the chest press, pull downs, triceps extension, biceps curl, 
shoulder press, leg press, leg extensions, leg curls, squats, split squats, calf raises, and 
abdominal exercises. During each session, HR was monitored to ensure that the 
participant maintained a HR of between 60–80% of their age-predicted maximum HR. 
Each session began with a 5-minute aerobics warmup and ended with 15 minutes of 




2.3.4.1 Aerobics Session 
Participants completed an aerobics-only session once per week. They were given 
the choice to perform their aerobics activity on either the treadmill, stationary bike, or 
elliptical trainer. The aerobics session workloads were determined by HR response and 
increased by five-minute increments over the eight weeks reaching a maximum of 60 
minutes per session. HR was monitored throughout the session to ensure the participant 
was in the target HR range. 
2.3.5 Statistical Analysis 
Statistical analyses were performed using GraphPad Prism software, version 6.0 
data. Data are presented as mean (standard deviation (SD)). P values less than 0.05 were 
considered significant. Differences in baseline variables between groups were tested 
using a two-tailed Student’s t-test and chi-square test for gender distribution. Within 
group differences for pre-post-BDI, MoCA, BMI, and VO2max were tested using a 
paired t-test. A two-way repeated measures analysis of variance (ANOVA) was used to 
determine any group × time of interactions and to compare the changes between the two 
treatment groups. Cohen’s d was used to represent the effect size within each group. For 
between group effect sizes, we used dppc2 [67] which uses the difference between Hedge’s 
g of two different treatment groups in pre-post research designs. 
2.3.6 Associative Memory Task 
To evaluate the encoding and retrieval processes of memory, fMRI studies 
frequently use a recognition memory paradigm that consists of an “encoding” and 
“recall” phase [5, 68]. Associative memory refers to memory for the relationships 
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between memoranda rather than memory for objects themselves [69–71]. The role of the 
hippocampus in memory formation has also been specifically linked to associative 
memory [72]. A specific version of an associative paradigm [17] using face-name pairing 
known to reliably activate the hippocampus during the successful encoding event and 
sensitive enough to detect hippocampal dysregulation in a MDD sample [16] was used to 
investigate activation patterns of the hippocampus during the encoding process inside the 
MRI scanner (see Figure 2.1). During the encoding phase inside the MRI, participants 
were presented with face-name pairs and used a response box provided to indicate if the 
name suited the face. The retrieval phase was performed after the MRI scan. Participants 
were presented with a face and two names and instructed to indicate which name was 
paired with that face during the encoding phase. Participants also rated the confidence of 
their responses. Trials during the encoding phase were then reclassified based on the 
responses during the retrieval phase into correct (the participant selected the correct name 
for the face and indicated a high confidence in their response, suggesting that the face-
name association was successfully encoded), guesses (a correct selection with low 




Figure 2. 1 - (A) During the encoding task, participants viewed 240 face name pairs over 
two nine minute fMRI runs. Participants were asked if they thought the name suited the 
face and responded using a response box. Each run included 120 face name pairs 
presented for a duration of 3000 ms, jittered with 34 fixation crosses ranging from 3000-
9000 ms in increments of 3000 ms. (B) The retrieval task was then performed on a laptop 
computer outside the MR scanner. Participants were instructed to choose which of the 
two names was originally paired with the face shown and then asked if they were 
confident with their choice. This was used to identify the correct successful encoding 
trials as remembered (correct) vs lucky guesses. 
 
2.3.7 fMRI Scanning Parameters 
Participants were scanned on a 3-Tesla Tim trio MRI scanner equipped with a 32-
channel phased array head coil. E-prime software version 2.0 (Psychology Software 
Tools) was used to present stimuli on a rear-projection system (Avotec, Inc., Stuart, FL) 
in two separate nine-minute functional runs. To obtain optimal hippocampal resolution, 
all scans were acquired in the oblique coronal plane perpendicular to the long axis of the 
hippocampus to maximize the anatomic delineation. A total of 416 functional scans were 
acquired with a T2-weighted gradient echo planar imaging sequence (TR =2500 ms, 
TE = 27 ms, FOV = 192 mm, 3 mm × 3 mm × 3 mm, and flip angle = 70°; in-plane 
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resolution = 3 mm × 3 mm; and 50 slices with 3.5 mm slice thickness). The first 4 
volumes of each run were discarded to allow for T1 equilibration. The anatomical scan 
lasted six minutes and was acquired with a T1 MPRAGE imaging sequence 
(TR = 2000 ms, TE = 2.63 ms, FOV 256 mm, 1 mm × 1 mm × 1 mm voxels, and flip 
angle = 9°). 
2.3.8 fMRI Analysis 
Image preprocessing was performed using SPM12 methods (Statistical Parametric 
Mapping, Wellcome Department of Cognitive Neurology, London, UK: 
http://www.fil.ion.ucl.ac.uk/spm) within MatLab 8.3 (The MathWorks Inc., MA). 
Individual functional images were slice time corrected and realigned to the first image in 
the series to correct for motion. The EPI images were coregistered to the T1, and 
segmentation was applied to the T1 anatomical images to extract grey matter, white 
matter, and CSF masks and calculate a deformation field to transform the data into MNI 
space. All EPI images were then spatially normalized to the ICBM template using the 
deformation field, resampled to 3 × 3 × 3, and smoothed using a 6 mm full-width-half 
maximum isotropic Gaussian filter. General linear model (GLM) was performed at the 
single-subject level and statistical contrasts were created modeling the hemodynamic 
response function (HRF) of remembered items with high confidence (correct), 
remembered items with low confidence (lucky guess), and incorrect trials (incorrect). Six 
head motion parameters (three rigid body translations and three rotations) were included 
in the model to reduce the potential effects of motion. Second-level random effects 
analysis was performed using the contrast of t-test of correct > incorrect. Correct retrieval 
requires well encoding of the items. As such, this contrast which differentiates between 
65 
 
poorly and well-encoded trials, known as the subsequent memory effects, is a powerful 
tool for examining successful memory encoding in the brain [73, 74]. As our primary 
hypothesis was related to activity in the hippocampus, a hippocampal mask was defined 
using the automated anatomical labeling (AAL) atlas. Significant clusters from an 
independent sample t-test within the hippocampus (p < .01 uncorrected, 10 voxels, for 
this a priori ROI-defining analysis only) for correct > incorrect at baseline were used as 
an ROI to extract contrast beta values for correct > incorrect in pre- and postscans for 
each participant. The average beta values from each ROI were imported into SPSS 
version 20, and a 2 × 2 repeated measures ANOVA (group × time) was run. We then 
conducted an exploratory whole brain analysis to determine if other brain regions showed 
task-related effects. For our whole brain analysis, significant clusters were defined as 20 
contiguous voxels (180 mm3) with p < .005 uncorrected. A 2 × 2 repeated measures 
ANOVA (group × time) was run on β values for the correct > incorrect contrast in order 
to identify regions in which there was a difference in pre-post changes across groups. 
Additionally, an exploratory analysis was run examining a group × time interaction across 
the whole brain. 
2.4 Results 
2.4.1 Baseline Characteristics 
At baseline, there were no significant differences between groups for BMI, 
VO2max, and MoCA scores (all p < .05). BDI scores for the MDD group scores 
indicated severe depression while the healthy group BDI scores indicated no depression 
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(p < .0001). The depressed group was also older than the healthy group (p < .0001). See 
Table 2.1. 
Table 2. 1 - Baseline characteristics of participants 
Variables MDD n Healthy N df p 
Sex: (male/female) 1/7 8 4/4 8 1 .106a 
Age (years) 37.25 (8.00) 8 20.63 (1.19) 8 14 <.0001b 
Body mass index 
(kg/m2) 28.33 (5.12) 8 28.29 (7.91) 8 14 .993
b 
VO2max (ml.kg-1.min-1) 24.82 (8.00) 7 20.81 (6.48) 8 12 .326b 
BDI 41.75 (3.50) 8 5.88 (5.03) 8 14 <.0001b 
MoCA 24.63 (1.41) 8 26.13 (3.23) 8 14 .248b 
aPearson’s chi-square 
bStudent’s t-test 
VO2max = maximum oxygen consumption; BDI = Beck Depression Inventory; 
MoCA=Montreal Cognitive Assessment 
Data are expressed as the mean with the standard deviation in parentheses. 
 
2.4.2 Psychometric, memory and fitness results 
A 2 x 2 repeated measures ANOVA revealed a group x time interaction for BDI 
scores (f (1,14) = 30.42, p<0.0001) indicating the MDD group had a greater decrease in 
depression scores pre-post. There were no significant changes in BMI, MoCA scores, or 
performance on the associative memory task (p>.05) for either group pre-post. Although 
baseline memory scores between groups was not significantly different (p=.477), our 
results showed that the MDD group performed more poorly on the associative memory 
task compared to the Healthy group (71.48% vs 75.32%) indicating likely memory 
impairments in the MDD group. One MDD (n=1) participant discontinued baseline 
VO2max testing due to exhaustion and was excluded from VO2max analysis. Baseline 
VO2max scores revealed that one MDD participant (n=1) was in the Good Health Benefit 
Rating Zone and the remaining participants (n=14) were in the Poor Health Benefit 
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Rating Zone based on the Canadian Society for Exercise Physiology guidelines [63]. The 
Healthy group showed a 47% increase in VO2max that was significant (p=.014) while the 
MDD group showed a marginally significant increase of 31% (p=.073). There was no 
significant difference in VO2max between groups (p=.661). These improvements in 
VO2max suggest that the exercise intervention was successful at improving 
cardiorespiratory fitness (see Table 2.2). 
2.4.3 fMRI results 
Using a main effects contrast of correct > incorrect, collapsing across groups, at 
baseline, we identified active voxels in the hippocampus, and created ROIs for right and 
left hippocampus (see Fig. 2.2a). A repeated measures ANOVA examining group x time 
using β values for the correct > incorrect contrasts for pre and post revealed a marginal 
main effect of time (f(1,14) = 3.3, p = 0.09), no main effect of group (f(1,14) = 0.005, p = 
0.957) or group x time interaction (f(1,14) = 0.165, p = 0.69). This marginal main effect 
of time is driven by a decrease in the correct > incorrect contrast in the hippocampus 
indicating that there was a decrease in hippocampal activity during successful encoding 
in both groups following the exercise intervention (see Fig. 2.2b).  
The exploratory whole brain analysis did not reveal any clusters in which there 
were group differences in the pre-post changes following exercise, or a main effect of 
group differences. Given the lack of interaction of main effects of group or group x time 
interaction, a post-hoc whole brain analysis was run in which both groups were collapsed. 
Given the relatively small sample size, this analysis maximizes the power to detect 
changes in brain activity following the exercise intervention that are common to both 
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Healthy and MDD, using the more powerful paired samples t-test. Changes in neural 
activity in the correct > incorrect contrast were compared from the pre-treatment to post-
treatment MRI scans. Decreases in activity following exercise were noted in several 
regions (see Fig. 2.3 and Table 2.3). Regions included a larger cluster in the left posterior 
insula, and smaller clusters in the medial superior frontal/mid cingulate and post-central 
superior parietal gyrus. 
In order to examine regions in which changes in neural activity were related to 
changes in BDI score an additional contrast was run, regressing change in BDI against 
the paired t-test described above. Again, in order to maximize power the Healthy and 
MDD cases were both included in this analysis. The justification for including both 
groups are as follows: firstly, although the Healthy group was not clinically depressed 
there was some pre-post reduction in BDI scores for the Healthy group, and secondly, 
since cases with depression tended to have a larger decrease in BDI this analysis may be 
more sensitive to group x time effects, reflected as BDI changes, while also better 
reflecting areas in which the pre-post differences were behaviorally meaningful.  The 
regression against BDI for pre-post changes found a negative relationship between 
changes in depression scores and activation in the right occipital, left occipital/fusiform 
and left precentral gyrus (see Fig. 2.4 and Table 2.4).
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Table 2. 2 - Results of pre-post changes for depression scores, cognitive assessment, memory performance, body mass index and 
fitness 
 MDD   Healthy   Between Group Analysis 
Measure n Pre  Mean (SD) 
Post  
Mean (SD) p d  n 
Pre 
 Mean (SD) 
Post  
Mean (SD) p d  F p dppc2 
BDI 8 41.75 (3.50) 15.50 (10.43) .0004 2.89  8 5.88 (5.03) 3.25 (4.53) .072 .545  30.42 <.0001 5.34 
MOCA 8 24.63 (1.41) 25.75 (2.38) .229 .564  8 26.13 (3.23) 27.13 (1.81) .286 .338  .011 .920 .047 
Memory task (high 
confidence correct %) 8 71.48 (9.50) 69.08 (12.03) .359 .210  8 75.32 (9.29) 75.13 (9.07) .942 .020  .418 .529 .230 
BMI (kg/m2) 8 28.33 (5.12) 28.29 (4.48) .934 .007  8 28.29 (7.91) 27.95 (6.61) .530 .023  .205 .657 .044 
VO2max  
(ml.kg-1.min-1) 
7 24.82 (8.00) 32.52 (10.12) .073 .834  8 20.81 (6.48) 30.57 (8.66) .014 1.26  7.96 .661 .279 
Note: BDI = Beck Depression Inventory; MoCA = Montreal Cognitive Assessment; BMI = body mass index; VO2max = maximum 
oxygen consumption; d = Cohen’s D 












Figure 2. 2 - (A) Regions within the hippocampus found to be active in the correct > 
incorrect contrast for both Healthy and MDD at baseline, used as an ROI to extract Beta 
values for an analysis of activity in the hippocampus. (B) Beta values for correct > 
incorrect from both groups at pre-treatment and post-treatment. Both groups showed a 
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reduction in hippocampal activity within the bilateral ROI following exercise. Error bars 






Figure 2. 3 - Pre to post changes in neural activity in the correct > incorrect contrast 
(parried-samples t-test). Decreases in activity following exercise were noted in several 
regions, irrespective of group.  
 
Table 2. 3 - Brain regions showing pre-post changes in activity for the correct > incorrect, 
irrespective of group 
  MNI Coordinates   
Voxels Peak T X Y Z BA Location 
37 -6.27 -6 17 41 32 Medial Superior Frontal/Mid Cingulate 
35 -5.85 -18 -10 8  Left Putamen 
35 -5.79 -30 -46 44 40 Left Supramarginal/Intraparietal Sulcus 
45 -5.61 -42 -28 35 3 Post-central, superior parietal gyrus 
50 -5.34 3 -16 -7  Thalamus/midbrain  
139 -5.3 -42 -37 8 41 Left posterior insula 
30 -5.22 -18 -70 47 7 Left superior parietal 
36 -5.17 30 -28 14  Right Posterior Insula 
20 -4.75 54 -43 -4 21 Right Posterior mid temporal 
25 -3.82 12 -82 -7 18 Right Occipital Gyrus 








Figure 2. 4 - Pre-post changes found a negative relationship between changes in 
depression scores and activation in the right occipital, left occipital/fusiform and left 
precentral gyrus, irrespective of group. 
 
 
Table 2. 4 - Regions showing decreased activation associated with depression, irrespective 
of group 
  MNI Coordinates   
Voxels Peak T X Y Z BA Location 
58 -6.41 36 -88 11 19 Right Occipital 
27 -4.92 -39 -22 56 4 Left Precentral Gyrus 
29 -4.1 -24 -73 -13 18 Left Occipital/Fusiform 
Note: MNI=Montreal Neurological Institute, BA=Broadman’s Area 
 
4. Discussion 
This small fMRI pilot study used a subsequent memory paradigm to investigate 
the effects of an eight-week structured, supervised exercise intervention on hippocampal 
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function and overall brain activity in low active patients with MDD and low active 
healthy individuals. The current study yielded two main findings. First, our ROI analysis 
of the hippocampus showed a marginal decrease in activation for both groups pre-post 
exercise. Although this decrease in hippocampal activation was only marginally 
significant, a deactivation pattern was present in both groups and was consistent across 
other memory-related brain regions noted in the whole brain analysis. These data provide 
the first evidence that improved cardiovascular fitness, following eight weeks of the 
minimum recommended dose of exercise, affects neural function alike in healthy and 
MDD brains. The overall deactivation pattern that we observed in the hippocampus and 
several other brain regions despite similar memory performance pre-post suggests 
increased cortical inhibition that attenuated neural activity in a subset of brain regions 
known to inhibit memory encoding and/or an increase in neural network efficiency 
during the memory encoding process. Second, our study showed that exercise had a 
robust antidepressant effect on the MDD group who went from the severe to mild 
depression range, providing additional support to the growing body of literature that 
exercise is an effective adjunctive therapy for MDD [75]. 
A common theme in the neurocognitive literature is that brain activity for 
remembered items is greater than brain activity for forgotten items, as this suggests 
successful memory encoding [17, 76–79]. However, neuroimaging studies employing a 
subsequent memory design have identified a negative relationship between remembered 
items and neural activity in brain regions such as the insula and the supramarginal gyrus, 
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and hyperactivity in these regions may be detrimental to new memory formation [76, 80–
82]. A candidate mechanism for the decrease in neural activity that we observed 
following the exercise intervention may be a modulation in the main inhibitory 
neurotransmitter γ-aminobutyric acid (GABA). Cortical inhibition, mediated by GABA 
via cortical interneurons, is an essential mechanism that eliminates task-irrelevant 
distractors that increase neural noise, which negatively affects attention for task demands. 
Inhibitory pathways consisting of GABAergic projections between the thalamus and 
cortex provide a mechanism that may eliminate task-irrelevant distractors by suppressing 
irrelevant sensory inputs early in sensory processing [83, 84]. A plethora of evidence has 
identified GABA deficits in MDD, and it has been postulated that GABAergic 
dysregulation may play a significant role in the pathogenesis of the disorder [85–88]. For 
example, neuroimaging studies have identified GABA deficits in the dorsolateral 
prefrontal and occipital cortex in depressed individuals [89–91]. Histopathological 
studies of postmortem tissue from MDD brains have revealed a reduction in both the 
density and size of GABAergic neurons in the prefrontal and occipital cortex that 
conceivably underlie the low levels of GABA seen in neuroimaging studies [92, 93]. 
Research has shown that exercise may facilitate cortical inhibition by regulating the 
interplay between glutamatergic excitatory neurons and GABAergic inhibitory 
interneurons. In mice, running engaged inhibitory mechanisms in the hippocampus 
through an increased expression of vesicular GABA transporter and extracellular GABA 
release that was also associated with improved anxiety regulation [94]. In humans with 
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early Parkinson’s disease, a neurophysiological study used transcranial magnetic 
stimulation (TMS) to examine cortical inhibition of the primary motor cortex (M1) 
following an eight-week, high-intensity aerobics exercise intervention. In addition to 
improving clinical symptoms, the exercise intervention normalized corticomotor 
excitability through an increase in GABA-mediated cortical inhibition [95]. Nonetheless, 
literature supporting the role of exercise in normalizing cortical inhibition via the 
GABAergic system remains sparse. 
Our observed decrease in brain activity during successful memory encoding pre-
post the exercise intervention also suggests lowered demands on neural networks and 
increased neural processing efficiency. Our results provide additional support to a recent 
body of literature, which postulates that exercise increases neural efficiency. In children, 
an eight-month aerobics exercise program was associated with decreased activity in 
several brain regions during an antisaccade task alongside improvements in performance 
[96]. In elderly adults, a 12-week aerobics exercise program was associated with 
decreased prefrontal activation despite improvements in visual short-term memory [97]. 
A similar study conducted in elderly adults with mild cognitive impairment found that 12 
weeks of aerobics exercise decreased brain activity in 11 brain regions during memory 
retrieval despite improvements in memory performance [98]. In adolescence, high-fit 
individuals showed a pattern of decreased activation in the hippocampus and right 
superior frontal gyrus combined with a deactivation in the default mode network (DMN) 
during the encoding of subsequently remembered items, that was absent in low-fit 
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individuals [99]. To determine if aerobics exercise influences learning and memory-
associated neural circuitry, a group of researchers examined the brain activity in high-fit 
and low-fit adolescents during an SME paradigm. Despite comparable memory 
performance between the two groups, there were notable differences in memory-related 
and default mode (DMN) brain regions during encoding of successfully remembered 
word pairs versus forgotten word pairs. Results showed that high-fit individuals displayed 
a robust deactivation pattern in the DMN areas, such as the ventral medial prefrontal 
cortex and posterior cingulate cortex, which was absent in the low-fit group. The low-fit 
group also showed a greater bilateral hippocampal and right superior frontal gyrus 
activation during encoding of later remembered versus forgotten word pairs. Our results 
taken together with previous research suggest that improvements in aerobics fitness from 
the exercise intervention can promote neural processing efficiency during memory 
encoding processes. 
Finally, the neurocognitive benefits associated with exercise may be attributed to 
increases in cerebral blood flow and neural growth factors, particularly brain-derived 
neurotrophic factor (BDNF), a key mediator of neuroplasticity in the brain [36, 37]. 
BDNF, a member of the neurotrophin family, upregulates neurogenesis, promotes neural 
survival, improves neural structure, and increases synaptic efficacy [100–103]. BDNF 
also modulates the formation and plasticity of GABAergic synapses and promotes 
maturation of GABAergic inhibitory networks [104–106]. Reduced BDNF levels are a 
consistent finding in animal models of depression [107], and administration of exogenous 
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BDNF into the hippocampus is able to produce antidepressant behavioral responses 
comparable to antidepressant medications [108]. Exercise is known to elevate BDNF 
production in the hippocampus [35, 109] and has been postulated as a leading candidate 
mechanism underlying the antidepressant effects of exercise [110, 111]. 
5. Limitations 
This pilot study has some limitations. First, the sample size used is rather small 
and therefore statistically underpowered. We did not age match our groups, which 
resulted in the MDD group being significantly older than the healthy group. Intrinsically, 
we wanted to compare MDD brains to young healthy brains with no history of mental 
health illness or other confounding comorbidities that increase with age and determine if 
exercise affects neural function in healthy populations who are . Also, we did not 
measure sedentary behavior time which has been shown to have deleterious health 
consequences independent of daily physical activity levels [112]; as a result, future work 
must consider sedentary behavior independent of physical activity levels and 
cardiorespiratory fitness. Another limitation is that our MDD samples were all medicated 
which may have also affected results. However, this is the typical patient seen in clinical 
practice, and in any real-world clinical intervention using exercise, the participants would 
likewise be similarly medicated. Next, even though our analysis collapsing across groups 
mediates some of the power issues for a transdiagnostic analysis of the effects of exercise 
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on neural activity, the analysis was still underpowered to detect group × time interaction 
effects. 
While we did not closely replicate the results of Fairhall et al., it should be noted 
that they used a contrast comparing correct trials to fixation, while we made use of a 
more standard subsequent memory contrast (correct > incorrect). Nevertheless, we did 
observe a decrease in the correct > incorrect contrast in the hippocampus indicating that 
there was a decrease in hippocampal activity during successful encoding in both groups 
following the exercise intervention. We did not however observe any group effects. 
Given the small sample size, we were likely underpowered to detect any subtle group 
effects, though it remains possible that the decreases in activity observed following the 
intervention are common across low active individuals regardless of diagnostic status. In 
fact, it should also be noted there was even a small decrease in BDI scores amongst the 
healthy group. The physiological effects of exercise on the brain may be common 
amongst both healthy and MDD while still resulting in a substantially greater mood effect 
for those suffering from depression. 
6. Future Research 
This small pilot study demonstrates that eight weeks of the minimum 
recommended dose of exercise improved cardiorespiratory and significantly reduced 
depression severity in the MDD group. Importantly, we were able to demonstrate that 
combining the minimum recommended dose of exercise with conventional treatments 
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was effective in treating the typical patient seen in the primary care setting who continues 
to experience severe depressive symptoms despite being treated with antidepressant 
medication. On the other hand, prescribing exercise to MDD patients presents many 
challenges to the practitioner since many patients lack motivation to initiate and maintain 
an exercise routine. Introducing patients to the minimum recommended dose of exercise 
as an add-on therapy may offer a practical approach for practitioners to help patients 
initiate and maintain a routine of daily exercise [113, 114]. 
An interesting finding from this pilot study was that eight weeks of exercise 
affected healthy and MDD brains similarly. The deactivation pattern we observed in 
several brain regions warrants further investigation with a larger sample size to allow a 
more robust statistical analysis. Future work must also include an MDD control group, as 
this will help us understand the magnitude of the effect of exercise, in combination with 
other therapies, on depressive symptomology and neural function. Moreover, there is a 
shortage of reporting sedentary behavior, physical activity levels, and cardiovascular 
fitness parameters in the MDD literature. As such, some of the differences observed in 
studies comparing MDD to controls might be confounded by a low active lifestyle, which 
may be more prevalent in MDD. To address this gap, future research should compare 
“fit” and “low-fit” MDD groups to identify markers independent of cardiorespiratory 
fitness and unique to MDD. Furthermore, the exercise and cognitive literature have not 
established whether the psychological effects from engaging in exercise, independent of 
changes in fitness, are still beneficial to mental health and brain function. Future research 
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must indicate whether the effects seen following an exercise intervention are associated 
with improved cardiovascular fitness or from the psychological benefits from engaging in 
exercise. 
Lastly, MDD is a heterogeneous disorder, and it is likely to be a multifaceted 
interaction of psychological and neurobiological mechanisms that underlie or mediate the 
effects of exercise. Future research must consider using a combination approach of 
multimodal imaging techniques, behavioral assessments, and biochemical analysis to 
delineate the biological and clinical signatures of fit and unfit MDD populations. Once 
we are able to elucidate these key biomarkers unique to MDD, novel intervention 
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Connecting statement I 
Study one showed that eight weeks of exercise, based on the minimal 
recommended guidelines, improved fitness in both MDD and young and healthy adults 
and significantly improved depressive symptoms in those with MDD. Results also 
showed that the MDD group performed significantly more poorer on the associative 
memory task when compared to young and healthy adults, indicating impaired episodic 
memory. Although no pre-post change in memory performance was observed for either 
group, fMRI results showed a marginally significant decrease in hippocampal activity in 
both groups following the exercise intervention. The exploratory whole brain analysis 
collapsed across groups revealed a similar deactivation pattern across several memory 
associated regions. These results indicate that the effects of exercise on neural function is 
not specific to those with MDD but may be a generalized effect in people who are 
considered low active and low-fit.  
The following study examined the effects of an eight-week exercise intervention 
in MDD patients who were undergoing ADM treatment and cognitive behavioural group 
therapy (CBGT) versus ADM plus CBGT only. A power calculation yielded six 
participants based on a previous meta-analysis that examined the effects of exercise on 
depressive symptoms revealing an overall effect size of -0.80 (Rethorst, Wipfli et al. 
2009). The purpose of recruiting MDD patients undergoing CBGT was twofold; 1) to 
control for the confounding variable of increased social contact that the exercise group 
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would receive from the exercise professional, 2) to compare the additional effects of 
exercise in those undergoing ADM treatment and CBGT. Since we did not observed any 
change in memory performance from the first study, I chose a battery of cognitive tests 
from CANTAB that have previously shown to be sensitive to MTL impairments and 
detect small changes in cognitive function. Sleep quality was also measured since sleep 
disturbance is the most frequently reported residual symptom in remissive patients.  To 
determine whether behavioural changes were linked physiological changes, salivary 
cortisol, plasma BDNF, plasma CTHB and plasma pro-inflammatory IL-1β, IL-6, TNF-α, 
and anti-inflammatory IL-1ra and IL-10 cytokines were quantified. 
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 Chapter 3: Exercise leads better clinical outcomes in those 
receiving medication plus cognitive behavioural therapy for 
major depressive disorder 
Adapted from: Gourgouvelis, J., Yielder, P., Clarke, S.T, Behbahani, H. & Murphy, B. 
(2017). Exercise leads better clinical outcomes in those receiving medication plus 
cognitive behavioural therapy for major Depressive Disorder. Frontiers in Psychiatry 
(under revision) 
3. 1 Abstract 
Objective 
To investigate the effects of exercise as an add-on therapy with antidepressant medication 
and cognitive behavioural group therapy (CBGT) on treatment outcomes in MDD 
patients.  We explored whether exercise reduces the residual symptoms of depression, 
notably cognition and sleep quality, and to identify putative biochemical markers related 
to treatment response.  
Methods 
Sixteen  MDD patients were recruited from a mental health day treatment program at a 
local hospital. Eight medicated patients performed an eight-week exercise intervention in 
addition to CBGT, and eight medicated patients attended the CBGT only. Twenty-two , 
healthy participants with no history of mental health illness were also recruited to provide 




Results showed exercise resulted in greater reduction in depression symptoms (p=0.007, 
d=2.06), with 75% of the patients showing either a therapeutic response or complete 
remission of symptoms versus 25% of those who didn’t exercise. In addition, exercise 
was associated with greater improvements in sleep quality (p=0.046, d=1.28) and 
cognitive function (p=0.046, d=1.08). The exercise group also had a significant increase 
in plasma brain-derived neurotrophic factor (BDNF), p=0.003, d=6.46 that was 
associated with improvements in depression scores (p=0.002, R2 = 0.50) and sleep 
quality (p=0.011, R2 = 0.38). 
 
Conclusion 
We provide evidence that exercise as an add-on to conventional antidepressant therapies 
improved the efficacy of standard treatment interventions. Our result emphasize the 
clinical importance of measuring peripheral BDNF concentrations and sleep quality in 
MDD patients, to monitor markers most significant in clinical recovery. 
 
Key words 
Major Depressive Disorder (MDD), exercise, brain-derived neurotrophic factor (BDNF), 







Major depressive disorder (MDD) is a global public-health problem being the 
second leading cause of disability worldwide (Ferrari, Charlson, & Norman, 2013) and 
projected to be the leading cause by 2030 (WHO, 2008). Despite many efforts to develop 
effective antidepressant therapies, depression remains a severely undertreated and under 
recognized disorder in the primary care setting. It has been estimated that merely half of 
depressed individuals seek medical treatment and among those who do seek help, just 
over 30% receive an efficacious treatment (Andrews, Sanderson, Corry, & Lapsley, 
2000; Diverty & Beaudet, 1997; Fava & Ruini, 2002; Insel & Charney, 2003; Rush et al., 
2008). Furthermore, over 40% of MDD patients who are considered in partial or full 
remission continue to experience residual symptoms and are at greater risk for relapse, 
highlighting the need for more efficacious antidepressant therapies (Fava et al., 2006; 
Paykel et al., 1995). 
MDD is a clinically and biologically heterogeneous disorder that frequently 
coexists with other medical illnesses (Moussavi et al., 2007). Consequently, the etiology 
and pathogenesis of MDD is thought to be multifaceted, making it very challenging for 
researchers to develop novel efficacious antidepressant therapies. Converging evidence 
from brain imaging and neuropathological studies in humans and animals have linked 
MDD to structural, functional and cellular changes within the hippocampal formation. 
People with MDD have consistently been found to have reduced hippocampal volumes 
(McKinnon, Yucel, Nazarov, & MacQueen, 2009; Schmaal et al., 2016; Videbech & 
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Ravnkilde, 2004) and impaired hippocampal function during memory encoding and 
retrieval processes (Fairhall, Sharma, Magnusson, & Murphy, 2010; Milne, MacQueen, 
& Hall, 2012; Sweeney, Kmeic, & Kupfer, 2000; Toki et al., 2014; Zakzanis, Leach, & 
Kaplan, 1998).  
Compelling evidence has shown that reductions in neurotrophins and growth 
factors, particularly brain-derived neurotrophic factor (BDNF), to be a central player for 
both the onset of MDD and recovery once levels are normalized (Bocchio-Chiavetto et 
al., 2010; Brunoni, Lopes, & Fregni, 2008; Calabrese, Molteni, Racagni, & Riva, 2009; R 
S Duman & Monteggia, 2006; Ronald S Duman, Malberg, Nakagawa, & D’Sa, 2000; 
Karege, Vaudan, Schwald, Perroud, & La Harpe, 2005). BDNF is necessary for the birth, 
survival and function of neurons in the adult brain (Allen & Dawbarn, 2006; Autry & 
Monteggia, 2012; Kubo, Nonomura, Enokido, & Hatanaka, 1995; Li & Liu, 2010). 
Furthermore, BDNF is an activity-dependent secreted protein that plays a critical role in 
synaptic plasticity processes underlying learning and memory (Cunha, Brambilla, & 
Thomas, 2010). Consequently, therapeutic interventions that augment neuroplasticity, via 
increases in BDNF, have been shown to reverse the pathological effects of depression 
(Jacobs, Van Praag, & Gage, 2000; Serafini, 2012; Wainwright & Galea, 2013). 
A growing body of research is now suggesting that a chronic inflammatory 
response may also play a role in the pathogenesis of MDD (Krishnadas & Cavanagh, 
2012; Raison & Miller, 2011). The inflammatory hypothesis of depression was founded 
on the common comorbidity of depression-like behaviors with systemic infection, cancer 
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and autoimmune diseases (Dantzer, O’Connor, Freund, Johnson, & Kelley, 2008). 
Increased levels of pro-inflammatory interleukin (IL)-1 beta, IL-6, and tumor necrosis 
factor (TNF) alpha, and decreased levels of anti-inflammatory IL-1 receptor antagonist 
(ra) and IL-10 are the most commonly reported cytokines in the depression literature 
(Dowlati et al., 2010; Hiles, Baker, de Malmanche, & Attia, 2012; Howren, Lamkin, & 
Suls, 2009; Liu, Ho, & Mak, 2012; Miller & Raison, 2016; Schiepers, Wichers, & Maes, 
2005; Zorrilla et al., 2001). Chronic inflammation has been shown to have a detrimental 
impact on neuroplasticity, such as reductions in BDNF expression, neurogenesis, and 
neuronal survival (Calabrese et al., 2009; Goshen et al., 2008; Guan & Fang, 2006)..  
Several studies have reported that exercise alone or in combination with other 
therapies to be as efficacious in treating mild to moderate depression with response rates 
similar to antidepressant medication and cognitive behavioural therapy (Babyak et al., 
2000; J. A. Blumenthal et al., 2007; J. a Blumenthal et al., 1999; Hallgren et al., 2015; 
Martinsen, Medhus, & Sandvik, 1985; Stathopoulou, Powers, Berry, Smits, & Otto, 
2006).  Furthermore,  exercise for depression has been shown to improve cognitive 
function (Khatri et al., 2001) and sleep quality (Rethorst et al., 2013) which are the two of 
the most frequently reported residual symptoms among patients with MDD who achieve 
remission (Conradi, Ormel, & de Jonge, 2011). The beneficial effects of exercise on 
overall brain health has also been observed in other populations. In elderly adults, 
exercise has been shown to protect against the development of neurodegenerative 
diseases (Cotman, Berchtold, & Christie, 2007), reverse age associated brain volume loss 
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(Colcombe et al., 2006; Erickson et al., 2009), improve memory performance (Erickson 
et al., 2011; Voss et al., 2013) and improve executive function (Voss et al., 2010). 
Exercise has also been shown to facilitate neurocognitive recovery from traumatic brain 
injury (Devine & Zafonte, 2009; Mossberg, Amonette, & Masel, 2010) and increase 
hippocampal volume in schizophrenics (Pajonk et al., 2010). In rodents, exercise 
increases adult neurogenesis (Pereira et al., 2007; H van Praag, Kempermann, & Gage, 
1999) , synaptogenesis (Dietrich, Andrews, & Horvath, 2008), angiogenesis (Lopez-
Lopez, LeRoith, & Torres-Aleman, 2004), improves dendritic morphology (Redila & 
Christie, 2006; Yau et al., 2011) and enhances learning and memory (Henriette van 
Praag, Shubert, Zhao, & Gage, 2005).  
The mechanism which exercise improves depression and overall brain health 
remains unclear. However, the molecular link may be partly mediated by increases in 
neurotrophic growth factors that promote neuroplasticity, particularly BDNF. Robust 
evidence from the animal literature has shown that exercise improves memory and 
increases hippocampal BDNF (Cotman & Berchtold, 2002; Marlatt, Potter, Lucassen, & 
van Praag, 2012). However, in humans, the link between exercise and BDNF is less clear. 
Acute exercise has consistently been shown to increase peripheral BDNF levels in 
healthy (Dinoff, Herrmann, Swardfager, & Lanctôt, 2017; Ferris, Williams, & Shen, 
2007; Heyman et al., 2012) MDD (Gustafsson et al., 2009; Laske et al., 2010), and 
elderly (Håkansson et al., 2016) individuals, whereas, the long-term effects of exercise on 
resting BDNF concentrations have been mixed (Köhler et al., 2014; Toups et al., 2011; 
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Zoladz et al., 2008). Exercise has also been shown to reduce systemic inflammation in 
other pathological conditions such as cardiovascular disease and Type 2 diabetes mellitus 
(Balducci et al., 2010; Meirelles et al., 2014; Pedersen, 2006). Studies have reported a 
simultaneous increase in the systemic levels of cytokines with anti-inflammatory 
properties including IL-10, IL-1ra and a decrease in the pro-inflammatory cytokines IL-6, 
TNF-α, (Júnior, Lopes, Seelaender, & Lopes, 2009; Petersen & Pedersen, 2007). 
Nonetheless, the literature examining the relationship between exercise and inflammatory 
markers in MDD populations remains scant. More recently, Moon et al., (2016) identified 
the cysteine proteinases cathepsin B (CTHB), to be a novel protein that may play a key 
role in the beneficial effects of exercise on neural function .  
The main objective of this exploratory feasibility study was to explore the effects 
of combining exercise as an add-on therapy with antidepressant medication and cognitive 
behavioural group therapy (CBGT) treatment outcomes in  individuals.  Sedentary time 
has been shown to be positively associated with low grade chronic inflammation in non 
depressed populations (Henson et al., 2013) while BDNF levels are higher in 
cardiorespiratory fit individuals versus unfit individuals (Zoladz et al., 2008). As such, 
the research investigating the underlying mechanism involved in the etiology and 
pathogenesis of MDD may be confounded by physical activity variables that are often not 
reported. For this reason, we specifically recruited  MDD patients and controls to control 
for variations in baseline fitness level. In addition to reduction in depressive symptoms, 
we were interested in exploring if exercise reduces the residual symptoms of depression, 
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notably cognition and sleep quality, and identifying putative biochemical biomarkers 
(such as BDNF, cytokines, and CTHB) related to treatment response. These findings 
provide preliminary evidence which can be used to focus future research aimed at 
understanding of the etiology and pathophysiology of MDD as well as indicators 
associated with treatment response in exercise.  
3.3 Methods 
All procedures were approved by the University and Hospital Institutional Review 
Boards and all participants provided written informed consent. The study was registered 
with Clinicaltrials.gov (#NCT03191994) 
3.3.1 Participants  
Sixteen  patients (mean age=39.31 years, SD=7.02; 12 females) with comorbid 
MDD and anxiety were recruited from an outpatient cognitive behavioural group therapy 
(CBGT) program at a local hospital in Oshawa, Ontario, Canada. Twenty-two , healthy 
participants (mean age=20.63, SD=1.19; 11 females) with no history of mental health 
illness or neurological disease were also recruited from a local university in Oshawa, 
Ontario Canada to provide normal healthy values for comparison. Depressed participants 
(n = 16) had a confirmed diagnosis of MDD according to an unstructured clinical 
interview by hospital psychiatrists based on criteria from the Diagnostic and Statistical 
Manual of Mental Disorders – Fourth Edition (DSM-IV-TR: American Psychiatric 
Association, 1994) and a score ≥20 on the Beck Depression Inventory – Second Edition 
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(BDI-II: Beck, Steer, & Brown, 1996). Eligible MDD participants had no co-existing 
DSM-IV-TR Axis I disorders apart from anxiety. MDD participants were eligible if their 
pharmacological medication was stabilized a minimum of six weeks prior to study 
enrolment, experienced depression symptoms for a minimum of six months and screened 
negative on the Global Appraisal of Individual Needs (GAIN) for substance abuse 
(Dennis, Chan, & Funk, 2006). MDD and healthy participants were considered  if they 
exercise less than 20 minutes, three times per week. All participants were screened with 
the Physical Activity Readiness Questionnaire (PAR-Q) to ensure they had no medical 
contraindications to physical activity.  
3.3.2 Psychometric measures: anxiety, depression, sleep quality 
The BDI-II (Beck et al., 1996) was used to measure depression severity. The BDI-
II is the most commonly used self-reported instrument that measures depression severity 
ranging from mild to severe. The Hospital Anxiety and Depression Scale (HADS) was 
used to measure both depression and anxiety (Zigmond & Snaith, 1983). The HADS is 
also a reliable and widely used self-reporting instrument that consists of two 7 item 
subscales, one measuring anxiety (HADS-A) and one measuring depression (HADS-D) 
that assesses feelings of anxiety and depression. Poor sleep quality is one of the two most 
frequently reported residual symptom among patients with MDD who achieve remission 
(Conradi et al., 2011). The Pittsburgh Sleep Quality Index (PSQI) was used to measure 
sleep quality during the previous month (Buysse, Reynolds, Monk, Berman, & Kupfer, 
1989). The PSQI is a 19-item questionnaire that measures seven components of sleep 
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quality including, subjective sleep quality, sleep latency, sleep duration, habitual sleep 
efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. The 
maximum PSQI score is 21 points and an overall PSQI score > 5 points indicates that the 
individual has poor sleep quality. 
3.3.3 Cognitive measures  
Cognitive impairment is one of the two most frequently reported residual 
symptom among patients with MDD who achieve remission (Conradi et al., 2011). To 
assess cognitive performance within selected domains we used a computerized cognitive 
battery, the Cambridge Neuropsychological Test Automated Battery (CANTAB) 
(Cambridge Cognition, Cambridge, UK; 
http://www.cambridgecognition.com/cantab/cognitive-tests/). The CANTAB is a fast and 
accurate method to assess cognitive functioning (Fray & Robbins, 1996) and shown to 
possess acceptable to high levels of concurrent validity and test–retest reliability (Fowler, 
Saling, Conway, Semple, & Louis, 1995). Each test is presented on a computer touch 
screen and  uses non-verbalizable patterns presented in a game-like format that provides 
immediate feedback to maintain interest and reduce boredom (Levaux et al., 
2007)(Levaux, Potvin et al. 2007)(Levaux, Potvin et al. 2007)(Levaux, Potvin et al. 
2007). Three CANTAB tests were included in our assessment battery that have been 
previously used to identify impaired cognitive function in MDD and shown to be 
sensitive to changes in the hippocampus and frontal lobes (de Rover et al., 2011; Heinzel, 
Northoff, Boeker, Boesiger, & Grimm, 2010; Porter, Gallagher, Thompson, & Young, 
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2003). The Paired Associates Learning (PAL) assesses visual learning and memory. The 
Delayed Matching to Sample (DMS) assesses recognition memory for patterns. The 
Intra–Extra Dimensional Set Shift (IED) is a measure of rule acquisition and reversal, 
often considered a test of cognitive flexibility. In addition, the Montreal Cognitive 
Assessment (MoCA), a brief neurocognitive tool with high sensitivity for screening 
patients with mild cognitive impairment, was used to assess global function. The 
maximum MoCA score is 30 and an overall score <25 is indicative of mild cognitive 
dysfunction (Nasreddine et al., 2005). 
3.3.4 Plasma collection 
Non-fasting peripheral venous blood was collected mid-day from each participant 
at baseline and eight weeks by venipuncture into ethylenediaminetetraacetic acid 
(ECBGTA) tubes. Blood samples were prepared within 30 minutes by centrifugation and 
the plasma was stored at -85°C until assayed. Plasma proteins IL-1β, IL-1Ra, IL-6, IL-10 
TNF-α, BDNF and total CTHB were quantified using enzyme-linked immunosorbant 
assays (ELISA) following manufacturer’s protocols (R&D Systems, MN, USA; 
BioLegend, CA, USA). ELISA plates were read at a wavelength of 450nm using a 
Synergy HTTR microplate reader (Bio-Tek Instrumentation, VT, USA). 
3.3.5 Fitness assessment 
The YMCA cycle ergometer test recommended by the American College of 
Sports Medicine was used to measure cardiorespiratory fitness at baseline and eight 
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weeks (Beekley, Brechue, and Dehoyos 2004; Golding, Myers, and Sinning 1989; 
Pescatello and American College of Sports Medicine. 2014). The YMCA protocol is an 
indirect submaximal exercise test that uses heart rate (HR) measurements to estimate 
maximal oxygen consumption (VO2max). The test consists of two or more consecutive 3-
minute stages at a given workload. The objective was to elevate the participant’s HR 
between 110 bpm and 85% of age-predicted maximal HR for two consecutive stages. The 
first stage of the test was a 25 Watt workload at 50 revolutions per minute. Radial pulse 
was used to measure HR during the final 15 seconds of each minute to determine the 
workload of the following stages.  After a steady state HR (two successive measures that 
differ < 5 bpm) was within 10 bpm of the 85% age-predicted maximum HR the test was 
complete. VO2max was predicted using the YMCA formula that includes workload, body 
mass and predetermined constants.  
3.3.6 Exercise intervention 
The eight week exercise prescription was based on the international 
recommendation to perform a minimum of 150 minutes per week of moderate to 
vigorous intensity aerobic exercise in addition to resistance activities two times per week, 
for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor 
fitness in healthy adults (Canadian Society for Exercise Physiology 1998; Garber et al. 
2011). This minimum recommended dose of exercise was prescribed to increase 
participant adoption and adherence since  people with depression generally lack 
motivation to begin an exercise program (Stanton & Reaburn, 2014). The research has 
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also found that a combining aerobic with resistance training is more effective than 
aerobic exercise alone in improving depressive symptoms and cognitive function 
(Cooney, 2013; Smith et al., 2010). The CBGT + exercise (exercise) group performed 
one aerobic only and two resistance (with a shorter bout of aerobic activity) weekly 
sessions for a duration of eight weeks. All exercise sessions were performed alone, on 
non-consecutive days and each session was supervised by a qualified exercise 
professional to increase participant compliance and to ensure all participants fulfilled the 
exercise prescription (Felipe B. Schuch et al., 2016). The exercise intensity for aerobic 
and resistance sessions was based on a target HR between 60-80% of their age-predicted 
maximum HR. The aerobic workloads were determined by HR response and increased by 
five-minute increments over the course of the eight weeks, reaching a maximum of 60 
minutes per session. Resistance sessions incorporated a whole-body exercise prescription 
using the larger muscle groups and workloads were approximately 95% of the 10 
repetition maximum to ensure proper form. Resistance exercises were performed in two 
or three supersets (one set of each exercise with no rest between sets) with an 8-12 
repetition range to decrease rest times and to maintain target HR. Radial pulse was 
measured throughout each exercise session to ensure that participants maintained their 
target HR. Attendance was recorded and only those participants who completed >80% of 
the exercise sessions were included in the analysis. For a full description of the exercise 
intervention, please see Gourgouvelis et al., 2017.  
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3.3.7 Statistical analysis 
All statistical analyses were conducted using GraphPad Prism, v6 (La Jolla, CA, 
USA). Continuous data are presented as means and standard deviations (SD). Categorical 
data are presented as frequencies. Baseline group differences were compared using a two-
tailed Student’s t-test and Fisher's exact test. Paired t-tests were used to compare the pre-
post change for each group and a two-way repeated measures analysis of variance 
(ANOVA) was used to determine group-by-time interactions. P values less than 0.05 
were considered statistically significant. Effects sizes were determined using a modified 
version of Cohen’s D (dppc2) method which divides the difference in mean pre-post 
change between groups by the baseline pooled standard deviation to account for any 
baseline differences (Morris, 2007). The criterion used to determine remission and 
response rates were BDI cut off scores ≤11 and ≥47% respectively (Riedel et al., 2010). 
Simple linear regression analyses were performed to examine the relationship between 
pre-post changes in plasma BDNF levels and BDI scores, sleep quality and correct 
response latency.  
3.4 Results 
3.4.1 Baseline characteristics between MDD and healthy groups 
Analysis revealed no significant difference in gender distribution between groups 
(p = 0.182). As expected, the MDD group was significantly older than the healthy group, 
t (36)=12.31, p < 0.0001, given that we intentionally recruited younger individuals to 
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provide normative data for comparison from healthy individuals with no history of 
mental health illness or other confounding pathologies that increase with age. Results 
showed that patients with MDD had a significantly elevated BDI score, t (36)=12.90, p < 
0.0001, HADS-A score, t (36)=13.07,p < 0.0001 and PSQI score, t (36)=9.94, p < 
0.0001, compared to the healthy controls. The MDD group had a significantly greater 
body mass index (BMI) compared to the healthy group, t (36)=2.08, p = 0.045. A single 
participant from the exercise group discontinued baseline VO2max testing due to 
exhaustion and was excluded from VO2max analysis. There were no significant 
differences between the groups for VO2max, BDNF, and CTHB. Cytokine data for IL-1β, 
IL-1ra, IL-6, and TNF-α were not included in the parametric analysis since greater than 
50 percent of the values were below the level of detection. Therefore, we compared the 
frequencies of detectable cytokine concentrations between the groups using Fisher’s 
exact test. Results showed no differences between groups in frequency of individuals 
with detectable circulating concentrations of IL-1β, IL-1ra, IL-6, IL-10 and TNF-α (p > 
0.05), suggesting that depressed subjects were not displaying classical signs of systemic 
inflammation at the study baseline. Cognitive tests revealed that the MDD group 
performed significantly poorer on the MoCA, t(36)=2.32, p = 0.026, had significantly 
more errors for the PAL test, t(35)=3.90, p = 0.0004, and had a significantly longer 
correct response latency for the DMS test t(35)=2.44, p = 0.020, suggesting cognitive 
impairment. Performance did not differ between groups for the DMS and IED cognitive 
tests (p > 0.05). See Table 3.1.  
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3.4.2 Baseline characteristics between MDD groups 
At baseline, the exercise group had a significantly higher BDI score compared to 
the CBGT only (non-exercise) group, t(14)=2.38,p=0.032, indicating greater depression 
severity. The non-exercise group had significantly higher plasma BDNF concentrations 
compared to the exercise group, t(14)=2.40,p=0.031. There were no other baseline 
differences between groups (see Table 3.2). More than 50 percent of the patients did not 
have detectable plasma cytokine concentrations and were not included in the parametric 
analysis. We therefore conducted a Fisher’s exact text on the frequencies of detectable 
plasma cytokine concentrations and found no group differences at baseline (p > 0.05).  
3.4.3 Pre-post  measures for MDD groups 
Depressive Symptoms: Both MDD groups showed a statistically significant decrease in 
BDI and HADS-D scores following treatment. A two way repeated measures ANOVA 
revealed a group-by-time interaction, f (1,14)=10.18, p=0.007, and a large effect size of 
d=2.06 indicating that the exercise group had a greater reduction in BDI scores compared 
to the non-exercise group at eight week (see Figure 3.1a; 63% vs. 27%). Moreover, 75% 
of the patients in the exercise group showed either a therapeutic response or complete 
remission of symptoms versus 25% of the non-exercise group (see Figure 3.2).  
Sleep quality: The exercise group showed a significant decrease in PSQI scores 
(p=0.010) while the non-exercise group showed no significant change (p=0.09). There 
was also a significant group-by-time interaction, f (1,14)=4.81, p=0.046, and an effect 
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size of d=1.28 indicating that exercise was effective in improving sleep quality (see 
Figure 3.1b).  
Biological markers: There was no group-by-time interaction for VO2max pre-post. 
However, the exercise group showed a 31% increase in VO2max that was marginally 
significant t(6)=2.17, p=0.073, suggesting that the exercise intervention was successful at 
improving cardiorespiratory fitness (see Table 3.3). Biochemical marker analyses 
revealed a significant increase in plasma BDNF levels for the exercise group at eight 
weeks with a group-by-time interaction (f (1,14)=12.47, p=0.003) and a large effect size 
of d=6.46 (see Figure 3.1c). There were no pre-post changes in CTHB or cytokines in 
either group. A simple linear regression revealed that changes in BDNF were 
significantly associated with changes in BDI and PSQI scores indicating that those who 
experienced a greater increase in BDNF also experienced greater improvement in 
depression and sleep quality (see Figure 3). No significant relationship for changes in 
BDNF and correct response latency was found (p=0.190).  
Cognition: There were no changes in performance for the MoCA, DMS, PAL, or IED 
tasks for either group at eight weeks. A two way repeated measures ANOVA revealed a 
group-by-time interaction for the DMS correct response latency (f (1,13)=4.85, p=0.046) 
and a large effect size of d=1.08 indicating that the exercise group was significantly faster 
in making a correct decision post intervention (see Table 3.3). 
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Demographic    
Sex: (male/female) 4/12 11/11 .452 
Age (years) 39.31 (7.02) 20.95 (1.25) <.0001 
Psychometric    
BDI (depression) 37.50 (8.18) 7.55 (6.15) <.0001 
HADS-Anxiety 15.13 (2.73) 4.77 (3.24) <.0001 
PSQI (sleep) 13.81 (3.47) 4.36 (2.40) <.0001 
Biological    
Body mass index (kg/m2) 28.79 (5.17) 24.89 (5.17) .045 
VO2max (ml.kg-1.min-1) 23.40 (6.05) a 21.79 (7.77) .510 
BDNF (pg/ml) 8,237 (2163) 8,935 (2837) .415 
CTHB (pg/ml) 29,253 (9066) 37,551 (14,867) .348 
Cognitive     
MoCA 24.56 (1.67) 26.18 (2.40) .026 
DMS % correct 85.78 (13.06) a 90.30 (10.02) a .241 
DMS latency (ms) 4817 (1770) a 3640 (1176) a .020 
PAL (errors) 24.27 (19.33) a 7.50 (5.03) a .0004 
IED (errors) 19.07 (12.41) a  22.80 (17.93) a .495 
Note: MDD; Major Depressive Disorder; BDI = Beck Depression Inventory; 
HADS=Hospital Anxiety and Depression Scale; MoCO = Montreal Cognitive 
Assessment; PSQI=Pittsburgh Sleep Quality Inventory; BMI = body mass index; VO2max 
= maximum oxygen; BDNF=brain-derived neurotrophic factor; CTHB=cathepsin B; 
DMS=Delayed Matching to Sample; PAL=Paired Associates Learning; IED=Intra/Extra 
Dimensional Shift 
Data are expressed as mean with SD in parentheses. 




Table 3. 2 - Baseline characteristics of depressed groups 
Variables CBGT + Exercise (n=8) CBGT (n=8) p 
Demographic    
Sex: (male/female) 1/7 3/5 .248 
Age (years) 37.25 (8.00) 41.38 (5.66) .253 
Education (years) 13.25 (2.19) 13.50 (1.41) .790 
Cumulative illness duration 
(years) 3.57 (3.21) 3.00 (3.02) .432 
Psychometric    
BDI (depression score) 41.75 (3.50) 33.25 (9.48) .032 
HADS-Anxiety 15.63 (1.77) 14.63 (3.50) .483 
PSQI (sleep score) 14.38 (3.46) 13.25 (3.62) .535 
Biological    
Body mass index (kg/m2) 28.33 (5.12) 29.25 (5.52) .734 
VO2max (ml.kg-1.min-1) 24.82(8.00) a 22.16(3.80) .416 
BDNF (pg/ml) 7,108.48(596.51) 9,363.74(730.75) .031 
CTHB (pg/ml) 37,580 (10,284) 48,102 (25,327) .295 
Cognitive    
MoCA 24.63 (1.41) 24.50 (2.00) .887 
DMS % correct 90.48 (6.50) a 81.67 (16.23) a .203 
DMS latency (ms) 4,857 (1,648) a 4,781 (1,983) a .938 
PAL (errors) 22.14 (20.93) a 26.13 (19.05) a .706 
IED (errors) 20.57 (16.09) a 17.75 (9.04) a .677 
Note: CBGT = cognitive behavioural group therapy; BDI = Beck Depression Inventory; 
HADS=Hospital Anxiety and Depression Scale; MoCA = Montreal Cognitive 
Assessment; PSQI=Pittsburgh Sleep Quality Inventory; BMI = body mass index; VO2max 
= maximum oxygen consumption; BDNF=brain-derived neurotrophic factor; 
CTHB=cathepsin B; DMS=Delayed Matching to Sample; PAL=Paired Associates 
Learning; IED=Intra/Extra Dimensional Shift 
Data are expressed as mean with SD in parentheses. 




Table 3. 3 - Pre-post changes for depressed groups 
 CBGT + Exercise (n=8)   CBGT (n=8)  Between Group Analysis 
Measure  Pre  Mean (SD) 
Post  
Mean (SD) p d   
Pre 
 Mean (SD) 
Post  
Mean (SD) p d  F p dppc2 
Psychometric                
BDI  41.75 (3.50) 15.50 (10.43) .0004 2.89   33.25  (9.48) 24.38 (10.01) .042 0.91  10.80 .007  2.38 
HADS-Depression  13.63 (2.97) 5.88 (2.23) <.0001  2.86   12.00 (3.59) 9.75 (3.73) .034 0.61  20.91 .0004  1.63 
HADS-Anxiety  15.63 (1.77) 11.38 (4.53) .010 0.90   14.63 (3.50) 11.25 (2.38) .030 1.11  0.253 .623 0.31 
PSQI (sleep)  14.38 (3.46) 7.75 (4.20) .011  1.68   13.25 (3.62) 11.38 (3.30) .090 0.54  4.81 .046  1.32 
Biological                
BMI (kg/m2)  28.33 (5.12) 28.29 (4.48) .934 0.01   29.25 (5.52) 29.95 (5.36) .068 0.13  1.84 .196 0.14 
VO2max  
(ml.kg-1.min-1) 
 24.82 (8.00) a 32.52 (10.12) a .073 0.83   22.16 (3.80) 26.42 (8.17) .130 0.60  0.659 .432 0.54 
BDNF (pg/ml)  7107 (596.51) 10,642 (957.45) .008 1.54   9363 (730.75) 8497 (943.75) .304 0.36  12.47 .003  6.46 
CTHB (pg/ml)  37,580 (10,284) 39,293 (14,278) .697 0.13   48,102 (25,327) 55,477 (22,450) .109 0.30  0.947 .347 0.28 
Cognitive                 
MoCA  24.63 (1.41) 25.75 (2.38) .229 0.56   24.50 (2.00) 25.75 (2.71) .380 0.40  0.006 .938 0.07 
DMS % correct  90.48 (6.50) a 89.48 (3.50) a .721 0.19   81.67 (16.23) 80.00 (21.97) .844 0.09  0.005 .943 0.05 
DMS latency (ms)  4857 (1,648) a 2650 (510.50) a .010 1.68   4781 (1,983) 4601 (3785) .800 0.02  4.85 .046 1.08 
PAL (errors)  22.14 (20.93) a 19.86 (11.44) a .772 0.13   25.13 (19.05) 19.63 (21.14) .056 0.33  0.304 .591 0.16 
IED (errors)  20.57 (16.09) a 18.57 (7.59) a .774 0.16   17.75 (9.04) 19.50 (7.62) .666 0.21  0.252 .624 0.28 
Note: CBGT = cognitive behavioural group therapy; BDI = Beck Depression Inventory; HADS = Hospital Anxiety and Depression 
Scale; PSQI = Pittsburgh Sleep Quality Inventory; BMI = body mass index; VO2max = maximum oxygen consumption; MoCA = 
Montreal Cognitive Assessment; DMS = Delayed Matching to Sample; PAL = Paired Associates Learning; IED = Intra/Extra 












































Figure 3. 1 -  Individual group plots illustrating pre-post changes for (A) BDI depression 
scores, (B) PSQI scores and (C) BDNF levels. Abbreviations: CBGT=cognitive 
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behavioural group therapy; BDI=Beck Depression Inventory; PSQI=Pittsburgh Sleep 












Figure 3. 2 Responders, non-responders and remissive MDD patients at 8 weeks for each 
group. Benefit of exercise was greater as defined by treatment response and remission 
(N=6) compared to (N=2) in the non-exercise group. Responders represent patients with a 
greater than or equal to a 47% reduction BDI score at 8 weeks compared to baseline and 
remission represents patients with a BDI score less than or equal to 11. Abbreviation: 
CBGT=cognitive behavioural group therapy 
 
A. B. 
Figure 3. 3 A) Linear regression of pre-post changes for BDI and PSQI scores against 
BDNF change, irrespective of group. (A) A significant negative correlation was found for 
(A) BDI scores and BDNF levels (p=0.002, R2 = 0.50) and (B) PSQI scores and BDNF 
levels (p=0.011, R2 = 0.38) indicating that improvements in depression and sleep quality 
scores are associated with an increase in BDNF levels. Abbreviations: BDI, Beck 
Depression Inventory, BDNF, brain-derived neurotropic factor, PSQI, Pittsburgh Sleep 
Quality Index 
3.5 Discussion 
This feasibility study investigated the effects of an eight-week exercise 
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prescription, based on the minimal recommended dose, on a series of symptom, 
biochemical, and cognitive measures. Our preliminary study provides evidence that 
exercise as an add-on therapy led to higher remission/treatment response rates versus more 
common treatment approaches alone. In addition, we found that exercise improves sleep 
quality and cognitive function, and BDNF levels increased in the exercise group post-
treatment. These changes in BDNF were significantly associated with symptom 
improvement in depression and sleep quality scores, providing potential biomarkers of 
treatment response. We also did not observe any significant differences between MDD 
patients and healthy controls for plasma CTHB, anti-inflammatory and pro-inflammatory 
cytokines, and no changes pre-post, suggesting BDNF may be a specific marker for the 
positive changes which come about following an exercise intervention in patients who do 
not have co-morbid inflammation.  
To the best of our knowledge, this is the first study to investigate the effects of 
exercise in combination with ADM and CBGT specifically in a  MDD population. As 
such, there are limited data to compare our research findings. Our results provide evidence 
for the therapeutic use of exercise in treating MDD collaborating with previous findings 
that exercise as an add-on therapy to ADM is more efficacious in alleviating MDD 
symptoms than ADM alone (Pilu et al., 2007; Schuch, Vasconcelos-Moreno, Borowsky, & 
Fleck, 2011). While the sample in our study was small, the added benefit of an exercise 
intervention had a large effect size with respect to the changes in clinical scores. The 
efficacy of exercise is further substantiated by the fact that 75% of the patients in the 
exercise group achieving either remission or a therapeutic response versus only 25% in the 
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non-exercise group. This represents substantive improvement in outcomes with the 
addition of a relatively low-cost add-on intervention.  
The increase in plasma BDNF concentration and the associated decrease in 
depressive symptoms and improvements in sleep quality observed in the exercise group 
adds further support to the interplay between depression, sleep quality and BDNF that may 
underlie the onset and recovery of MDD (Schmitt, Holsboer-Trachsler, & Eckert, 2016). 
Sleep disturbances are reported by up to 90% of depressed subjects (Mendlewicz, 2009; 
Palagini, Baglioni, Ciapparelli, Gemignani, & Riemann, 2013) and sleep studies have 
shown that depression is associated with reductions in slow-wave activity (SWA), a 
reliable EEG marker of sleep homeostasis (Borbély et al., 1984; Hoffmann, Hendrickse, 
Rush, & Armitage, 2000). SWA is an essential mechanism for restoring synaptic plasticity 
processes associated with learning and memory (Gorgoni et al., 2013; Huber, Ghilardi, 
Massimini, & Tononi, 2004). BDNF, a mediator of activity-dependent synaptic plasticity, 
has been suggested to be the molecular mechanism that links synaptic plasticity and the 
homeostatic sleep response (Bachmann et al., 2012; Huber, Tononi, & Cirelli, 2007). Rats 
administered higher levels of intracortical injections of BDNF during wakefulness show a 
stronger SWA response during subsequent sleep and stronger synaptic potentiation during 
waking. However, this effect is reversed when blocking BDNF during wakefulness 
(Faraguna, Vyazovskiy, Nelson, Tononi, & Cirelli, 2008). As such, one possible 
mechanisms of the improved sleep quality of patients in the exercise group may be the 
increase in plasma BDNF concentrations brought about via increased physical activity.  
Our initial baseline comparison between MDD patients and healthy controls 
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revealed that the MDD patients performed below the healthy controls on the hippocampal-
dependent cognitive tests. These behavioural results complement our previous fMRI 
findings that explored the effects of an eight week exercise intervention on hippocampal 
function during a memory encoding task, in low fit MDD and healthy individuals 
(Gourgouvelis, Yielder, & Murphy, 2017). Despite no pre-post change in memory 
performance for either group, there was a consistent deactivation pattern in the 
hippocampus and other memory related brain regions during the memory encoding 
process. This deactivation pattern was common amongst both the MDD and healthy 
groups, suggesting that exercise may have a generalized effect on brain function in /low fit 
individuals by enhancing neural network processing efficiency while still resulting in a 
greater mood effect for those suffering from MDD. Electroencephalographic studies have 
also found that active individuals showed less PFC activation and significantly faster 
reaction times compared to  individuals indicating that physically active individuals require 
less cognitive resources and effortful task preparation that results in faster information 
processing speeds (Berchicci, Lucci, & Di Russo, 2013).  
3.6 Limitations 
The sample size of this feasibility study is small, thus even though the exercise 
group experienced a concomitant decrease in depression severity and increase in plasma 
BDNF, these results must be considered preliminary. Another possible limitation is that 
our MDD sample were all undergoing ADM which may have affected our baseline 
comparison with healthy controls. However, given that we wanted to replicate the typical 
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patient seen in “real-world” clinical practice, to maximize the external validity of our 
results, including patients already on ADM actually increases the external validity. 
Furthermore, since our sample was comprised of  MDD patients, we cannot be certain if 
the link between BDNF, depression and sleep quality exists in high-fit/high-active MDD 
patients. There is a lack of reporting physical activity levels and cardiorespiratory fitness 
parameters in the MDD literature. Therefore, significant differences observed in studies 
that compare MDD to healthy individuals may be confounded by a sedentary lifestyle that 
may be more common in MDD. Future studies must compare ‘fit’ versus ‘low fit’ MDD 
groups to identify biological markers, independent of cardiorespiratory fitness and specific 
to MDD. 
3.7 Conclusion 
The design of this feasibility study allowed for a “real-world” therapeutic approach 
that addresses effectiveness while also measuring biochemical markers shown to be altered 
in MDD. We provide evidence that exercise as an add-on to conventional antidepressant 
therapies is more efficacious in treating MDD than no exercise. We also found that 
improvements in depression and sleep quality were associated with an increase in plasma 
BDNF concentration following exercise, providing a potential biological marker for 
treatment outcome. These results emphasize the clinical importance of measuring 
peripheral BDNF concentrations and sleep quality in MDD patients, to monitor changes 
over the course of treatment that may elucidate markers most significant in clinical 
recovery. Finally, our study demonstrated that a combined aerobic and resistance exercise 
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prescription, based on the minimum recommended dose, is well tolerated and adhered to 
throughout the eight weeks by  MDD patients, giving health care practitioners guidelines 
for prescribing exercise to their patients. 
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Connecting statement II 
This study demonstrated that exercise in addition to ADM and CBGT produced 
significantly better outcomes in people with MDD than ADM plus CBGT with no exercise. 
Results showed that exercise as an add-on treatment improved depressive symptoms, sleep 
quality and cognitive function significantly more than no exercise. Results also showed 
that improvements in depression scores and sleep quality were associated with an increase 
in plasma BDNF concentrations suggesting that exercise mediates these effects through an 
upregulation of BDNF secretion. Findings also indicate that the MDD groups were not in 
an inflamed state at baseline suggesting that chronic low-grade inflammation was either 
resolved with ADM treatment or that these individuals had normal immune function. 
Salivary cortisol was not included in the analysis since 19% of the sample tubes did not 
contain saliva samples. Also, 28% of participants showed an inverse CAR indicating errors 
in sampling methods. 
The purpose of study three was to examine the effects of exercise on cognitive 
function, plasma BDNF and CTHB concentrations in young and healthy adults. Since 
study one showed a change in neural activity during the encoding process of the memory 
task in young and healthy adults, I wanted to determine whether these changes in neural 
function were paralleled by changes in plasma BDNF and CTHB concentrations that have 
been shown to increase following long-term exercise.  
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Chapter 4: You can’t fix what isn’t broken: Effects of eight 
weeks of exercise on cognitive function and biochemical 
markers in young and healthy adults 
Adapted from: Gourgouvelis, J., Yielder, P., Clarke, S., Behbahani, H. & Murphy, B. 
(2017). You can’t fix what isn’t broken: Effects of eight weeks of exercise on cognitive 
function and biochemical markers in young and healthy adults. PeerJ (under review) 
4.1 Abstract 
Objective 
The benefits of exercise on brain health is well known in aging and psychiatric 
populations. However, the relationship between habitual exercise in young and healthy 
adults remains unclear. This study explored the effects an eight week exercise prescription 
on cognitive function, brain-derived neurotrophic factor (BDNF) and cathepsin B (CTHB) 
in young and healthy adults.   
Methods 
Twenty-two untrained, young and healthy adults were recruited from a local 
university. Twelve participants performed an eight-week exercise prescription and twelve 
participants served as controls. Cognitive assessments, cardiorespiratory fitness and plasma 




Results showed exercise improved cardiorespiratory fitness (p=0.011, d=1.48) with 
no improvements in cognitive function or no changes in plasma BDNF and CTHB 
concentrations. 
Conclusion 
We provide evidence that eight weeks of exercise does not improve cognitive 
function or change plasma biochemical markers concentrations in young and healthy 
adults, despite improvements in cardiorespiratory fitness. These results suggest that 
cognitive health may peak during early adulthood leaving little room for improvement 
throughout this period of the lifespan. 
 
4.2 Introduction 
Research has consistently demonstrated the health benefits of habitual exercise.  
Not only has exercise been shown to prevent disease, but exercise is considered an 
effective treatment for several medical conditions (Naci & Ioannidis, 2013; Pedersen & 
Saltin, 2006). More recently, considerable attention has focused on the positive effects of 
exercise on brain structure and function. In elderly populations, exercise has been shown to 
increase brain volume in selective areas such as the hippocampus and prefrontal cortex 
(Colcombe et al., 2006; Erickson et al., 2009; Erickson, Voss, Prakash, Basak, Szabo, 
Chaddock, Kim, Heo, Alves, White, et al., 2011). Additionally, exercise improves memory 
(Erickson, Voss, Prakash, Basak, Szabo, Chaddock, Kim, Heo, Alves, & White, 2011; 
Voss et al., 2013), executive function (Voss et al., 2010a), attention (Salthouse & Davis, 
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2006) and decreases cognitive processing speed (Salthouse & Davis, 2006).  Exercise has 
also shown to be effective in treating mental health disorders such as anxiety (Herring, 
O’Connor, & Dishman, 2010), depression (Blumenthal et al., 1999; Stathopoulou, Powers, 
Berry, Smits, & Otto, 2006) and schizophrenia (Stathopoulou et al., 2006). Complementing 
human findings, the rodent literature has shown exercise to upregulate adult neurogenesis 
(van Praag, Kempermann, & Gage, 1999), increase neuronal survival (Kobilo et al., 2011), 
enhance dendritic growth (Leggio et al., 2005), increase dendritic spine density (Eadie, 
Redila, & Christie, 2005), enhance synaptic plasticity (Farmer et al., 2004), induce 
angiogenesis (Swain et al., 2003), enhance learning (Henriette van Praag, Shubert, Zhao, & 
Gage, 2005), and improve memory (Marlatt, Potter, Lucassen, & van Praag, 2012).   
Exercise activates cascades of molecular and cellular signalling mechanisms within 
the central nervous system. Although the precise mechanisms underlying the neurogenic 
effects of exercise remain unclear, a growing body of literature suggests that exercise 
activates neurotrophic mechanisms known to promote neuroplasticity. Most notably, brain-
derived neurotrophic factor (BDNF) is emerging as a key molecule underlying the benefits 
of exercise on brain function (Cotman, Berchtold, & Christie, 2007). BDNF is an activity-
dependent secreted protein essential for neural growth, neural survival (Barde, 1990) and 
synaptoplastic processes critical for learning and memory (Pang & Lu, 2004; Yamada, 
Mizuno, & Nabeshima, 2002). The brain contributes to approximately 70–80% of 
peripheral BDNF concentrations at rest and during exercise (Rasmussen et al., 2009). 
BDNF is also produced in various peripheral tissues which is stored and released from 
circulating platelets upon activation (Fujimura et al., 2002; Yamamoto & Gurney, 1990). 
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In rodents, exercise rapidly increases the BDNF gene expression in brain regions involved 
with learning and memory formation, particularly in the hippocampus (Berchtold, Chinn, 
Chou, Kesslak, & Cotman, 2005; Cotman & Berchtold, 2002; Cotman et al., 2007; Neeper, 
Gómez-Pinilla, Choi, & Cotman, 1995). Similar to the increases of central BDNF 
expression observed in rodents, research has consistently shown that acute exercise 
increases peripheral BDNF concentrations in humans (Ferris, Williams, & Shen, 2007; 
Knaepen, Goekint, Heyman, & Meeusen, 2010; Rojas Vega et al., 2006). However, the 
literature supporting elevations in resting peripheral BDNF concentrations following a 
long-term exercise intervention have been mixed.  In older adults, a one year moderate 
intensity aerobic intervention significantly increased resting plasma and serum BDNF 
concentrations (Erickson, Voss, Prakash, Basak, Szabo, Chaddock, Kim, Heo, Alves, 
White, et al., 2011) that was positively associated with age (Leckie et al., 2014). In patients 
with Major Depressive Disorder (MDD), an eight week moderate aerobic and resistance 
intervention significantly increased plasma BDNF concentrations (Gourgouvelis, Murphy, 
& Yielder, 2017) while no change in serum BDNF concentrations were observed following 
a three month aerobic exercise intervention (Krogh et al., 2014). In young and healthy 
adults, a five week moderate aerobic intervention significantly increased resting plasma 
BDNF concentrations (Zoladz et al., 2008) while no increase in plasma BDNF 
concentrations were observed following 12 weeks of strength or 12 weeks of moderate 
endurance training (Schiffer, Schulte, Hollmann, Bloch, & Strüder, 2009) and no change in 
serum BDNF concentrations following three weeks of moderate aerobic activity (Griffin et 
al., 2011). Nonetheless, the lack of consistent findings examining the effects of long-term 
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exercise on BDNF might be attributed to the heterogeneity of exercise interventions 
between studies and lack of reporting baseline physical activity levels. 
It was recently demonstrated that cathepsin B (CTHB), a cysteine proteinases 
produced by contracting skeletal muscle, is capable of penetrating the blood-brain barrier 
and upregulating both BDNF expression and hippocampal neurogenesis in wild-type mice 
(Moon et al., 2016). Following long-term running, researchers also observed an increase in 
plasma CTHB concentrations that was associated with improved memory performance in 
mice, Rhesus monkeys and humans. CTHB is an autophagy-related protein also shown to 
prevent memory deficits in Alzheimer’s disease by upregulating autophagic-lysosomal 
processes and reducing accumulations of amyloid-β peptides in the brain (Mueller-Steiner 
et al., 2006; Yang et al., 2011).  
Deficits in cognitive function and BDNF expression have been mainly observed in 
several age associated neurodegenerative diseases and psychiatric disorders (Bocchio-
Chiavetto et al., 2010; Diniz & Teixeira, 2011; Erickson & Barnes, 2003). As such, 
research investigating the exercise-cognition relationship has focused on these populations, 
with few studies examining this relationship in young and healthy adults. The objectives of 
this study were to investigate the effects of a well characterized eight-week exercise 
intervention on cognitive function in untrained young and healthy adults. We also 
investigated whether changes in cognitive function were linked to changes in plasma 





Twenty-two university students (mean age=21.10, SD=1.27; 12 females) were 
recruited from a local university in Oshawa, Ontario Canada. All participants completed 
the Physical Activity Readiness Questionnaire (PAR-Q) to screen for contraindications to 
exercise. Inclusion criteria included: male or female age 18-30, no history of mental health 
illness, low active (exercise less than 20 minutes, three times weekly) and low 
cardiorespiratory fitness based on the Canadian Society for Exercise Physiology guidelines 
(Canadian Society for Exercise Physiology, 1998). Participants were then randomly 
assigned to an exercise intervention group or a control group to provide baseline and post 
assessment comparisons. This study was approved by the Ontario Institute of Technology 
Research Ethics Board. All participants provided written consent. 
4.3.2 Neuropsychological measures 
Cambridge Neuropsychological Test Automated Battery (CANTAB) 
Cognitive performance was evaluated using the Cambridge Neuropsychological Test 
Automated Battery (CANTAB) software (Cambridge Cognition, Cambridge, UK; 
http://www.cambridgecognition.com/cantab/cognitive-tests/). CANTAB is currently the most 
widely published automated neuropsychological test battery (Wild, Howieson, Webbe, 
Seelye, & Kaye, 2008) possessing high levels of concurrent validity and test–retest 
reliability (Fowler, Saling, Conway, Semple, & Louis, 1995). CANTAB is an accurate, 
faster and more efficient method to assess cognitive functioning than traditional pen and 
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paper tools (Fray & Robbins, 1996). All tests use non-verbalisable patterns and are 
presented on a computer touch screen in a game-like format that provides immediate 
feedback to reduce boredom (Levaux et al., 2007)(Levaux, Potvin et al. 2007)(Levaux, 
Potvin et al. 2007)(Levaux, Potvin et al. 2007). The CANTAB tests included in our 
assessment battery assess executive function, learning and memory which have previously 
shown to improve following an exercise intervention (Colcombe et al., 2004; Erickson, 
Voss, Prakash, Basak, Szabo, Chaddock, Kim, Heo, Alves, White, et al., 2011; 
Ruscheweyh et al., 2011; Voss et al., 2010b) and to be sensitive to changes in the 
hippocampus and frontal lobes (de Rover et al., 2011; Owen, Roberts, Polkey, Sahakian, & 
Robbins, 1991; Winocur, Wojtowicz, Sekeres, Snyder, & Wang, 2006). A brief description 
of each test included in this study is provided below. 
Delayed Matching to Sample (DMS): This test assesses recognition memory for patterns. 
The subject is shown a complex visual pattern and then must choose one of four similar 
patterns that matches the original pattern. Trials consist of either the original pattern that is 
obscured before the choices appear, or there is a brief delay of 0, 4 and 12 seconds between 
these steps. Outcome measures included accuracy and response latency.  
The Paired Associates Learning (PAL): This test assesses visual memory and new 
learning and is sensitive to changes in the temporal and frontal lobes. In this test, boxes are 
displayed on the screen and are opened in a randomized order with one or more containing 
a pattern. Each pattern is then displayed one at a time in the middle of the screen and the 
participant must identify the box where the pattern was located. The participant proceeds to 
the next stage when all the correct locations are identified. The test has an increasing level 
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of difficulty that ranges from two to eight patterns to be remembered. The total number of 
errors was used as the outcome measure for this test.  
The Spatial Recognition Memory (SRM): This test is a measure of visual spatial 
recognition that uses a forced-choice discrimination paradigm in which participants must 
choose between previously learned and novel stimuli. The percentage of total responses 
correct was used as the outcome measure. 
The Intra–Extra Dimensional Set Shift (IED): This test is a measure of rule acquisition 
and reversal. This test assesses visual discrimination and attentional set formation, as well 
as maintenance, shifting, and flexibility of attention. The number of stages completed and 
total number of errors were used as the outcome measures.  
4.3.3 Plasma collection 
Non-fasting blood was collected mid-day from each participant at baseline and eight weeks 
by venipuncture into ECBGTA tubes and centrifuged within 30 minutes. Plasma was 
aliquotted and stored at -85°C until analysis. Plasma BDNF and total CTHB were 
quantified using enzyme-linked immunosorbant assays (ELISA) following manufacturer’s 
protocols (R&D Systems, MN, USA; BioLegend, CA, USA). ELISA plates were read at a 




4.3.4 Fitness assessment 
In order to assess baseline fitness levels to determine eligibility and starting 
intensity for the exercise intervention baseline cardiovascular fitness was assessed with the 
YMCA cycle ergometer protocol recommended by the American College of Sports 
Medicine (Beekley, Brechue, & Dehoyos, 2004; Golding, Myers, & Sinning, 1989; 
Pescatello & American College of Sports Medicine., 2014). This protocol is a submaximal 
exercise that estimates maximal oxygen consumption (VO2max) from heart rate (HR) 
measurements and perceived exertion. The protocol consisted of two or more consecutive 
3-minute stages at a given workload. The objective was to elevate the participant’s HR to a 
target zone between 110 beats per minute and approximately 85% of the age-predicted 
maximum heart rate for two consecutive stages. The initial workload consisted of a 25 
Watt workload at a cadence of 50 revolutions per minute. The workload of the subsequent 
stages increased by the amount specified by the YMCA protocol based on the average HR 
during the last 2 min of each stage. When the target HR was achieved for two consecutive 
stages, the test was considered complete. Participants were also assessed at eight weeks to 
determine changes in cardiorespiratory fitness.  
4.3.5 Exercise prescription 
The exercise prescription was based on international guidelines of a minimum of 
150 minutes per week of moderate to vigorous intensity aerobic exercise in combination 
with resistance activities two times per week, for developing and maintaining 
cardiorespiratory, musculoskeletal, and neuromotor fitness in healthy adults (Canadian 
Society for Exercise Physiology, 1998; Garber et al., 2011). All exercise sessions were 
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supervised by a qualified exercise professional. The exercise group performed one aerobic 
only and two sessions per week on non-consecutive days for a duration of eight weeks. The 
exercise intensity for aerobic and resistance sessions were individualized based on each 
participant’s target HR that ranged between 60-80% of their age-predicted maximum HR. 
Radial pulse was measured throughout each aerobic and resistance exercise session to 
confirm that participants maintained their target HR range.  
Aerobic session 
Participants were given the opportunity to choose their aerobic activity on either the 
treadmill, stationary bike or elliptical machine. Aerobic workloads were based on HR 
response and were increased by five-minute increments, over the eight weeks, reaching a 
maximum of 60 minutes per session.  
Resistance sessions 
Resistance sessions combined a whole-body exercise prescription engaging the 
larger muscle groups. For each session, participants performed eight resistance exercises 
using free weights and resistance training machines. Exercises were performed 
consecutively in two or three supersets (with an 8-12 repetition range) to minimize rest 
times and to maintain target HR range. Initial workloads were individualized for each 
participant based on approximately 95% of their 10 repetition maximum. Subsequent 
workloads were increased approximately 5% once participants were able to complete three 
sets of 12 repetitions. Exercises were changed every four weeks to avoid adaptation; 
although still targeting the same muscle groups. Each session incorporated a 5 minute 
aerobic warmup and concluded with a 15 minute aerobic activity.  
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4.3.6 Statistical analysis 
All data were analyzed using Prism GraphPad software, version 6.0. Continuous data are 
presented as means and standard deviation (SD) and categorical data are presented as 
frequencies. Independent samples t-tests were used to compare baseline variables across 
groups for continuous variables and Fisher's exact tests were used to compare categorical 
variables. Paired t-tests were used to determine within-group changes from pre-post 
testing. A two-way analysis of variance (ANOVA) with repeated measures (Group by 
Time) was used to determine pre-post changes and between‐group differences. Statistical 
significance was set at p< 0.05 (two-tailed). A modified version of Cohen’s D (dppc2) 
specifically designed for pre-post experiments to account for any differences at baseline 
was used to calculate effects sizes (Morris, 2007).  
4.4 Results 
4.4.1 Baseline characteristics between groups 
Baseline group analyses revealed no significant differences for sex, age, BMI, BDNF and 
CTHB (see Table 4.1). One (n=1) participant from the control group discontinued VO2max 
testing due to exhaustion and was excluded from the VO2max analysis. The control group 
showed a significantly higher mean VO2max than the exercise group, t(19)=3.29, p=.004, 
however all participants met the Poor Health Benefit Rating Zone for cardiorespiratory 
fitness criteria based on the Canadian Society for Exercise Physiology guidelines 
(Canadian Society for Exercise Physiology, 1998).  
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4.4.2 Pre-post  measures 
The exercise group showed a significant increase in VO2max indicating that the exercise 
intervention was able to improve cardiorespiratory fitness (see Table 4.2). Biochemical 
marker analysis revealed no significant group-by-time effects for BDNF, f (1,20)=1.29, 
p=.296; d=.39, or CTHB, f (1,19)=.812, p=.379; d=.253, see Figure 4.1.  Cognitive 
analyses from the CANTAB battery revealed no significant group-by-time effects for the 
DMS,  f (1,20)=0.022, p=.884; d=.52, PAL,  f (1,20)=0.035, p=.854; d=.077, SRM , f 
(1,20)=2.20, p=.154; d=.61, or IED,  f (1,20)=2.41, p=0.136; d=.68, tests (see Figure 4.2). 
There were no significant group-by-time effects found for correct response latencies on the 
DMS, f (1,20)=0.838, p=.371; d=.52, or SRM, f (1,20)=0.019, p=.891; d=.071, tests. 
 
Table 4. 1 - Baseline characteristics of participants 
Variables Exercise Group (n=12) Controls (n=10) df p 
Sex: (male/female) 6/12 4/10 1 .639a 
Age (years) 21.08 (1.24) 21.16 (1.30) 20 .976b 
BMI (kg/m2) 24.67 (3.68) 22.90 (4.42) 20 .319b 
VO2max 17.06 (6.12) 26.17 (6.53)c 20 .004b 
aPearson’s chi-square 
bStudent’s t-test 
c One missing value 
Abbreviation: BMI=body mass index; VO2max = maximum oxygen consumption 





Table 4. 2 - Pre-post changes for BMI and VO2max 
 Exercise (n=12)  Control (n=10)   Group Differences 







BMI (kg/m2) 24.66 (3.68) 24.98 (3.19) 
 
22.90 (4.42) 22.64 (4.35) 
 
.040 .84 .14 
VO2max 
(mL/kg/min) 17.06  (6.12) 25.79 (11.29) 
 
26.17 (6.53) 25.42 (3.24) a 
 
7.90 .011 a 1.48 
BDNF (pg/ml) 9079 (3479) 8680 (3781) 
 
8751 (2198) 9528 (2612) 
 
1.29 .27 .39 
CTHB (pg/ml) 36,011 (10,778) 36,332 (15,178) 
 
40,972 (18,366) 37,526 (10,826) a 
 
.81 .379 .25 
aOne missing value 
Abbreviations: BMI=body mass index; VO2max = maximum oxygen consumption; BDNF 
= brain derived neurotrophic factor; CTHB = cathepsin B 












Figure 4. 1 - Group plots illustrating pre-post biomarker changes for (A) plasma BDNF 
concentrations, (B) plasma CTHB concentrations. Abbreviations: BDNF=brain-derived 
neurotropic factor; CTHB=cathepsin B 
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Figure 4. 2 - Group plots illustrating pre-post CANTAB changes for (A) DMS, (B) PAL, 
(C) SRM, (D) IED. Abbreviations: DMS=delayed matching to sample;  PAL=paired 




This present study demonstrated that an eight-week exercise intervention, based on 
the minimum recommended guidelines, was able to significantly improve cardiorespiratory 
fitness in young and healthy adults who were untrained. We provide evidence that exercise 
did not significantly improve cognitive function or change resting plasma BDNF or CTHB 
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levels are within normal ranges at baseline, then exercise does not change these ranges in 
young and healthy adults. Cognitive function peaks during this time and thus to show 
effects of exercise on brain function may require more sensitive tests than provided by 
standardize cognitive testing batteries.  
Our findings that we did not observe a significant pre-post change in cognitive 
function for the exercise group collaborates with a previous meta-analysis that used meta-
regression techniques to examine the relationship between cardiorespiratory fitness and 
cognitive performance in elderly and young adults. Researchers found that although elderly 
adults showed improvements in cognitive function following an exercise intervention, 
young adults did not. However, cross-sectional analyses revealed that cardiorespiratory 
fitness was negatively predictive of cognitive performance for children and young adults, 
and not the elderly. These results are of significant importance as they provide evidence 
that the exercise-cognition relationship changes across the life span. These same 
researchers also suggested that the lack of behavioural findings in the exercise-cognition 
literature, might be a consequence from using cognitive performance measures alone 
which may not be a sensitive enough to detect changes in high-functioning young adults 
(Etnier, Nowell, Landers, & Sibley, 2006).  
To help understand the exercise-cognition relationship in young and healthy adults, 
electrophysiological studies have examined the effects of physical activity levels and 
cardiorespiratory fitness on behavioral and neuroelectric indices of executive control 
processes. Using a task-switching paradigm, researchers measured the error-related 
negativity (ERN) component of an event related potentions (ERP), as well as behavioural 
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measures of response time (RT) and accuracy.  Despite no difference in cognitive 
performance between the groups, there were decreases in ERN amplitude and increases in 
post-error response slowing for high-active and high-fit participants compared to their 
sedentary counterparts (Themanson & Hillman, 2006; Themanson, Hillman, & Curtin, 
2006). A similar study conducted by Kamijo and Takeda investigated the effects of 
physical activity on executive control in young adults, using measures of RT and the P3 
component of an ERP during a task switching task. Researchers observed a smaller task 
switching cost on RTs and P3 amplitudes for the active group relative to the sedentary 
group. Taken together, these data suggest that physically active individuals require less 
demands on neural networks and have more efficient neural processes associated with 
executive function than their sedentary counterparts (Kamijo & Takeda, 2010). Further 
supporting that long-term exercise is associated with decreases neural activity despite no 
change in overt cognitive performance, a recent fMRI study used a subsequent memory 
paradigm to investigate the effects of an eight-week exercise intervention on hippocampal 
function and overall brain activity in  depressed adults and  young and healthy adults. 
Although no pre-post changes in memory performance were observed, fMRI data revealed 
that both the depressed and healthy young adults had a consistent pre-post deactivation 
pattern in the hippocampus and across several other memory-associated brain regions, 
suggestive of an increase in neural network efficiency during the memory encoding process 
(Gourgouvelis, Yielder, & Murphy, 2017).  
In an attempt to link a physiological mechanism underlying the effects of exercise 
on cognitive function, we measured plasma BDNF and CTHB concentrations. We did not 
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observe any change in plasma BDNF concentrations following the exercise intervention 
agreeing with previous research conducted in young and healthy adults (Griffin et al., 
2011; Schiffer et al., 2009). Though our study did not replicate Moon et al., who observed 
an increase in plasma CTHB following four months of aerobic exercise, our intervention 
was much shorter in duration. It is worth noting that the animal literature has reported 
reduced CTHB gene expression in the cardiac muscle of mice following five days of 
treadmill running (Smuder, Kavazis, Min, & Powers, 2013) and no change in CTHB 
activity in skeletal muscle following eight hours of exhaustive exercise (Salminen, 1984). 
However, little is known about the role that CTHB plays in cognitive function.  
4.6 Limitations 
This study was limited by the small sample size.  Second, while our eight-week exercise 
intervention was able to significantly increase in cardiorespiratory fitness in young and 
healthy adults who were untrained, all participants in the exercise group remained in the 
poor fitness category following the intervention. As such, significant improvements in 
cognitive function may have been observed with a longer intervention. Future research 
should investigate the dose–response effects of exercise on cardiorespiratory fitness, 
cognitive function and biomarkers by comparing various durations of exercise. 
Furthermore, the CANTAB battery used for this study might not have been sensitive 
enough to detect changes in this high-functioning group of young and healthy adults. It is 
possible that the effects of exercise on cognitive behavior may only emerge when the task 




This study provides evidence that eight weeks of the minimum recommended dose of 
exercise does not change cognitive function, BDNF or CTHB concentrations in young and 
healthy adults who are untrained. Our sample is representative of the a 95% of the adult 
population in the United States and Canada who do not meet the recommended physical 
activity guidelines for health benefits (Colley et al., 2011; Troiano et al., 2008). As such, 
neurodegenerative changes observed in aging and psychiatric populations are likely 
confounded by sedentary behaviour and poor cardiorespiratory fitness. In order to 
understand the magnitude of the effects of exercise on cognitive function in 
neurodegenerative disorders, it is critical that we understand the impact of exercise on 
cognitive function young and healthy population who are trained and untrained. 
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Chapter 5: General Discussion 
Human and animal experiments have shown long-term exercise to improve mood, 
sleep quality, cognitive function and neural function in both aging populations and those 
affected with neuropathological disease including MDD. The MDD and exercise literature 
have also identified a convergence of mechanisms that are associated with neuroplasticity 
and neural function (see Figure 5.1). However, it remains unclear whether exercise-related 
variables such as physical activity and cardiorespiratory levels underlie the symptoms and 
mechanisms associated with MDD. It is also unknown whether exercise affects cognitive 
and neural function in young and healthy adults who are considered low active and 
cardiorespiratory unfit. To address these gaps, this thesis investigated the effects of 
exercise, and mechanisms associated with both MDD and exercise, on cognitive and neural 
function in low-active MDD patients and young and healthy individuals.  Using a multi-
disciplinary research approach, this study examined the relationship between cognitive 
behavioural performance, neural function and physiological mechanisms to identify 
biomarkers that are unique to MDD independent of fitness levels. This thesis also 
examined the effects of exercise as an add-on therapy to ADM and CBT to identify 
exercise-related mechanisms underlying treatment response. fMRI results showed a similar 
deactivation pattern in several memory-related brain regions, despite no pre-post change in 
memory performance, for both the MDD and healthy groups following the eight weeks of 
exercise. These results suggest that low levels of cardiorespiratory fitness may potentially 
be an underlying variable that contributes to the alterations in neural function reported in 
the MDD neuroimaging literature. The increase in plasma BDNF concentrations observed 
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exclusively in the MDD group following exercise, suggests plasma BDNF to be a 
candidate mechanism underlying the clinical recovery of MDD. This study also showed 
that exercise did not significantly improve cognitive function in young and healthy adults 
despite changes in neural activation. These results indicate that exercise changes brain 
function in high-functioning, young, healthy adults and future work must consider using a 
more sensitive cognitive measure to identify behavioural changes. This research study 
provides clinical implications that eight weeks of exercise, based on the minimum 
recommended guidelines, in addition to ADM and cognitive therapy leads to significantly 
better clinical outcomes in those suffering with MDD. 
Figure 5. 2 - Converging mechanisms associated with MDD and exercise on neural 
function: Previous and current findings.  
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  Although this study revealed a large effect (Cohen’s d=6.46) for exercise and 
increased plasma BDNF, this relationship remains unclear. Previous studies have found no 
change in serum BDNF concentrations following a supervised aerobic exercise 
intervention based on a public health dose, despite significant improvements in depression 
(Toups, Greer et al. 2011b, Krogh, Rostrup et al. 2014).  The inconsistent results between 
studies may be explained by the variation in methodologies to quantify circulatory BDNF 
concentrations, particularly plasma versus serum. For instance, circulatory BDNF 
concentrations have been shown to increase exclusively in plasma but not in the serum of 
MDD patients, in response to ECT (Haghighi, Salehi et al. 2013) and ADM (Piccinni, 
Marazziti et al. 2008). Additionally, a recent study also showed that a four week aerobic 
exercise intervention of moderate intensity, significantly improved depressive symptoms 
and increased plasma BDNF concentrations in MDD patients (Salehi, Hosseini et al. 2016). 
Over 90% of BDNF in the circulatory is stored in blood platelets and is released into the 
plasma via activation or clotting processes (Fujimura, Altar et al. 2002). This suggests that 
the inconsistent research findings between serum and plasma BDNF concentrations during 
the clinical recovery of MDD, may be an increase in platelet release of BDNF that is more 
easily detected in plasma (Castren and Rantamaki 2010). Since exercise did not increase 
plasma BDNF in the young and healthy group, it suggests that the BDNF increases in 
MDD may be associated with a dysfunction in the platelet release of BDNF that may be 
upregulated with exercise.   Further studies examining the differences between serum and 
plasma BDNF during the course of illness in MDD, would provide further insight. 
165 
 
No signs of inflammation were observed in the MDD patients at study enrolment. 
These results provide direction for future studies, to consider whether cytokine analysis is 
feasible when using a sample of MDD patients with no comorbid inflammatory disorder 
and undergoing SSRI therapy.  Despite the mounting evidence that implicates chronic 
inflammation in the pathophysiology of MDD, there are several limitations to consider. 
First, not all patients with MDD show signs of inflammation (Yoon, Kim et al. 2012) and 
not all patients with inflammatory disorders or undergoing cytokine therapy develop MDD. 
SSRI treatment has been shown to reduce inflammation yet many people still suffer with 
depressive symptoms (Sacre, Medghalchi et al. 2010, Tynan, Weidenhofer et al. 2012). 
There is an extensive gap in the cytokine literature investigating inflammatory biomarkers 
throughout the course of depression, and there is gap in the research indicating healthy 
normal levels for comparison. There are no cut-off criteria for cytokine concentrations that 
are considered to be toxic or beneficial, and no values that indicate normal, healthy 
variations (Kim, Na et al. 2016). Additionally, the various immunoassay methodologies 
within the literature, makes it challenging for researchers to conduct cross-study 
comparisons (Leonard 2007, Kim, Na et al. 2016).  
A strength of this study was the multi-modal scientific approach in measuring 
psychological and neurobiological mechanisms that identified changes at the behavioural, 
neural and physiological levels in recovering with MDD. It demonstrated very large effect 
sizes for exercise-related improvements in depression, cognitive function, sleep quality and 
plasma BDNF for the MDD patients. This study is able to provide a solid foundation for 
future work. It has shown that an exercise prescription based on the minimum guidelines, 
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is able to improve cardiorespiratory fitness and is well tolerated by low active MDD 
patients. Findings also suggests that a lower dose of exercise for low active individuals 
may be better tolerated, yet still effective, since the MDD patients remained in the poor 
cardiorespiratory fitness range following the eight weeks of exercise. In fact, findings 
suggest that it may be the engagement and increase in physical activity levels that underlie 
the anti-depressant effects of exercise. This study highlights feasible biomarkers in MDD 
patients undergoing SSRI treatment providing a framework for future study designs. 
Nonetheless, the present research findings must be replicated with future research and 
limitations of this study need to be addressed before implementing the clinical use of 
biomarkers such as sleep quality, plasma BDNF and neural activity during the recovery of 
MDD.  
5.1 Limitations 
This study did not include no-intervention control groups and therefore it cannot be 
certain that the deactivation pattern observed in both the MDD and healthy groups was 
exercise-induced. The inclusion of both MDD and healthy control groups would confirm 
the deactivation pattern to be exercise induced. Also, the MDD and healthy groups were 
not age-matched and it cannot be certain that the pre-post changes observed in the MDD 
group were not age-related. Furthermore, this study measured total BDNF and not the ratio 
of pro-BDNF to mature BDNF. Therefore, it is unknown whether there was an alteration in 
mature BDNF to pro-BDNF underlying the improvements in depression and sleep quality. 
This study was also limited to individuals who were considered low active with low levels 
167 
 
of cardiorespiratory fitness. As such, it remains unclear whether physical activity and 
fitness levels were associated with the treatment response in the MDD group. The 
relationship between fitness and MDD would be clearer with the inclusion of patients with 
higher levels of physical activity and cardiorespiratory fitness for comparison.  
5.2 Future directions 
An initial objective of this research study was to investigate HPA axis functioning 
through measures of morning saliva. Participants were instructed to provide morning 
salivary samples immediately upon awakening and 30 minutes post awakening. Our 
findings revealed that several participants in the healthy and MDD groups did not provide 
saliva samples for all time points, and several participants showed a negative CAR. These 
findings indicate methodological issues, particularly adhering to sampling protocols. The 
literature has shown that when in ambulatory settings, reliance upon self-sampling at 
required times can often lead to invalid results (Elder, Wetherell et al. 2014). A negative 
CAR may be valid, however, it is more likely a result of poor adherence to the timing of 
sampling during the CAR period. Future outpatient studies, should consider measuring 
salivary cortisol at several time points throughout the day that will identify levels and 
variability of daily life cortisol secretion and HPA activity (Peeters, Nicolson et al. 2004). 
Although the young and healthy participants in this study revealed no change in 
cognitive function following exercise, we did observe a decrease in brain activity during 
the memory encoding process. The absence of behavioural findings could be that the 
CANTAB battery is not sensitive enough to detect subtle changes in cognitive function in 
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this high-functioning group. Future research must consider to build on this literature base 
throughout the lifespan. The inclusion of young and healthy adults in future studies, will 
not only provide normal data for comparison, but will illustrate how cognitive function 
changes throughout adulthood.  
Finally, MDD is a clinically and biologically heterogeneous disorder and it is likely 
to be a multifaceted interaction of psychological and neurobiological mechanisms that 
underlie the antidepressant effects of exercise. Future research must adopt a multi-
disciplinary scientific approach to converge the mechanisms between exercise, depression, 
and neuroplasticity that will elucidate novel biomarkers. Once we are able to elucidate 
these key biomarkers unique to MDD, novel treatment strategies can be developed. 
5.3 Clinical implications 
Poor sleep quality is a frequently reported symptom of depression and a core 
residual symptom following remission. This study showed that sleep quality significantly 
improved following exercise. This finding has practical implications for mental health 
practitioners, highlighting the importance of measuring sleep quality during routine visits. 
It must be recognized that sleep quality is a potential biomarker of treatment response in 
MDD and also a risk factor for relapse.   
Furthermore, there is a lack of attention to physical activity during routine visits to 
mental health practitioners, reducing the opportunity to improve both the physical and 
mental health of their patients (Janney, Brzoznowski et al. 2017). This study provides 
evidence that low active depressed individuals are able to tolerate an exercise prescription 
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based on the minimum recommended guidelines. This study also shows that by 
incorporating physical activity into mental health care, improves both cardiorespiratory 
fitness and clinical outcomes in patients suffering with severe MDD. 
5.4 Qualitative observations 
Understanding patient perspectives and preferences is critical if exercise is to be 
effectively implemented into the treatment plan for MDD (Janney, Brzoznowski et al. 
2017). The following section summarizes some qualitative observations that were observed 
during this research study. In order to improve clinical outcomes for all patients in this 
research study, the non-exercise group was offered four personal training sessions 
following study completion. As such, the following observations were based on 16 
patients. 
Specifically I will discuss the attitudes, current knowledge and barriers to perform 
regular exercise that were discussed among participants. First, the term ‘exercise’ was 
perceived negatively among the MDD sample in this study and therefore the term physical 
activity was substituted. Several patients perceived exercise to be analogous to marathon 
running or something that only bodybuilders do. Many patients expressed that they were 
intimidated fitness facilities as they were not educated on the use of the equipment. Most 
patients indicated that their low mood and negative body image was a barrier to participate 
in exercise. Interestingly, very few patients indicated that lack of time was a barrier, 
however, cost of a gym membership was a frequently mentioned barrier. Many patients in 
this study indicated that they had never been educated on the positive impact of exercise on 
170 
 
mood during routine mental health visits, nor had their clinician recommended them to 
increase their physical activity levels. All patients indicated that they did not know how to 
exercise or how to initiate an exercise program. 
At study enrolment, all patients were very motivated to participate in this research 
study with the expectation they would recover from their debilitating disease. The 
inclusion of an exercise professional to educate and supervise them was well accepted. 
Participants expressed that the exercise professional was able to increase their knowledge 
about the benefits of exercise and how to perform exercise safely and effectively. 
Motivation to attend exercise sessions was maintained throughout the eight weeks through 
positive feedback from both the exercise professionals and exercise log that illustrated their 
progress. Surprisingly, very few patients missed an exercise session. 
Worth noting, there were distinguishable features between the two groups. The 
exercise group entered the study during a period of severe depression. Consequently, 
attending both CBGT and the exercise sessions concurrently, was overwhelming for some 
during the initial weeks. However, this was not observed in the non-exercise group who 
performed their four exercise sessions following the eight weeks of CBGT. Based on these 
observations, it may be beneficial to delay the introduction of regular exercise in the early 
phase of severe depression in clinical practice.   
Finally, the increases in self-efficacy for exercise and overall improvements in 
emotional and physical well-being that I observed in each participant throughout the study 
was beyond rewarding.  Although few patients indicated that adhering to the eight week 
exercise prescription was a challenge, all participants completed the study with high levels 
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of satisfaction. Overall, patients indicated that learning how to exercise was a life-changing 
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When you answer the following questions we ask that you please chose only one response for each 
question and give the response that immediately comes into your head.  
Place a tick or mark beside the answer that best relates to how you feel.  
 
I feel tense or ‘wound up’: 
o Most of the time 
o A lot of the time 
o From time to time, occasionally 
o Not at all 
 
I still enjoy the things I used to enjoy: 
o Definitely as much 
o Not quite so much 
o Only a little bit 
o Hardly at all 
 
 
I get a sort of frightened feeling as if something 
awful is about to happen: 
o Very definitely and quite badly 
o Yes, but not too badly 
o A little, but it doesn’t worry me 
o Not at all 
I can laugh and see the funny side of things: 
o As much as I always could 
o Not quite so much now 
o Definitely not so much now 
o Not at all 
 
 
Worrying thoughts go through my mind: 
o A great deal of the time 
o A lot of the time 
o From time to time, but not too often 
o Only occasionally 
 
 
I feel cheerful: 
o Not at all 
o Not often 
o Sometimes 
o Most of the time 
 
I can sit at ease and feel relaxed: 
o Definitely 
o Usually 
o Not often 
o Not at all 
 
 
I feel as if I am slowed down: 
o Nearly all the time 
o Very often 
o Sometimes 
o Not at all 
 
I get a sort of frightened feeling like 
‘butterflies’ in the stomach: 
o Not at all 
o Occasionally 
o Quite often 
o Very often 
 
 
I have lost interest in my appearance: 
o Definitely 
o I don’t take as much care as I should 
o I may not take quite as much care  
o I take just as much care as ever 
 
 
I feel restless as I have to be on the move: 
o Very much indeed 
o Quite a lot 
o Not very much 
o Not at all 
 
I look forward with enjoyment to things: 
o As much as I ever did 
o Rather less than I used to 
o Definitely less than I used to 
o Hardly at all 
 
I get sudden feelings of panic: 
o Very often indeed 
o Quite often 
o Not very often 
o Not at all 
 




o Not often 
o Very seldom 
 
 
(Modified from Zigmond & Snaith, 1983) 
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Appendix 4: PSQI 
 
Sleep Quality 
Instructions: The following questions relate to your usual sleep habits during the 
past two weeks ONLY. Your answers should indicate the most accurate reply for the 
majority of days and nights in the past 2 weeks. Please answer all questions. 
1. During the past 2 weeks, when have you usually gone to bed at night? 
  USUAL BED TIME______________________________ 
2. During the past 2 weeks, how long (in minutes) has it usually taken you to fall 
asleep each night? 
  NUMBER OF MINUTES__________________________ 
3. During the past 2 weeks, when have you usually gotten up in the morning? 
  USUAL GETTING UP TIME_______________________ 
4. During the past 2 weeks, how many hours of actual sleep did you get at night? 
(This may be different than the number of hours you spend in bed) 
  HOURS OF SLEEP PER NIGHT____________________ 





5. During the past 2 weeks, how often have 





















































Cannot get to sleep within 30 minutes     
Wake up in the middle of the night or early 
morning 
    
Have to get up to use the bathroom     
Cannot breathe comfortably     
Cough or snore loudly     
Feel too cold     
Feel too hot     
Had bad dreams     
Have pain     
Other reason(s) please 
describe______________________________ 
    
 




Very bad………………Fairly bad………….…..Fairly good……..……Very good 
 
7. During the past 2 weeks, how often have you taken medicine (prescribed or 
“over the counter”) to help you sleep? (Please circle) 
Not during the  Less than      Once or        Three or more 
past 2 weeks   once a week      twice a week      times a week 
8. During the past 2 weeks, how often have you had trouble staying awake while 
driving, eating meals, or engaging in social activity? (Please circle) 
Not during the  Less than      Once or        Three or more 
past 2 weeks   once a week      twice a week      times a week  
9. During the past 2 weeks, how much of a problem has it been for you to keep up 
enough enthusiasm to get things done? (Please circle) 
No problem   Only a very   Somewhat      A very  
at all    slight problem  of a problem     big problem 
 
10. Do you have a bed partner or share a room? 
No bed partner or do not share a room  ______________ 
Partner/flat mate in other room   ______________ 
Partner in the same room, but not same bed  ______________ 
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Partner in the same bed    ______________ 
 
11. If you have a bed partner or share a room, ask him/her how often in the past 2 










































Loud snoring     
Long pauses between breaths 
while asleep 
    
Legs twitching or jerking 
while you sleep 
    
Episodes of disorientation or 
confusion during sleep 
    
Other restlessness while you 
sleep (please describe) 
    
 





SALIVA COLLECTION METHOD 
 
Exercise and Brain Function Study 
 
During this study, you will be collecting saliva samples to be tested for the stress hormone cortisol.  Levels of 
cortisol change in a predictable way throughout the day.  Because of this, you need to collect saliva samples at 
the exact times instructed for the results to be accurate.  Also, activities such as eating and drinking can affect 
your saliva, so please make sure you follow the instructions for how to collect your sample.  Please tell us if you 
have any sores in your mouth. 
 
Week 0 and Week 12 
• You will be given two Salimetrics Oral Swab devices and an insulation pack at your orientation session 
at the UOIT fitness centre 
• You will be collecting saliva samples on the WEDNESDAY following this appointment 
• These vials will be labelled “Weds – waking” , “Weds – 30 min” 
• Collect ONE sample using the two “Weds – waking” vials immediately on awakening on Wednesday 
• Remove swab from tube leaving tube insert in place. Place into mouth under tongue. Keep in place for 
1-2 minutes. 
• Collect ONE more sample in the same way 30 min later in the “Weds– 30min”vial 
• DO NOT consume caffeinated drinks, eat, brush teeth, smoke or use steroid creams/inhalers between 
collection of first two samples 
• Freeze both samples immediately in your freezer 
• Bring samples with you to your first exercise session in the insulated pack provided 
•  
 
Appendix 5: Saliva collection instructions 























Appendix 8: MRI safety form 
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Appendix 9: Par-Q & You 
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Professor Bernadette Murphy 
University of Ontario Institute of Technology 
Faculty of Health Sciences 
2000 Simcoe St. North 
Oshawa, Ontario 
CANADA  L0B 1J0 
Email: Bernadette.Murphy@uoit.ca 




The role of exercise in improving brain function: Part A: Exercise 
MHDT group 
 
You are invited to participate in a research study entitled “The role of exercise in improving brain 
function”.  This study (# REB 10-104) has been reviewed by the University of Ontario Research Ethics Board 
and has been approved as of  May 13, 2013. Please read this form carefully, and feel free to ask any 
questions you might have. If you have any questions about your rights as a participant in this study, please 
contact the Compliance Officer at 905 721 8668 ext 3693 or compliance.uoit.ca. 
Researchers 
Dr. Bernadette Murphy, Professor, Head-Kinesiology Specialization, Faculty of Health Sciences, 
University of Ontario Institute of Technology, Phone: (905) 721-8668 ext 2778, email: 
Bernadette.Murphy@uoit.ca, Fax: (905) 721-3179 
Dr. Paul Yielder, Professor, Director-Bachelor of Health Sciences, Faculty of Health Sciences, 
University of Ontario Institute of Technology, Phone: (905) 721-8668 ext 2768, email: Paul.Yielder@uoit.ca, 
Fax: (905) 721-3179 
Dr. Nancy Wilkinson, Client Care Manager/Psychologist, Mental Health and Pinewood Program, 
Lakeridge Health, Phone: (905) 576-8711 ext 6233, email: nwilkinson@lakeridgehealth.on.ca 
Dr. Stephen Strother, Professor, Dept. of Medical Biophysics, University of Toronto, Senior 
Scientist, Rotman Research Institute, Baycrest, Phone: (416) 785-2500 ext 2956, email: sstrother@rotman-
baycrest.on.ca 
 




Joanne Gourgouvelis, PhD Candidate, Faculty of Science, University of Ontario Institute of 
Technology, Phone: (905) 550-4055, email: Joanne.Gourgouvelis@uoit.ca, Fax: (905) 721-3179 
 
 
Purpose of the Study 
This research study is being conducted to study the effect of exercise on your levels of the stress 
hormone cortisol and a number of other biomarkers known to be altered in depression. We will also be 
looking at the way your brain functions during certain memory tasks.  We are interested in how exercise 
may change these things in depressed participants.  We are also interested in how exercise may affect the 
intensity of depression symptoms.  These will be assessed over the course of a 8 week structured, 
supervised exercise program, in addition to the treatment you already receiving as part of the Lakeridge 
Mental Health Day Treatment program.  Once this phase of the study is complete we will be recruiting a 
group of patients in the Mental Health Day Treatment program who are of a similar age and gender to 
investigate the effects of the Day Treatment program on its own in order to compare to the results of the 
exercise group. 
 
Potential Benefits to Participants and/or to Society 
Exercise has been shown in past studies to be an effective treatment for depression.  In this study 
we want to learn more about how and why it works in order to help us design the most effective types of 
exercise interventions.  Following the exercise program, participants may receive additional relief from their 
depression.  This study offers a structured exercise program suitable for beginners and may also help you 
resolve any physical issues you have.  If we show a strong effect, it may become a future part of the Day 
Treatment program and you will be making an important contribution to improving treatment options for 
future patients. 
 
Participation and Withdrawal 
Your participation to take part in this study is voluntary.  You may choose not to participate or you 
may withdraw from the study at any time.  However, if you decide to stop participating in the study, we 
encourage you to talk to the study staff first.  The staff here is very flexible about meeting your needs and if 
there is anything we can do to accommodate your needs, we are more than willing to help.  You are still 
free to withdraw at any time without giving a reason, and your decision not to participate will not affect 
your care at this center.  
 
Rights of Research Participants 
You are free to ask any questions that you may have about your treatment and your rights as a 
research participant.  You may withdraw your consent at any time and discontinue participation without 
penalty.   
If any questions come up during or after the study or if you have a research-related injury, contact 
the study researchers listed on the first page. 
 
Should you have any questions or concerns regarding your rights as a participant in this research 
study, or if you wish to speak with someone who is not related to this study, you may contact the Chair of 
the Lakeridge Health Corporation Research Ethics Board at (905) 576-8711 or UOIT Research Ethics Board 
through the Compliance Office (905) 721-8668 ext 6393. 
 
You are one of 20 individuals being asked to participate in this study and have been referred to us 
by Lakeridge Mental Health Day Treatment program with a diagnosis of depression and you are between 
the ages of 18 and 50.  Please take your time to review this consent form and discuss any questions you 
may have with the study staff.  You may take your time to make your decision about participating in this 
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study and you may discuss it with your friends, family or your doctor before you make your decision.  This 
consent form may contain words that you do not understand.  Please ask the study staff to explain any 
words or information that you do not clearly understand. 
 
Eligibility 
In order to be eligible for either group, you must not be currently doing regular exercise; that 
means your levels of exercise should be less than 20 minutes, three times per week.  People suffering from 
mental conditions other than depression, or with physical conditions that would prevent them from doing 
exercise, such as heart disease, will be excluded from the study. An understanding of English sufficient to 
answer questionnaires is required.   
 
If you have questions the stated procedures, timeline or exclusion criteria please feel free to 
discuss them with the study coordinator, Joanne Gourgouvelis or the investigators (contact details provided 
on page 1). 
 
The following sections will outline the various tests and procedures of the study, including: 1) the 
purpose of each test or procedure; 2) the respective timelines; 3) exclusion criteria (factors that might make 
you ineligible to participate). 
 
If you take part in this study, you will need to participate in several procedures.  Please read the 
following pages and tick the boxes to indicate if any of the exclusion criteria pertain to you:  A) 
Questionnaire completion (page 3),  B) Cognitive tasks (see Page 3) C) Saliva samples (page 4),  D) 





1. Purpose  
To determine the severity of your symptoms associated with depression, you will 
complete some demographic information and you will then complete two Questionnaires, 
called the Beck Depression Inventory II (BDI-II) and the Hospital Anxiety and Depression Scale 
(HADS).    
 
2. Timeline 
Questionnaires will be given at: 
i. Week 0 (prior to the exercise program)  
ii. Week 8 (after completion of the exercise program). 
 
3. Exclusion Criteria (please check box if you have any of the following) 
i. Do not understand English  
 
4. Risks:  There are no risks from completing these questionnaires, data will not contain any 
personal information that can identify you.  Privacy and confidentiality will be maintained and 
data will be stored in a secured location. 
 
B. COGNITIVE TASKS 
 
1. Purpose  
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To determine overall cognitive functioning, you will perform a series of computer 
generated tasks which will assess your ability to identify simple objects in space.   The benefits 
to you are that you will learn more about how your memory works and you will be increasing 
our knowledge of how exercise affects memory. 
 
2. Timeline 
Cognitive tasks will be given at: 
i. Week 0 (prior to the exercise program)  
ii. Week 8 (after completion of the exercise program). 
 
3. Exclusion Criteria (please check box if you have any of the following) 
i. Do not understand English  
 
Risks:  There are no risks from completing these computer generated tasks, data will not 
contain any personal information that can identify you.  Privacy and confidentiality will be 




1. Purpose  
Cortisol is a hormone which is known to be elevated in depressed individuals, and 
chronically high levels of cortisol have been linked with changes in the way the brain functions.  
It is possible that exercise may help depression by decreasing cortisol secretion. You will be 
given labelled tubes to collect a sample of your saliva (spit) to be tested at a laboratory for the 
stress hormone cortisol, which you will collect on the morning after your interview as soon as 
you wake up and then again 30 minutes after you wake up. The samples will then be put in the 
freezer and you will be given a small Styrofoam cooler to bring the samples back to the 
researcher on the next day that you attend the Lakeridge program. You will be given a set of 
simple instructions in case you forget what to do.   
 
2. Timeline 
Saliva samples will be taken at: 
i. Week 0: the day after your interview (when you wake up and 30 minutes after waking up) 
ii. Week 8: after completion of the exercise program (when you wake up and 30 minutes 
after waking up) 
 
3. Exclusion Criteria (please check box if you have any of the following) 
i. Ulcers or sores in your mouth  
 
5. Risks  
i. There are no complications or side effects when collecting saliva.  Your samples will be 
coded in a way that does not identify you, frozen in a special freezer and stored until the 




1. Purpose  
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A number of biomarkers found in blood are also known to be altered in depression 
and exercise may act to normalize their levels.  A technician from the Medical Laboratory 
Science Program at the University of Ontario Institute of Technology will collect blood samples 
from each participant twice during the study.  
 
2. Timeline 
Blood samples will be taken at: 
i. Week 0 (prior to the exercise program)  
ii. Week 8 (after completion of the exercise program). 
 
3. Exclusion Criteria (please check box if you have any of the following) 
i. Bleeding disorder  
ii. Medications that may interfere with blood clotting (heparin, wafarin)  
iii. Phobia of needles 
 
4. Risks  
Complications are very rare when acquiring blood samples through a sterile syringe. 
However, the following side effects have been reported: 
A. Excessive bleeding at site of puncture 
B. Bruising 
C. Feeling light-headed, fainting 
D. Infection 
 
Your blood and saliva samples will be coded in a way that does not identify you, frozen in 
a special freezer and stored until the end of the study when they will be analyzed.  Any unused 





E. BRAIN SCAN (functional MRI) 
 
1. Purpose  
Prior to commencing your program, fMRI images of your brain will be obtained to 
investigate the way that your brain activates when you are performing a task requiring your 
concentration.  We will also look at anatomical details of brain structures known to be 
involved in depression such as the hippocampus. Once you come out of the scanner, you will 
go to a separate room and be asked to go through some of the images from the task that you 
did in the scanner.  The scan will take about one hour and will be carried out at Baycrest 
hospital attached to the Rotman Brain Research Institute. We will then retest you at the end of 
your program (8 weeks) to see if exercise has changed the way your brain processes 
information.  There will be no cost to you for the scans and you will be provided with parking 
and gasoline vouchers to cover travel costs for each session.   
The MRI scan being done is designed to answer research questions, not to examine 
your brain medically.  This MRI scan is not a substitute for one that a doctor would order, and 
it may not show problems that would be picked up by a medical MRI scan.   However, in the 
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unlikely event that we note an atypical finding on your MRI scan, we will contact you to help 
you arrange medical follow-up to interpret the significance of the findings, if any.  We may 
also ask a radiologist, or other health professional, to look at your scan, and by signing this 
consent form you agree to releasing the scan for review.  It is possible that you could be 
unnecessarily worried if a problem were suspected, but not actually found.  
 
The MRI technique uses magnets and radiowaves to construct a picture of the brain 
on a computer.  Before the scan begins, you will be asked to remove any magnetic metals that 
you may be wearing.  For the procedure, you will be asked to lie on a padded bed that will be 
moved into a tunnel-like machine for the MRI scan of your brain. Since you will be inside the 
machine during the scan, and a screen will be in place for viewing the visual images, you may 
not be able to see the technicians operating the machine or the investigators.  However, there 
is an intercom system that will allow you to talk with them at any time.  If you feel 
uncomfortable during the scan and you wish to discontinue the procedure, you will be taken 
out of the machine at your request. 
 
We will obtain a series of MRI scans, separated by short breaks, and the entire 
procedure will take approximately one hour.  During the scans we will ask you to carry out a 
variety of tasks.  You should try to remain as still as possible during each scan.  Movement will 
not be dangerous to you in any way, but would blur the picture of your brain.  You will hear 
moderately loud knocking or beeping during the scan when the MRI machine is in operation.  
Although you may find this to be unsettling, the machine cannot hurt you in any way.  
Please note:  Prior to your first scan you will also be required to sign an additional 
consent form required by Baycrest hospital which provides similar information about fMRI as 




Brain scans will be taken at: 
i. Week 0 (prior to the exercise program)  
ii. Week 8 (after completion of the exercise program). 
 
3. Exclusion Criteria (please check box if you have any of the following) 
i. Phobia of small confined spaces  
i. Metal Implants, pieces of shrapnel, aneurysm clips, or wires in your head. etc.  
ii. Implanted Pace Maker 
iii. Pregnant 
iv. Inability to get to the scanner at Rotman Baycrest*.    
 
*We will compensate you for your parking and gasoline costs but you will need to be 
able to drive yourself or have someone else able to drive you in order to participate. 
 
4. Risks and Discomforts  
The MRI scan is not associated with any known risks to your health and there is no 
evidence that there will be either short-term or long-term side effects. Participants undergoing 
fMRI may feel uncomfortable or claustrophobic in the confined space.  Furthermore, the 
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machine makes a loud noise which some people may find distressing.  There will be someone 
with you at all times during the brain imaging, in case you should experience any adverse 
effects. If you have a tattoo, there is a very small possibility that you will feel a tingling or 




   
F. EXERCISE PROGRAM 
 
1. Description  
You will complete an exercise safety screening questionnaire called the Par-Q.  If 
there are any concerns about the safety of your participation, you will have the option of 
withdrawing or getting your family doctor to complete the ParMed-X to ensure it safe for you 
to exercise. 
Once enrolled and baseline assessments have been carried out you will commence a 
8 week exercise program as part of the Mental Health Treatment program.  The exercise 
sessions will take place at the Flex Center at Durham College/UOIT.  All sessions will be in 
groups of 2 to 5 participants and will be supervised by the Exercise Supervisor for three 
sessions per week and you must be prepared to commit to attending at least 80% of the 
exercise sessions. The role of the supervisor will be to give you verbal encouragement, 
monitor you for any possible adverse effects and provide aid as needed, and to help you 
monitor your heart rate to ensure they you are working at the correct intensity.  The exercise 
prescription will be individualized based on your starting fitness levels.  One session per week 
will be aerobic exercise only, and the remaining two will be resistance exercise followed by a 
shorter aerobic bout. Based on your experience and ability, one resistance exercise will be 
selected from each of six categories – horizontal push, anterior lower body, vertical pull, 
posterior lower body, horizontal pull, and vertical push in order to establish a balanced, whole-
body exercise prescription. Exercises will be changed after four weeks, to avoid adaptation. 
The aerobic bout following resistance sessions will be 20 minutes in the first week, and 30 
minutes in subsequent weeks. Sessions containing a resistance component will be performed 
at least 24 hours apart. All sessions begin with a ten-minute aerobic warm-up, and are 
supervised by a kinesiologist. Participants are advised to bring a drink bottle and keep well 
hydrated. Opportunities will be provided to make up missed sessions.  
 
2. Timeframe 
i. 3 one hour sessions per week for 8 weeks  
 
3. Exclusion Criteria (please check box if you have any of the following) 
i. Already exercise more than 20 minutes, three times per week  
ii. Physical conditions such as heart disease, or exclusions identified based on ParQ or 
ParMedX questionnaires. 
iii. I am unable to attend at least 80% of the exercise sessions 
 
4. Risks and Discomforts  
You may experience some physical discomfort both during exercise or stretching and 
following exercise or stretching, such as muscle soreness.  There is a small risk of injury 
occurring during any exercise program; however, the kinesiologists involved are trained in 
modifying exercise programs to minimize this risk and you will be supervised at all times.  
There will be someone with you at all times during the exercise sessions, in case you should 
experience any adverse effects. 
 
RESULTS 
You will also be given a log to keep track of each procedure required from you. This log is to be 




Once the information has been collected from all participants, the questionnaire responses will be 
examined to establish the effect of exercise on depression, cortisol secretion, several biomarkers, cognitive 
performance, TMS and fMRI results will be analyzed and a report will be written up.  A short version of this 
report will be available to participants who would like a copy.  You can indicate at the bottom of the 
consent form whether you would like to receive your report by email or by regular mail. 
 
If you have depression and you experience any worsening of your depression during your 
participation in the study, you will be referred immediately to the treatment team at Lakeridge Mental 
Health.  If you are concerned about any aspect of your participation, do not hesitate to contact the 
researchers at the numbers provided. 
 
Compensation for Participation 
There will be no direct compensation for participating in this research study, although you will be 
given a free supervised exercise program and you will be compensated for parking and gasoline costs. 
 
Disclosure 
Despite efforts to keep your personal information confidential, absolute confidentiality cannot be 
guaranteed.  Your personal information may be disclosed if required by law.  This legal obligation includes a 
number of circumstances, such as suspected child abuse and infectious disease, elevated risk or harm to 
you or others, and a court order by authorized agencies.  For your information, the research consent form 
will be inserted in the patient health record. 
 
Medical records that contain your identity will be treated as confidential in accordance with 
Ontario’s privacy legislation, the Personal Health Information Protection Act, 2004.  
 
The only people who will be accessing your patient records are the Lakeridge clinicians involved in 
your treatment.  The other information collected by the researchers is separate and will be seen only by the 
researchers and all identifying information will be removed in any publications.   
 
The Lakeridge Health Corporation Research Ethics Board and the University of Ontario Institute of 
Technology Research Ethics Board may review records related to the study for quality assurance purposes, 
as it oversees the conduct of this study at Lakeridge Health.  
 
Please read the following before signing the consent form and remember to keep a copy for your 
own records. 
 
By signing this form, I agree that: 
 
• The study has been explained to me.  All my questions were answered to my satisfaction. 
• The possible harms and discomforts and the possible benefits (if any) of this study have been explained 
to me. 
• I know about the alternatives to taking part in this study.  I understand that I have the right not to 
participate and the right to stop at any time.  The decision about whether or not to participate will not 
affect my health care at Lakeridge Health. 
• I am free now, and in the future, to ask any questions about the study. 
• I have been told that my medical records will be kept confidential, except where release of information 
is required by law  
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• I understand that no information that would identify me, will be released without asking me first, unless 
the disclosure is required by law 
• I hereby consent to participate.   
 
I have completed the individual procedure assessments on pages 3 to 8 of this form and hereby 
consent to participate in the following procedures (please tick the box): 
 
A. Questionnaire completion 
B. Cognitive tasks 
C. Saliva samples 





Information gathered in this research study may be published or presented in public forums; 
however your name and other identifying information will not be used or revealed.  We hope the 
information learned from this study will benefit other people and support the use of exercise as a treatment 
for depression in future patients.  
You will be provided with a summary of findings at the end of the study, if you so desire.  We will 
do our best to explain the findings to you in way that you understand and what these changes mean.  Often 
in research we don’t get the findings we expect.  This is often because we didn’t study enough participants 
or the changes are of a different nature then we expected.   This is okay and still makes a very important 
contribution to science and to our understanding of depression. If you are concerned about any of the study 
findings or you would like more information, please contact Dr. Bernadette Murphy or Dr. Paul Yielder to 
discuss. 
 
Please advise us of your preferable format for communication (check one and provide details in 
the space provided):    
 
Please indicated by ticking the box whether you wish to receive your summary by email  or 















I, the undersigned, have fully explained the relevant details of this research study to the participant 





















Professor Bernadette Murphy 
University of Ontario Institute of Technology 
Faculty of Health Sciences 
2000 Simcoe St. North 
Oshawa, Ontario 
CANADA  L0B 1J0 
Email: Bernadette.Murphy@uoit.ca 





The role of exercise in improving brain function: Part B: MHDTP 
control group 
 
You are invited to participate in a research study entitled “The role of exercise in improving brain 
function”.  This study (# REB 10-104) has been reviewed by the University of Ontario Research Ethics Board 
and has been approved as of  May 13, 2013. Please read this form carefully, and feel free to ask any 
questions you might have. If you have any questions about your rights as a participant in this study, please 
contact the Compliance Officer at 905 721 8668 ext 3693 or compliance.uoit.ca. 
Researchers 
Dr. Bernadette Murphy, Professor, Head-Kinesiology Specialization, Faculty of Health Sciences, 
University of Ontario Institute of Technology, Phone: (905) 721-8668 ext 2778, email: 
Bernadette.Murphy@uoit.ca, Fax: (905) 721-3179 
Dr. Paul Yielder, Professor, Director-Bachelor of Health Sciences, Faculty of Health Sciences, 
University of Ontario Institute of Technology, Phone: (905) 721-8668 ext 2768, email: Paul.Yielder@uoit.ca, 
Fax: (905) 721-3179 
Dr. Nancy Wilkinson, Client Care Manager/Psychologist, Mental Health and Pinewood Program, 
Lakeridge Health, Phone: (905) 576-8711 ext 6233, email: nwilkinson@lakeridgehealth.on.ca 
Dr. Stephen Strother, Professor, Dept. of Medical Biophysics, University of Toronto, Senior 
Scientist, Rotman Research Institute, Baycrest, Phone: (416) 785-2500 ext 2956, email: sstrother@rotman-
baycrest.on.ca 
 
Dr. Ron Heslegrave, Chair, Research Ethics Board, Baycrest, Phone: (416) 785-2500 ext. 2440, 
email: hesgrave@uhnres.utoronto.ca 
Joanne Gourgouvelis, PhD Candidate, Faculty of Science, University of Ontario Institute of 




Purpose of the Study 
This research study is being conducted to study the effect of the Lakeridge Mental Health Day 
Treatment Program on your levels of the stress hormone cortisol and a number of other biomarkers known 
to be altered in depression. We will also be looking at the way your brain functions during certain memory 
tasks.  We are interested in how the treatment may change these things in depressed participants.  We are 
also interested in how exercise may affect the intensity of depression symptoms.  Previously we recruited 
participants from the Lakeridge program who also performed a 8 week exercise program.  This phase of the 
study is now complete and we will be recruiting a group of patients in the Mental Health Day Treatment 
program who are of a similar age and gender to investigate the effects of the Day Treatment program on its 
own in order to compare to the results of the exercise group. 
 
Potential Benefits to Participants and/or to Society 
Exercise has been shown in past studies to be an effective treatment for depression.  In this study 
we want to learn more about how and why it works in order to help us design the most effective types of 
exercise interventions.  The control group will still receive the benefits of the Mental Health Day Treatment 
program.  Additionally you will have the opportunity to see your scans and learn more about how your 
brain functions. If we show a strong effect between exercise and depression, it may become a future part of 
the Day Treatment program and you will be making an important contribution to improving treatment 
options for future patients. 
 
Participation and Withdrawal 
Your participation to take part in this study is voluntary.  You may choose not to participate or you 
may withdraw from the study at any time.  However, if you decide to stop participating in the study, we 
encourage you to talk to the study staff first.  The staff here is very flexible about meeting your needs and if 
there is anything we can do to accommodate your needs, we are more than willing to help.  You are still 
free to withdraw at any time without giving a reason, and your decision not to participate will not affect 
your care at this center. 
 
Rights of Research Participants 
You are free to ask any questions that you may have about your treatment and your rights as a 
research participant.  You may withdraw your consent at any time and discontinue participation without 
penalty.   
If any questions come up during or after the study or if you have a research-related injury, contact 
the study researchers listed on the first page. 
 
Should you have any questions or concerns regarding your rights as a participant in this research 
study, or if you wish to speak with someone who is not related to this study, you may contact the Chair of 
the Lakeridge Health Corporation Research Ethics Board at (905) 576-8711 or UOIT Research Ethics Board 
through the Compliance Office (905) 721-8668 ext 6393. 
 
You are one of 20 individuals being asked to participate in this study and have been referred to us 
by Lakeridge Mental Health Day Treatment program with a diagnosis of depression and you are between 
the ages of 18 and 50.  Please take your time to review this consent form and discuss any questions you 
may have with the study staff.  You may take your time to make your decision about participating in this 
study and you may discuss it with your friends, family or your doctor before you make your decision.  This 
consent form may contain words that you do not understand.  Please ask the study staff to explain any 





In order to be eligible for either group, you must not be currently doing regular exercise; that 
means your levels of exercise should be less than 20 minutes, three times per week.  People suffering from 
mental conditions other than depression, or with physical conditions that would prevent them from doing 
exercise, such as heart disease, will be excluded from the study. An understanding of English sufficient to 
answer questionnaires is required.   
 
If you have questions the stated procedures, timeline or exclusion criteria please feel free to 
discuss them with the study coordinator, Joanne Gourgouvelis or the investigators (contact details provided 
on page 1). 
 
The following sections will outline the various tests and procedures of the study, including: 1) the 
purpose of each test or procedure; 2) the respective timelines; 3) exclusion criteria (factors that might make 
you ineligible to participate);  
 
If you take part in this study, you will need to participate in several procedures.  Please read the 
following pages and tick the boxes to indicate if any of the exclusion criteria pertain to you:  A) 
Questionnaire completion (page 3),  B) Cognitive tasks (page 3), C) Saliva samples (page 4),  D) Bloodwork 





4. Purpose  
To determine the severity of your symptoms associated with depression, you will 
complete some demographic information and you will then complete two Questionnaires, 
called the Beck Depression Inventory II (BDI-II) and the Hospital Anxiety and Depression Scale 
(HADS).    
 
5. Timeline 
Questionnaires will be given at: 
iii. Week 0  
iv. Week 8 
 
6. Exclusion Criteria (please check box if you have any of the following) 
ii. Do not understand English  
 
6. Risks:  There are no risks from completing these questionnaires, data will not contain any 
personal information that can identify you.  Privacy and confidentiality will be maintained and 
data will be stored in a secured location. 
 
 
F. COGNITIVE TASKS 
 
4. Purpose  
To determine overall cognitive functioning, you will perform a series of computer 
generated tasks which will assess your ability to identify simple objects in space.   The benefits 
to you are that you will learn more about how your memory works and you will be increasing 





Cognitive tasks will be given at: 
i. Week 0 (prior to the exercise program)  
ii. Week 8 (after completion of the exercise program). 
 
6. Exclusion Criteria (please check box if you have any of the following) 
i. Do not understand English  
 
Risks:  There are no risks from completing these computer generated tasks, data will not 
contain any personal information that can identify you.  Privacy and confidentiality will be 





4. Purpose  
Cortisol is a hormone which is known to be elevated in depressed individuals, and 
chronically high levels of cortisol have been linked with changes in the way the brain functions.  
It is possible that exercise may help depression by decreasing cortisol secretion. You will be 
given labelled tubes to collect a sample of your saliva (spit) to be tested at a laboratory for the 
stress hormone cortisol, which you will collect on the morning after your interview as soon as 
you wake up and then again 30 minutes after you wake up. The samples will then be put in the 
freezer and you will be given a small Styrofoam cooler to bring the samples back to the 
researcher on the next day that you attend the Lakeridge program. You will be given a set of 
simple instructions in case you forget what to do.   
 
5. Timeline 
Saliva samples will be taken at: 
iii. Week 0: the day after your interview (when you wake up and 30 minutes after waking up) 
iv. Week 8: when you wake up and 30 minutes after waking up 
 
 
6. Exclusion Criteria (please check box if you have any of the following) 
ii. Ulcers or sores in your mouth  
 
7. Risks  
ii. There are no complications or side effects when collecting saliva.  Your samples will be 
coded in a way that does not identify you, frozen in a special freezer and stored until the 





4. Purpose  
A number of biomarkers found in blood are also known to be altered in depression 
and exercise may act to normalize their levels. A technician from the Medical Laboratory 
Science Program at the University of Ontario Institute of Technology will collect blood samples 





Blood samples will be taken at: 
iii. Week 0  
iv. Week 8  
 
6. Exclusion Criteria (please check box if you have any of the following) 
iv. Bleeding disorder  
v. Medications that may interfere with blood clotting (heparin, wafarin)  
vi. Phobia of needles 
 
5. Risks  
Complications are very rare when acquiring blood samples through a sterile syringe. 
However, the following side effects have been reported: 
G. Excessive bleeding at site of puncture 
H. Bruising 
I. Feeling light-headed, fainting 
J. Infection 
  
Your blood samples will be coded in a way that does not identify you, frozen in a special 
freezer and stored until the end of the study when they will be analyzed.  Any unused sample will 
be disposed of. 
 
 
K. BRAIN SCAN (functional MRI) 
 
2. Purpose  
Prior to commencing your program, fMRI images of your brain will be obtained to 
investigate the way that your brain activates when you are performing a task requiring your 
concentration.  We will also look at anatomical details of brain structures known to be 
involved in depression such as the hippocampus. Once you come out of the scanner, you will 
go to a separate room and be asked to go through some of the images from the task that you 
did in the scanner.  The scan will take about one hour and will be carried out at Baycrest 
hospital attached to the Rotman Brain Research Institute. We will then retest you at the end of 
your program (8 weeks) to see if exercise has changed the way your brain processes 
information.  There will be no cost to you for the scans and you will be provided with parking 
and gasoline vouchers to cover travel costs for each session.   
The MRI scan being done is designed to answer research questions, not to examine 
your brain medically.  This MRI scan is not a substitute for one that a doctor would order, and 
it may not show problems that would be picked up by a medical MRI scan.   However, in the 
unlikely event that we note an atypical finding on your MRI scan, we will contact you to help 
you arrange medical follow-up to interpret the significance of the findings, if any.  We may 
also ask a radiologist, or other health professional, to look at your scan, and by signing this 
consent form you agree to releasing the scan for review.  It is possible that you could be 
unnecessarily worried if a problem were suspected, but not actually found.  
 
The MRI technique uses magnets and radiowaves to construct a picture of the brain 
on a computer.  Before the scan begins, you will be asked to remove any magnetic metals that 
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you may be wearing.  For the procedure, you will be asked to lie on a padded bed that will be 
moved into a tunnel-like machine for the MRI scan of your brain. Since you will be inside the 
machine during the scan, and a screen will be in place for viewing the visual images, you may 
not be able to see the technicians operating the machine or the investigators.  However, there 
is an intercom system that will allow you to talk with them at any time.  If you feel 
uncomfortable during the scan and you wish to discontinue the procedure, you will be taken 
out of the machine at your request. 
 
We will obtain a series of MRI scans, separated by short breaks, and the entire 
procedure will take approximately one hour.  During the scans we will ask you to carry out a 
variety of tasks.  You should try to remain as still as possible during each scan.  Movement will 
not be dangerous to you in any way, but would blur the picture of your brain.  You will hear 
moderately loud knocking or beeping during the scan when the MRI machine is in operation.  
Although you may find this to be unsettling, the machine cannot hurt you in any way.  
Please note:  Prior to your first scan you will also be required to sign an additional 
consent form required by Baycrest hospital which provides similar information about fMRI as 
this consent form. 
 
4. Timeline 
Brain scans will be taken at: 
iii. Week 0  
iv. Week 8 
 
 
5. Exclusion Criteria (please check box if you have any of the following) 
ii. Phobia of small confined spaces  
v. Metal Implants, pieces of shrapnel, aneurysm clips, or wires in your head. etc.  
vi. Implanted Pace Maker 
vii. Pregnant 
viii. Inability to get to the scanner at Rotman Baycrest*.    
 
*We will compensate you for your parking and gasoline costs but you will need to be 
able to drive yourself or have someone else able to drive you in order to participate. 
 
5. Risks and Discomforts  
The MRI scan is not associated with any known risks to your health and there is no 
evidence that there will be either short-term or long-term side effects. Participants undergoing 
fMRI may feel uncomfortable or claustrophobic in the confined space.  Furthermore, the 
machine makes a loud noise which some people may find distressing.  There will be someone 
with you at all times during the brain imaging, in case you should experience any adverse 
effects. If you have a tattoo, there is a very small possibility that you will feel a tingling or 








You will also be given a log to keep track of each procedure required from you. This log is to be 
completed and given to the researcher at the end of the study (see attached). 
 
Once the information has been collected from all participants, the questionnaire responses will be 
examined to establish the effect of the MHDTP on depression, cortisol secretion, several biomarkers, 
cognitive performance, and fMRI results will be analyzed and a report will be written up.  A short version of 
this report will be available to participants who would like a copy.  You can indicate at the bottom of the 
consent form whether you would like to receive your report by email or by regular mail. 
 
If you have depression and you experience any worsening of your depression during your 
participation in the study, you will be referred immediately to the treatment team at Lakeridge Mental 
Health.  If you are concerned about any aspect of your participation, do not hesitate to contact the 
researchers at the numbers provided. 
 
Compensation for Participation 
There will be no direct compensation for participating in this research study, although you will be 
given a free supervised exercise program and you will be compensated for parking and gasoline costs. 
  
Disclosure 
Despite efforts to keep your personal information confidential, absolute confidentiality cannot be 
guaranteed.  Your personal information may be disclosed if required by law.  This legal obligation includes a 
number of circumstances, such as suspected child abuse and infectious disease, elevated risk or harm to 
you or others, and a court order by authorized agencies.  For your information, the research consent form 
will be inserted in the patient health record. 
Medical records that contain your identity will be treated as confidential in accordance with 
Ontario’s privacy legislation, the Personal Health Information Protection Act, 2004.  
 
The only people who will be accessing your patient records are the Lakeridge clinicians involved in 
your treatment.  The other information collected by the researchers is separate and will be seen only by the 
researchers and all identifying information will be removed in any publications.   
 
The Lakeridge Health Corporation Research Ethics Board and the University of Ontario Institute of 
Technology Research Ethics Board may review records related to the study for quality assurance purposes, 
as it oversees the conduct of this study at Lakeridge Health.  
 
Please read the following before signing the consent form and remember to keep a copy for your 
own records. 
 
By signing this form, I agree that: 
 
• The study has been explained to me.  All my questions were answered to my satisfaction. 
• The possible harms and discomforts and the possible benefits (if any) of this study have been explained 
to me. 
• I know about the alternatives to taking part in this study.  I understand that I have the right not to 
participate and the right to stop at any time.  The decision about whether or not to participate will not 
affect my health care at Lakeridge Health. 
• I am free now, and in the future, to ask any questions about the study. 
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• I have been told that my medical records will be kept confidential, except where release of information 
is required by law  
• I understand that no information that would identify me, will be released without asking me first, unless 
the disclosure is required by law 
• I hereby consent to participate.   
 
I have completed the individual procedure assessments and hereby consent to participate in the 
following procedures (please tick the box): 
 
A. Questionnaire completion 
B. Cognitive task  
C. Saliva samples 




Information gathered in this research study may be published or presented in public forums; 
however your name and other identifying information will not be used or revealed.  We hope the 
information learned from this study will benefit other people and support the use of exercise as a treatment 
for depression in future patients. 
You will be provided with a summary of findings at the end of the study, if you so desire.  We will 
do our best to explain the findings to you in way that you understand and what these changes mean.  Often 
in research we don’t get the findings we expect.  This is often because we didn’t study enough participants 
or the changes are of a different nature then we expected.   This is okay and still makes a very important 
contribution to science and to our understanding of depression. If you are concerned about any of the study 
findings or you would like more information, please contact Dr. Bernadette Murphy or Dr. Paul Yielder to 
discuss.    
 
Please indicated by ticking the box whether you wish to receive your summary by email or regular 









Participant Printed Name_________________________________  
 
 
I, the undersigned, have fully explained the relevant details of this research study to the participant 


























Professor Bernadette Murphy 
University of Ontario Institute of Technology 
Faculty of Health Sciences 
2000 Simcoe St. North 
Oshawa, Ontario 
CANADA  L0B 1J0 
Email: Bernadette.Murphy@uoit.ca 




The role of exercise in improving brain function: Part C: Non-
depressed exercise control group 
 
 
You are invited to participate in a research study entitled “The role of exercise in improving brain 
function”.  This study (# REB 10-104) has been reviewed by the University of Ontario Research Ethics Board 
and has been approved as of  May 13, 2013. Please read this form carefully, and feel free to ask any 
questions you might have. If you have any questions about your rights as a participant in this study, please 
contact the Compliance Officer at 905 721 8668 ext 3693 or compliance.uoit.ca. 
Researchers 
Dr. Bernadette Murphy, Professor, Head-Kinesiology Specialization, Faculty of Health Sciences, 
University of Ontario Institute of Technology, Phone: (905) 721-8668 ext 2778, email: 
Bernadette.Murphy@uoit.ca, Fax: (905) 721-3179 
Dr. Paul Yielder, Professor, Director-Bachelor of Health Sciences, Faculty of Health Sciences, 
University of Ontario Institute of Technology, Phone: (905) 721-8668 ext 2768, email: Paul.Yielder@uoit.ca, 
Fax: (905) 721-3179 
Dr. Nancy Wilkinson, Client Care Manager/Psychologist, Mental Health and Pinewood Program, 
Lakeridge Health, Phone: (905) 576-8711 ext 6233, email: nwilkinson@lakeridgehealth.on.ca 
Dr. Stephen Strother, Professor, Dept. of Medical Biophysics, University of Toronto, Senior 
Scientist, Rotman Research Institute, Baycrest, Phone: (416) 785-2500 ext 2956, email: sstrother@rotman-
baycrest.on.ca 
 
Dr. Ron Heslegrave, Chair, Research Ethics Board, Baycrest, Phone: (416) 785-2500 ext. 2440, 
email: hesgrave@uhnres.utoronto.ca 
Joanne Gourgouvelis, PhD Candidate, Faculty of Science, University of Ontario Institute of 
Technology, Phone: (905) 550-4055, email: Joanne.Gourgouvelis@uoit.ca, Fax: (905) 721-3179 
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Hushyar Behbahani, Master’s Student, Faculty of Health Sciences, University of Ontario Institute of 
Technology, Phone: (905) 441-5706, email: Hushyar.Behbahani@uoit.ca, Fax: (905) 721-3179 
 
 
Purpose of the Study 
This research study is being conducted to study the effect of exercise on your levels of the stress 
hormone cortisol and a number of other biomarkers known to be altered in depression. We will also be 
looking at the way your brain functions during certain memory tasks.  We are interested in how exercise 
may change these things in depressed participants as well as non depressed individuals.  These will be 
assessed over the course of a 8 week structured, supervised exercise program.  
 
Potential Benefits to Participants and/or to Society 
Exercise has been shown in past studies to be an effective treatment for depression.  In this study 
we want to learn more about how and why it works in order to help us design the most effective types of 
exercise interventions.  Following the exercise program, you may be rewarded with several benefits that 
exercise is associated with.  This study offers a structured exercise program suitable for beginners and may 
help you resolve any physical issues you have.  If we show a strong effect, it may become a future part of 
the Mental Health Day Treatment program at Lakeridge Health and you will be making an important 
contribution to improving treatment options for future patients. 
 
Participation and Withdrawal 
Your participation to take part in this study is voluntary.  You may choose not to participate or you 
may withdraw from the study at any time.  However, if you decide to stop participating in the study, we 
encourage you to talk to the study staff first.  The staff here is very flexible about meeting your needs and if 
there is anything we can do to accommodate your needs, we are more than willing to help.  You are still 
free to withdraw at any time without giving a reason, and your decision not to participate will not affect 
your care at this center. 
 
Rights of Research Participants 
You are free to ask any questions that you may have about your treatment and your rights as a 
research participant.  You may withdraw your consent at any time and discontinue participation without 
penalty.   
If any questions come up during or after the study or if you have a research-related injury, contact 
the study researchers listed on the first page. 
 
Should you have any questions or concerns regarding your rights as a participant in this research 
study, or if you wish to speak with someone who is not related to this study, you may contact the Chair of 
the Lakeridge Health Corporation Research Ethics Board at (905) 576-8711 or UOIT Research Ethics Board 
through the Compliance Office (905) 721-8668 ext 6393. 
 
You are one of 20 individuals being asked to participate in this study and you are between the ages 
of 18 and 50.  Please take your time to review this consent form and discuss any questions you may have 
with the study staff.  You may take your time to make your decision about participating in this study and 
you may discuss it with your friends, family or your doctor before you make your decision.  This consent 
form may contain words that you do not understand.  Please ask the study staff to explain any words or 
information that you do not clearly understand. 
 
Eligibility 
In order to be eligible for this study, you must not be currently doing regular exercise; that means 
your levels of exercise should be less than 20 minutes, three times per week.  People suffering from any 
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mental conditions including depression, or with physical conditions that would prevent them from doing 
exercise, such as heart disease, will be excluded from the study. An understanding of English sufficient to 
answer demographic information is required.   
 
The following sections will outline the various tests and procedures of the study, including: 1) the 
purpose of each test or procedure; 2) the respective timelines; 3) exclusion criteria (factors that might make 
you ineligible to participate);  
 
If you have questions the stated procedures, timeline or exclusion criteria please feel free to 
discuss them with the study coordinator, Joanne Gourgouvelis or the investigators (contact details provided 
at bottome of page 1). 
 
If you take part in this study, you will need to participate in several procedures.  Please read the 
following pages and tick the boxes to indicate if any of the exclusion criteria pertain to you:  A) 
Questionnaire completion (page 3),  B) Cognitive tasks (see Page 3) C) Saliva samples (page 4),  D) 
Bloodwork (see page 4),  E) Brainscan (see page 5), F) Transcranial Magnetic Stimulation (TMS) (see page 6)  





7. Purpose  
Since we will be comparing your results to a group of depressed individuals, we need 
you to complete the complete some demographic information and as well as the same two 
Questionnaires, called the Beck Depression Inventory II (BDI-II) and the Hospital Anxiety and 
Depression Scale (HADS).    
 
8. Timeline 
Questionnaires will be given at: 
v. Week 0 (prior to the exercise program)  
vi. Week 8 (after completion of the exercise program). 
 
9. Exclusion Criteria (please check box if you have any of the following) 
iii. Do not understand English  
 
8. Risks:  There are no risks from completing these questionnaires, data will not contain any 
personal information that can identify you.  Privacy and confidentiality will be maintained and 
data will be stored in a secured location. 
 
 
I. COGNITIVE TASKS 
 
7. Purpose  
To determine overall cognitive functioning, you will perform a series of computer 
generated tasks which will assess your ability to identify simple objects in space.   The benefits 
to you are that you will learn more about how your memory works and you will be increasing 





Cognitive tasks will be given at: 
i. Week 0 (prior to the exercise program)  
ii. Week 8 (after completion of the exercise program). 
 
9. Exclusion Criteria (please check box if you have any of the following) 
i. Do not understand English  
 
Risks:  There are no risks from completing these computer generated tasks, data will not 
contain any personal information that can identify you.  Privacy and confidentiality will be 






7. Purpose  
Cortisol is a hormone which is known to be elevated in depressed individuals, and 
chronically high levels of cortisol have been linked with changes in the way the brain functions.  
It is possible that exercise may help depression by decreasing cortisol secretion. You will be 
given labelled tubes to collect a sample of your saliva (spit) to be tested at a laboratory for the 
stress hormone cortisol, which you will collect on the morning after your interview as soon as 
you wake up and then again 30 minutes after you wake up. The samples will then be put in the 
freezer and you will be given a small Styrofoam cooler to bring the samples back to the 
researcher on the next day that you attend the Lakeridge program. You will be given a set of 
simple instructions in case you forget what to do.     
 
8. Timeline 
Saliva samples will be taken at: 
v. Week 0: the day before your first exercise session (when you wake up and 30 minutes 
after waking up) 
vi. Week 8: after completion of the exercise program (when you wake up and 30 minutes 
after waking up) 
 
 
9. Exclusion Criteria (please check box if you have any of the following) 
iii. Ulcers or sores in your mouth  
 
9. Risks  
iii. There are no complications or side effects when collecting saliva.  Your samples will be 
coded in a way that does not identify you, frozen in a special freezer and stored until the 




7. Purpose  
A number of biomarkers found in blood related to brain function may be improved by 
exercise and we want to find out if similar changes in the level of these biomarkers happen 
with exercise for both depressed and non-depressed individuals. A technician from the 
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Medical Laboratory Science Program at the University of Ontario Institute of Technology will 
collect blood samples from each participant twice during the study.  
 
8. Timeline 
Blood samples will be taken at: 
v. Week 0 (prior to the exercise program)  
vi. Week 8 (after completion of the exercise program). 
 
9. Exclusion Criteria (please check box if you have any of the following) 
vii. Bleeding disorder  
viii. Medications that may interfere with blood clotting (heparin, wafarin)  
ix. Phobia of needles 
 
6. Risks  
Complications are very rare when acquiring blood samples through a sterile syringe. 
However, the following side effects have been reported: 
L. Excessive bleeding at site of puncture 
M. Bruising 
N. Feeling light-headed, fainting 
O. Infection 
  
Your blood and saliva samples will be coded in a way that does not identify you, frozen in 
a special freezer and stored until the end of the study when they will be analyzed.  Any unused 




P. BRAIN SCAN (functional MRI) 
 
3. Purpose  
Prior to commencing your program, fMRI images of your brain will be obtained to 
investigate the way that your brain activates when you are performing a task requiring your 
concentration.  We will also look at anatomical details of brain structures known to be 
involved in depression such as the hippocampus. Once you come out of the scanner, you will 
go to a separate room and be asked to go through some of the images from the task that you 
did in the scanner.  The scan will take about one hour and will be carried out at Baycrest 
hospital attached to the Rotman Brain Research Institute. We will then retest you at the end of 
your program (8 weeks) to see if exercise has changed the way your brain processes 
information.  There will be no cost to you for the scans and you will be provided with parking 
and gasoline vouchers to cover travel costs for each session.  
The MRI scan being done is designed to answer research questions, not to examine 
your brain medically.  This MRI scan is not a substitute for one that a doctor would order, and 
it may not show problems that would be picked up by a medical MRI scan.   However, in the 
unlikely event that we note an atypical finding on your MRI scan, we will contact you to help 
you arrange medical follow-up to interpret the significance of the findings, if any.  We may 
also ask a radiologist, or other health professional, to look at your scan, and by signing this 
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consent form you agree to releasing the scan for review.  It is possible that you could be 
unnecessarily worried if a problem were suspected, but not actually found.  
The MRI technique uses magnets and radiowaves to construct a picture of the brain 
on a computer.  Before the scan begins, you will be asked to remove any magnetic metals that 
you may be wearing.  For the procedure, you will be asked to lie on a padded bed that will be 
moved into a tunnel-like machine for the MRI scan of your brain. Since you will be inside the 
machine during the scan, and a screen will be in place for viewing the visual images, you may 
not be able to see the technicians operating the machine or the investigators.  However, there 
is an intercom system that will allow you to talk with them at any time.  If you feel 
uncomfortable during the scan and you wish to discontinue the procedure, you will be taken 
out of the machine at your request. 
 
We will obtain a series of MRI scans, separated by short breaks, and the entire 
procedure will take approximately one hour.  During the scans we will ask you to carry out a 
variety of tasks.  You should try to remain as still as possible during each scan.  Movement will 
not be dangerous to you in any way, but would blur the picture of your brain.  You will hear 
moderately loud knocking or beeping during the scan when the MRI machine is in operation.  
Although you may find this to be unsettling, the machine cannot hurt you in any way.  
Please note:  Prior to your first scan you will also be required to sign an additional 
consent form required by Baycrest hospital which provides similar information about fMRI as 
this consent form. 
 
6. Timeline 
Brain scans will be taken at: 
v. Week 0 (prior to the exercise program)  
vi. Week 8 (after completion of the exercise program). 
 
7. Exclusion Criteria (please check box if you have any of the following) 
iii. Phobia of small confined spaces  
ix. Metal Implants, pieces of shrapnel, aneurysm clips, or wires in your head. etc.  
x. Implanted Pace Maker 
xi. Pregnant 
xii. Inability to get to the scanner at Rotman Baycrest*.    
 
*We will compensate you for your parking and gasoline costs but you will need to be 
able to drive yourself or have someone else able to drive you in order to participate. 
 
6. Risks and Discomforts  
The MRI scan is not associated with any known risks to your health and there is no 
evidence that there will be either short-term or long-term side effects. Participants undergoing 
fMRI may feel uncomfortable or claustrophobic in the confined space.  Furthermore, the 
machine makes a loud noise which some people may find distressing.  There will be someone 
with you at all times during the brain imaging, in case you should experience any adverse 
effects. If you have a tattoo, there is a very small possibility that you will feel a tingling or 






Q. Transcranial Magnetic Brain Stimulation (TMS) 
 
1. Purpose  
Prior to commencing your program, transcranial magnetic stimulation (TMS) data will 
be collected to investigate the way that your brain activates output to your muscles.  We will 
evaluate this again at the end of the program to determine if the exercise intervention has 
altered the excitability of certain brain pathways. Your participation in the TMS experiments 
will contribute to our understanding of how the brain and associated structures aids in the 
control of bodily movement. You will also further our knowledge of how motor training tasks 
can evoke cognitive learning, and how this subsequently affects the neural system.  
 
Should you agree to participate you will need to attend two evaluation sessions at the 
beginning and end of the exercise program. During the evaluation session we will collect some 
information about the way your brain is controlling a distal hand muscle. To do this it will be 
necessary to place some electrodes over the investigated muscle to record the signals from 
your brain to the muscle. Each evaluation session will take about 2-3 hours and you will be 
given feedback about your results following the procedure.  
 
2. Timeline 
TMS data will be collected at: 
i. Week 0 (prior to the exercise program)  
ii. Week 8 (after completion of the exercise program). 
 
3. Exclusion Criteria (please check box if you have any of the following) 
i. History of epilepsy  
ii. Metal Implants, pieces of shrapnel, aneurysm clips, or wires in your head. etc.  
iii. Implanted Pace Maker 
iv. Pregnant 
v. Previous brain surgery 
 
4. Risks and Discomforts  
The surface EMG techniques have low risks such as the person getting a skin irritation from the 
alcohol swab or electrode gel, but these are uncommon and not serious. Magnetic stimulation 
is a safe procedure that allows us to study the nerve pathways that go to the muscles of the 
hand. The stimulator produces a clicking sound and then a mild twitching feeling can 
sometimes be felt in the scalp muscles as well as the hand muscles. Occasionally, some people 
experience mild, transient scalp discomfort, due to the activation of the scalp muscles by the 
stimulation. Some people may also experience nausea or a mild headache. Both these 
reactions are uncommon and not serious. If you experience any of these effects let the 
investigator know. Certain people such as those with epilepsy, metal plates in their skull or 
prior brain surgery are not suitable candidates for magnetic brain stimulation, and this will be 
determined through the use of a screening questionnaire prior to your participation in this 
aspect of the study. Because the magnetic field discharges so quickly there is far less 
electromagnetic radiation than that from a television or mobile phone. At any time during the 




G. EXERCISE PROGRAM 
 
4. Description  
You will complete an exercise safety screening questionnaire called the Par-Q.  If 
there are any concerns about the safety of your participation, you will have the option of 
withdrawing or getting your family doctor to complete the ParMed-X to ensure it safe for you 
to exercise. 
Once enrolled and baseline assessments have been carried out you will commence a 
8 week exercise program.  The exercise sessions will take place at the Flex Center at Durham 
College/UOIT.  All sessions will be in groups of 2 to 5 participants and will be supervised by the 
Exercise Supervisor for three sessions per week and you must be prepared to commit to 
attending at least 80% of the exercise sessions. The role of the supervisor will be to give you 
verbal encouragement, monitor you for any possible adverse effects and provide aid as 
needed, and to help you monitor your heart rate to ensure they you are working at the correct 
intensity.  The exercise prescription will be individualized based on your starting fitness levels.  
One session per week will be aerobic exercise only, and the remaining two will be resistance 
exercise followed by a shorter aerobic bout. Based on your experience and ability, one 
resistance exercise will be selected from each of six categories – horizontal push, anterior 
lower body, vertical pull, posterior lower body, horizontal pull, and vertical push in order to 
establish a balanced, whole-body exercise prescription. Exercises will be changed after four 
weeks, to avoid adaptation. The aerobic bout following resistance sessions will be 20 minutes 
in the first week, and 30 minutes in subsequent weeks. Sessions containing a resistance 
component will be performed at least 24 hours apart. All sessions begin with a ten-minute 
aerobic warm-up, and are supervised by a kinesiologist. Participants are advised to bring a 
drink bottle and keep well hydrated..  
 
5. Timeframe 
ii. 3 one hour sessions per week for 8 weeks  
 
6. Exclusion Criteria (please check box if you have any of the following) 
iv. Already exercise more than 20 minutes, three times per week  
v. Physical conditions such as heart disease, or exclusions identified based on ParQ or 
ParMedX questionnaires. 
vi. I am unable to attend at least 80% of the exercise sessions 
 
5. Risks and Discomforts  
You may experience some physical discomfort both during exercise or stretching and 
following exercise or stretching, such as muscle soreness.  There is a small risk of injury 
occurring during any exercise program; however, the kinesiologists involved are trained in 
modifying exercise programs to minimize this risk and you will be supervised at all times.  
There will be someone with you at all times during the exercise sessions, in case you should 
experience any adverse effects. 
 
RESULTS 
You will also be given a log to keep track of each procedure required from you. This log is to be 




Once the information has been collected from all participants, cortisol secretion, several 
biomarkers, and fMRI results will be analyzed and a report will be written up.  A short version of this report 
will be available to participants who would like a copy.  You can indicate at the bottom of the consent form 
whether you would like to receive your report by email or by regular mail. 
 
If you are concerned about any aspect of your participation, do not hesitate to contact the 
researchers at the numbers provided. 
 
Compensation for Participation 
There will be no direct compensation for participating in this research study, although you will be 
given a free supervised exercise program and you will be compensated for parking and gasoline costs. 
 
Disclosure 
Despite efforts to keep your personal information confidential, absolute confidentiality cannot be 
guaranteed.  Your personal information may be disclosed if required by law.  This legal obligation includes a 
number of circumstances, such as suspected child abuse and infectious disease, elevated risk or harm to 
you or others, and a court order by authorized agencies.  For your information, the research consent form 
will be inserted in the patient health record. 
 
Medical records that contain your identity will be treated as confidential in accordance with 
Ontario’s privacy legislation, the Personal Health Information Protection Act, 2004.  
 
All information collected by the researchers will be seen only by the researchers and all identifying 
information will be removed in any publications.   
 
The University of Ontario Institute of Technology Research Ethics Board may review records 
related to the study for quality assurance purposes, as it oversees the conduct of this study.  
 
Please read the following before signing the consent form and remember to keep a copy for your 
own records. 
 
By signing this form, I agree that: 
 
• The study has been explained to me.  All my questions were answered to my satisfaction. 
• The possible harms and discomforts and the possible benefits (if any) of this study have been explained 
to me. 
• I am free now, and in the future, to ask any questions about the study. 
• I have been told that my medical records will be kept confidential, except where release of information 
is required by law  
• I understand that no information that would identify me, will be released without asking me first, unless 
the disclosure is required by law 
• I hereby consent to participate.   
 
I have completed the individual procedure assessments and hereby consent to participate in the 
following procedures (please tick the box): 
 
G. Questionnaire completion 
258 
 
H. Cognitive tasks 
I. Saliva samples 






Information gathered in this research study may be published or presented in public forums; 
however your name and other identifying information will not be used or revealed.  We hope the 
information learned from this study will benefit other people and support the use of exercise as a treatment 
for depression in future patients. 
You will be provided with a summary of findings at the end of the study, if you so desire.  We will 
do our best to explain the findings to you in way that you understand and what these changes mean.  Often 
in research we don’t get the findings we expect.  This is often because we didn’t study enough participants 
or the changes are of a different nature then we expected.   This is okay and still makes a very important 
contribution to science and to our understanding of depression. If you are concerned about any of the study 
findings or you would like more information, please contact Dr. Bernadette Murphy or Dr. Paul Yielder to 





Please indicated by ticking the box whether you wish to receive your summary by email  or 










Participant Printed Name_________________________________  
 
 
I, the undersigned, have fully explained the relevant details of this research study to the participant 













Role in the Study  (only authorized / qualified member of the research team) 
